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And now in Arabic:  
ﻢﻴﺣﺮﻟا ﻦﻤﺣﺮﻟا ﷲا ﻢﺴﺑ 
 
ﺮﻜﺷ 
 
ﺔﻤﻃﺎﻓ ﻲﺗاﻮﺧاو ﻒﻃﺎﻋ ﻲﺧاو ﻲﻣاو ﻲﺑا ﺮﻜﺷا نا دوا ﺔﻳاﺪﺒﻟا ﻲﻓ  ،فﺎﻄﻋ ، ﻢﻬﺗﻼﺋﺎﻋو ﻢﻬﺋﺎﻨﺑاو ﻒﻃاﻮﻋو
ﻊﻴﺠﺸﺘﻟا و ﻢﻋﺪﻟا ﻰﻠﻋ ؛ﻊﻴﺠﺸﺘﻟا ﻰﻠﻋ ﻢﻬﺋﺎﻨﺑاو تﻻﺎﺨﻟاو ﺔﻤﻌﻟاو لاﻮﺧﻻاو مﺎﻤﻋﻻا ﻚﻟﺬآ ﺮﻜﺷا نا دواو .  
ﻠﺜﻤﻣ سﺪﻘﻟا ﺔﻌﻣﺎﺟ ةرادا ﺮﻜﺷا نا دواو ﺪﻋﺎﺴﻣ ﻚﻳوﺪﻟا ﻦﺴﺣ رﻮﺘآﺪﻟاو ﺔﺒﻴﺴﻧ يﺮﺳ ﺪﻴﺴﻟا ﺔﻌﻣﺎﺠﻟا ﺲﻴﺋﺮﺑ ﺔ
ﺲﻴﺋﺮﻟا  ،يرادﻻا ﺮﻳﺪﻤﻟا دﺎﻴﻋ ﻢﻴﻠﺤﻟا ﺪﺒﻋ ذﺎﺘﺳﻻاو ؛ﺐﻴﻄﺨﻟا دﻮﻤﺤﻣ ءﺎﻗﺪﺻﻻا ﺮﻜﺷاو ﺎﻤآ ،ﻊﻳﺮﻗ ﺪﻨﻬﻣ ،
دﺎﻴﻋ ﺮﻤﻋ ، سﻮﻣﺎﺟ ﻲﻠﻋوﻲﻨﻋ لاﺆﺴﻠﻟ  
ﺨﻠﻣ ﺔﺑﺎﺘآ ﻲﻓ ﺔﻴﻨﻘﺘﻟا ﻪﺗﺪﻋﺎﺴﻤﻟ ادﺪﺠﻣ ﺐﻴﻄﺨﻟا دﻮﻤﺤﻤﻟ رﺎﺤﻟا ﺮﻜﺸﻟﺎﺑ مﺪﻘﺗا ﺎﻤآ فﺮﺣﻻﺎﺑ ﺚﺤﺒﻟا ﺺ
ﺎﻬﺘﻤﺟﺮﺗ ﻲﻓ ﻪﺗﺎﺣﺮﺘﻘﻣو ﺔﻴﺑﺮﻌﻟا 
ءﺎﻗﺪﺻﻼﻟ ﻞﻳﺰﺠﻟا ﺮﻜﺸﻟﺎﺑ مﺪﻘﺗا ﺎﻤآ :ءاﺮﻀﺨﻟا ﺲﻧﻮﺗ ﻦﻣ ﻲﻨﻏﺰﻣ ردﺎﻘﻟا ﺪﺒﻋو ﺎﺣﺎﺣ ﻦﺑ ﻦﺴﺤﻣ ، رﻮﺘآﺪﻟاو
ﻦﻴﻄﺴﻠﻓ ﻦﻣ ةﺮﻄﻋ ﺔﺘﺟوزو ﺔﻠﻳﻼﺧ مﺎﺼﻋ ، ﺮﻴﺒﻜﻟا ﻢﻬﻤﻋد ﻰﻠﻋ ﻲﻣﻮﻴﺒﻟا نﺎﻨﺣ ةﺰﻳﺰﻌﻟا ﺔﻘﻳﺪﺼﻟاو
نازﻮﻟ ﻲﻓ ﻢهدﻮﺟو ةﺮﺘﻓ لاﻮﻃ ﻲﺗﺪﻧﺎﺴﻣو.  
ﺷوﺔﻄﻴﺒﺷ جرﻮﺟ رﻮﺘآﺪﻠﻟ ﻞﻳﺰﺠﻟا يﺮﻜ ،يدﻮﻣﺎﻌﻟا فﺮﺷا رﻮﺘآﺪﻟاو ، ﺮﻴﻠآ ﻪﺘﺟوزو نﺎﻤﻠﺴﻟا سوا ﺪﻴﺴﻟاو
ةﺪﻧﺎﺴﻤﻟاو ﻪﻴﺟﻮﺘﻠﻟ 
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ABSTRACT 
 
 
 
Cell surface glycoproteins and glycolipids are responsible for cellular recognition processes.  
Vaccination is the procedure whereby the immune system is induced to create antibodies against a 
foreign molecule involved in disease or viral infection. In many disease states, the oligosaccharide 
chains presented on cell surface glycoprotein are altered. In some tumors, the glycan chains of 
glycoproteins are attenuated to only a few sugar residues. In the case of the TF-antigen, the 
polysaccharide chains have been shortened to a galactose-β-(1→3)-N-acetyl-galactosamine 
disaccharide structure α-linked to a serine or threonine. 
 
Immunogenicity of this epitope in synthetic vaccines has been demonstrated. However, this 
disaccharide conjugate is relatively short-lived in the blood stream because of its hydrolysis catalysed 
by ubiquitous glycosidases in vivo. 
 
C-disaccharides are sugar mimetics whose interglycosidic linkage is non-hydrolysable as required for 
a disaccharide-based vaccine. In the first part of the work, we report the first synthesis of TF-antigen 
analogues applying the methodology developed by our group for the synthesis of C(1→3)-
disaccharides. Conjugate addition of diethylaluminium iodide (Et2AlI) to isolevoglucosenone leads to 
an aluminium enolate, which reacts with the sugar derived carbaldehyde, 2,6-anhydro-3,4,5,7-
tetrakis-O-[(tert-butyldimethyl)silyl]-D-glycero-L-manno-heptose, to give an aldol. The convergent 
and stereoselective synthesis of this adduct allows us to obtain C(1→3)-disaccharides. Reduction of 
the moiety derived from isolevoglucosenone with lithium borohydride, followed by cleavage of the 
1,6-anhydro bridge produces C-disaccharides with D-galacto configuration. Königs-Knorr 
glycosidation of N-Fmoc-serine tert-butylester, followed by reduction of azide moiety to the 
corresponding acetamido group allows us to obtain TF-antigen analogues linked either by 
hydroxymethano (-CH(OH)-) or methano (-CH2-) group. 
 
In a second part we report the synthesis of a fully deprotected thio-glycotripeptide based on the TF-
antigen -C-analogues linked by hydroxymethano - N-acetyl-O-{α-D-glyco}-D-seryl-O-{α-D-glyco}-
D-seryl-rac-N-(3-[(acetylthio)amino]propyl)-O-{α-D-glyco}-D-serinamide, which was covalently 
conjugated to the KLH protein carrier via Michael addition reaction.  
Biological trials with the TF (analogues)-KLH are in progress. 
 
We report also the synthesis of fully deprotected TF-antigen -C-analogues linked by hydroxymethano 
(-CH(OH) and methano (-CH2-) group. their conformational analysis is currently in progress. 
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Résumé 
 
 
 
Les glycoprotéines et les glycolipides du calix des cellules sont responsables de la communication 
entre cellules et le monde extérieur, et leur sociologie. La vaccination est une opération consistant à 
stimuler la production d’anticorps qui s’associent à un composé ou un microorganismes étranger 
comme les bactéries et les virus. Au cours d’une maladie, l’état de la surface cellulaire peut être 
modifié. Par exemple certaines cellules cancéreuses se trouvent partiellement dénudées au niveau de 
leurs oligosaccharides  de surface. C’est le cas pour les cellules portant l’antigène de Thomsen-
Friedenreich où la chaîne polysaccharidique est réduite à un disaccharide, le β-D-Galp1→3-D-
GalNAcp-α-O-serine ou O-thréonine. Des vaccins anti-tumoraux artificiels de l’épitope de Thomsen-
Friedenreich ont montré une réponse immunitaire intéressante. Toutefois les O-disaccharides ne 
survivent pas longtemps dans le sang à cause de leur hydrolyse catalysée par des glycohydrolases 
omniprésents in vivo. 
 
 
Les C-disaccharides sont des mimes des O-disaccharides non hydrolysables. Ils présentent donc un 
intérêt pour la fabrication de vaccins artificiels anti-cancer. Dans une première partie de ce travail 
nous avons développé une méthode pour l’obtention de C-disaccharides du type C(1-3). La méthode 
utilise la réaction de Oshima-Nozaki qui condense l’isolevoglucosenone et les aldéhydes dérivés de 
monosaccharides en présence de Et2AlI, on obtient des aldols qui se laissent convertir en une gamme 
de C-disaccharides de façon hautement stéréosélective, par exemple en système de type β-D-
Gal(1→3)-(1,6-anhydrohexose). Les intermédiaires sont utilisés dans la glycosidation selon Königs-
Knorr sur une sérine semi-protégée (NFmoc-serine t-butyl ester). Après conversion de l’azoture en 
groupement N-acetamido, on aboutit à des analogues de l’épitope Thomsen-Friedenreich    ou le lien 
interglycosidique est un groupement hydroxyméthano ou un groupement méthano. 
 
 
Dans une deuxième partie, la synthèse d’un thioglycopeptide déprotégé attaché au  disaccharide β-D-
Gal 1(CH(OH))→3-D-GalNAc  est réalisé. Le cluster - N-acetyl-O-{α-D-glyco}-D-seryl-O-{α-D-
glyco}-D-seryl-rac-N-(3-[(acetylthio)amino]propyl)-O-{α-D-glyco}-D-serinamide est ensuite 
conjugué à la protéine immunogène KLH modifié de façon adéquate pour des additions selon 
Michael. Les produits ainsi obtenus ont été envoyés pour des tests biologiques. 
 
 
Les C-disaccharides déprotégés  mimant les disaccharides Thomsen-Friedenreich ont été préparés 
pour une étude d’analyse conformationnelle.   
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 ﺍﻟﻤﻠﺨﺹ
 
هﻮ إﺟﺮاء ﺑﻮاﺳﻄﺘﻪ ﻳﺘﻢ ﺣﺚ ﺟﻬﺎز  اﻟﺘﻠﻘﻴﺢ. ﻜﻮﺑﺮوﺗﻴﻨﺎت ﻋﻠﻰ ﺳﻄﺢ اﻟﺨﻠﻴﺔ ﻣﺴﺆوﻟﺔ ﻋﻦ ﻋﻤﻠﻴﺎت اﻟﺘﻤﻴﻴﺰ اﻟﺨﻠﻮﻳﺔاﻟﺠﻠﻴﻜﻮﻟﻴﺒﻴﺪات و اﻟﺠﻠﻴ
ﻓﻲ آﺜﻴﺮ ﻣﻦ اﻟﺤﺎﻻت . اﻟﻤﻨﺎﻋﺔ ﻟﺨﻠﻖ أﺟﺴﺎم ﻣﻀﺎدة  ﺗﻘﺎوم اﻟﺠﺰﻳﺌﺎت اﻟﻐﺮﻳﺒﺔ اﻟﻤﺘﻮرﻃﺔ ﺑﺤﺪوث اﻷﻣﺮاض أو اﻟﻌﺪوى اﻟﻔﻴﺮوﺳﻴﺔ
 اﻟﺴﻼﺳﻞ اﻟﺴﻜﺮﻳﺔ ،ﻓﻲ ﺑﻌﺾ اﻷورام. اﻟﺠﻠﻴﻜﻮﺑﺮوﺗﻴﻦ ﻳﺘﻢ ﺗﻐﻴﻴﺮهﺎ ﺳﻼﺳﻞ ﺳﻜﺮات اﻷوﻟﻴﺠﻮ اﻟﻤﻮﺟﻮدة ﻋﻠﻰ ﺳﻄﺢ ،اﻟﻤﺮﺿﻴﺔ
 : ﺳﻼﺳﻞ اﻟﺴﻜﺮات اﻟﻌﺪﻳﺪة ﻳﺘﻢ ﺗﻘﺼﻴﺮهﺎ ﻟﻠﺴﻜﺮ اﻟﺜﻨﺎﺋﻲ، FT- ﻓﻲ ﺣﺎﻟﺔ اﻟﻤﻮﻟﺪ اﻟﻤﻀﺎد .ﻟﻠﺠﻠﻴﻜﻮﺑﺮوﺗﻴﻨﺎت ﻳﺘﻢ ﺗﻔﻜﻴﻜﻬﺎ ﻟﺒﻀﻌﺔ ﺑﻘﺎﻳﺎ ﺳﻜﺮﻳﺔ
 .ﺛﺮﻳﻮﻧﻴﻦ أو ﺳﻴﺮﻳﻦ ﻣﺮﺗﺒﻄﺎ ﺑﺮاﺑﻄﺔ أﻟﻔﺎ ﺑﺎﻟﺤﻤﺾ اﻷﻣﻴﻨﻲ  اﺳﻴﺘﻞ ﺟﻼآﺘﻮز أﻣﻴﻦ-N-(3←1)- β-ﺟﻼآﺘﻮز
 
 ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ أن اﻟﺴﻜﺮ اﻟﺜﻨﺎﺋﻲ ،هﺎ إﻇﻬﺎرو ﻓﻌﺎﻟﻴﺘﻪ إﺛﺒﺎت  ﺗﻢ،ﻓﻲ اﻟﻠﻘﺎﺣﺎت اﻟﺼﻨﺎﻋﻴﺔ( اﻟﺠﺰيء اﻟﻐﺮﻳﺐ)اﻟﻤﻨﺎﻋﺔ اﻟﺠﻴﻨﻴﺔ ﻟﻼﻳﺒﻮﺗﻮب 
 . اﻟﺤﻲاﻟﻤﺸﺘﻖ ذو ﺣﻴﺎة ﻗﺼﻴﺮة ﻧﺴﺒﻴﺎ ﻓﻲ ﻣﺠﺮى اﻟﺪم ﻷﻧﻪ ﻳﺘﻔﻜﻚ ﺑﺘﺤﻔﻴﺰ ﻣﻦ أﻧﺰﻳﻢ اﻟﺘﺤﻠﻴﻞ اﻟﻤﺎﺋﻲ ﺟﻼﻳﻜﻮﺳﺎﻳﺪﻳﺰ آﻠﻲ اﻟﻮﺟﻮد ﻓﻲ اﻟﺠﺴﻢ 
( اﻟﺘﻲ ﺗﺮﺑﻂ ﺟﺰﻳﺌﺎت اﻟﺴﻜﺮ اﻷﺣﺎدﻳﺔ ﺑﺒﻌﻀﻬﺎ اﻟﺒﻌﺾ)   راﺑﻄﺘﻬﺎ اﻟﺠﻠﻴﻜﻮﺳﻴﺪﻳﺔ ،اﻟﺴﻜﺮﻳﺎت اﻟﺜﻨﺎﺋﻴﺔ آﺮﺑﻮﻧﻴﺔ اﻻرﺗﺒﺎط هﻲ ﺳﻜﺮﻳﺎت ﻣﻘﻠﺪة
ﻗﻤﻨﺎ ﺑﻮﺻﻒ أول ﺗﺤﻀﻴﺮ ،  ﻓﻲ اﻟﺠﺰء اﻷول ﻟﻬﺬا اﻟﻌﻤﻞ .ﻏﻴﺮ ﻗﺎﺑﻠﺔ ﻟﻠﺘﺤﻠﻴﻞ اﻟﻤﺎﺋﻲ آﻤﺎ هﻮ ﻣﺘﻄﻠﺐ ﻣﻦ اﻟﻠﻘﺎح اﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ اﻟﺴﻜﺮ اﻟﺜﻨﺎﺋﻲ
 . (3←1) و ذﻟﻚ ﺑﺘﻄﺒﻴﻖ اﻟﻤﻨﻬﺞ اﻟﺬي ﻃﻮرﺗﻪ ﻣﺠﻤﻮﻋﺘﻨﺎ ﻟﺘﺤﻀﻴﺮ اﻟﺴﻜﺮﻳﺎت اﻟﺜﻨﺎﺋﻴﺔ آﺮﺑﻮﻧﻴﺔ اﻻرﺗﺒﺎط FT-ﺎﻇﺮات اﻟﻤﻮﻟﺪ اﻟﻤﻀﺎدﻟﻤﺘﻨ
 
، ﺗﻨﺘﺞ اﻳﻨﻮﻻت اﻷﻟﻮﻣﻨﻴﻮم، اﻳﺰوﻟﻴﻔﻮﺟﻠﻮآﻮزﻳﻨﻮن ل )IlA2tE(ﺑﻴﻮدﻳﺪ ﺛﻨﺎﺋﻲ اﺛﻴﻞ اﻷﻟﻮﻣﻨﻴﻮم  -(ﻏﻴﺮ ﺑﺴﻴﻄﺔ) ﺛﻨﺎﺋﻴﺔ اﻻزدواج -إﺿﺎﻓﺔ 
 - D-[ﺳﻴﻠﻴﻞ(  ﺑﻴﻮﺗﻴﻞ ﺛﻨﺎﺋﻲ ﻣﺜﻴﻞ-ﺛﺎﻟﺜﻲ)] -O- رﺑﺎﻋﻲ آﻴﺲ-3,4,5,7- أﻧﻬﻴﺪرو-2,6  ، اﻟﺴﻜﺮﻣﻦ  ﻣﺸﺘﻖﻠﺪهﺎﻳﺪآﺎرﺑ  اﻟﺘﻲ ﺗﺘﻔﺎﻋﻞ ﻣﻊ
اﻟﺘﺤﻀﻴﺮ اﻟﻜﻴﻤﻴﺎﺋﻲ اﻟﻤﺠﺴﻢ ﻟﻬﺬا اﻟﻨﺎﺗﺞ ﻳﻤﻜﻨﻨﺎ ﻣﻦ اﻟﺤﺼﻮل ﻋﻠﻰ ﺳﻜﺮﻳﺎت ﺛﻨﺎﺋﻴﺔ آﺮﺑﻮﻧﻴﺔ . أﻟﺪول ﻹﻋﻄﺎء ال ، ﻣﺎﻧﻮهﺒﺘﻮز-L-ﺟﻠﻴﺴﻴﺮو
- 1,6) ﺛﻢ آﺴﺮ اﻟﺮاﺑﻄﺔ ﺑﺎﻟﻠﻴﺜﻴﻮم ﺑﻮروهﺎﻳﺪراﻳﺪ  اﻳﺰوﻟﻴﻔﻮﺟﻠﻮآﻮزﻳﻨﻮنﺘﻖ ﻣﻦ  اﺧﺘﺰال ﺟﺰء ﻣﻦ اﻟﻤﺮآﺐ اﻟﻤﺸ. (3←1)اﻻرﺗﺒﺎط 
 ﺳﻴﺮﻳﻦ ﺛﺎﻟﺜﻲ ﺑﻴﻮﺗﻴﻞ - ﻓﻤﻮك-Nب "  آﻨﻮر-آﻮﻧﻴﺠﺰ" ارﺗﺒﺎط .  ﺟﺎﻻآﺘﻮ-Dﺗﻨﺘﺞ ﺳﻜﺮﻳﺎت ﺛﻨﺎﺋﻴﺔ آﺮﺑﻮﻧﻴﺔ اﻻرﺗﺒﺎط ﺑﺘﺸﻜﻞ ( أﻧﻬﻴﺪرو
 ﻣﺮﺗﺒﻄﺔ FT- ﻳﻤﻜﻨﻨﺎ ﻣﻦ اﻟﺤﺼﻮل ﻣﺘﻨﺎﻇﺮات اﻟﻤﻮﻟﺪ اﻟﻤﻀﺎدهﺬا،  اﻟﻤﺮاﻓﻘﺔاﻷﺳﻴﺘﺎﻣﻴﺪو ﻳﻨﺘﺞ ﻣﺠﻤﻮﻋﺔ اﻷزاﻳﺪﻳﺘﺒﻌﻪ اﺧﺘﺰال ﻟﺠﺰء ، اﻳﺴﺘﺮ
 .(-HC2-)اﻟﻤﻴﺜﺎﻧﻮ   أو ﺑﻤﺠﻤﻮﻋﺔ )-)HO(-HC-(هﺎﻳﺪروآﺴﻲ ﻣﻴﺜﺎﻧﻮ إﻣﺎ ﺑﻤﺠﻤﻮﻋﺔ 
 
 ﺑﺮاﺑﻄﺔ FT-ﻳﻌﺘﻤﺪ ﻋﻠﻰ ﻣﺘﻨﺎﻇﺮات اﻟﻤﻮﻟﺪ اﻟﻤﻀﺎد ﺑﺒﺘﺎﻳﺪ يﺛﻼﺛ  ﺟﻼﻳﻜﻮ-ﺛﻴﻮﻓﻲ اﻟﺠﺰء اﻟﺜﺎﻧﻲ ﻣﻦ اﻟﺒﺤﺚ ﻗﻤﻨﺎ ﺑﻮﺻﻒ آﺎﻣﻞ ﻟﺘﺤﻀﻴﺮ 
 -  ﺳﻴﺮﻳﻞ - D- { ﺟﻼﻳﻜﻮ-D-α }-O - ﺳﻴﺮﻳﻞ -D- { ﺟﻼﻳﻜﻮ- D-α }-O - اﺳﻴﺘﻞ-N-هﺎﻳﺪروآﺴﻲ ﻣﻴﺜﺎﻧﻮﻮﻋﺔ آﺮﺑﻮﻧﻴﺔ ﻣﺮﺗﺒﻄﺔ ﺑﻤﺠﻤ
هﺬا اﻟﻤﺮآﺐ ﺗﻢ رﺑﻄﻪ ﺑﺮاﺑﻄﺔ ﺗﺴﺎهﻤﻴﺔ ،   ﺳﻴﺮﻳﻦ أﻣﺎﻳﺪ-D- { ﺟﻼﻳﻜﻮ-D-α }-O-( ﺑﺮوﺑﻴﻞ[أﻣﻴﻨﻮ( اﺳﻴﺘﻴﻞ ﺛﻴﻮ) ]-3 )-N – car
 . ﻋﻦ ﻃﺮﻳﻖ ﺗﻔﺎﻋﻞ ﻣﻴﻜﺎﺋﻴﻞ ﻟﻺﺿﺎﻓﺔHLK ﺘﻴﻨﻲﻟﺤﺎﻣﻞ اﻟﺒﺮوﻟ
 .ﻟﻢ ﺘﻧﺘﻬﻲ ﺒﻌﺪ  HLK-FT  ب ﻣﺘﻨﺎﻇﺮات  ﺗﺠﺮياﻟﺘﻲ ﺣﻴﻮﻳﺔاﻠﺘﺒﺎرات ﺧﻻ ا
    
-)HO(-HC-(هﺎﻳﺪروآﺴﻲ ﻣﻴﺜﺎﻧﻮ  ﺑﺮاﺑﻄﺔ آﺮﺑﻮﻧﻴﺔ ﻣﺮﺗﺒﻄﺔ ﺑﻤﺠﻤﻮﻋﺔ FT-آﺬﻟﻚ ﻓﻘﺪ وﺻﻔﻨﺎ ﺗﺤﻀﻴﺮ آﺎﻣﻞ ﻟﻤﺘﻨﺎﻇﺮات اﻟﻤﻮﻟﺪ اﻟﻤﻀﺎد
  .ﻳﺠﺮى ﺣﺎﻟﻴﺎ ﺗﺤﻠﻴﻞ ﻟﻠﺒﻨﺎء اﻟﻔﺮاﻏﻲ ﻟﻬﺬﻩ اﻟﻤﺮآﺒﺎت. (-HC2-)اﻟﻤﻴﺜﺎﻧﻮ   و ﺑﻤﺠﻤﻮﻋﺔ )
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ABBREVIATIONS 
 
 
 
Ab   Antibody 
Ac   Acetyl 
Ag   Antigen 
AIBN   2,2’-azobisisobutyronitrile 
Anh.   Anhydrous 
Aq.   Aqueous 
Bn   Benzyl 
Boc   Tert-butoxycarbonyl 
BSA   Bovine serum albumin 
CAN   Ceric ammonium nitrate 
DAST   Diethylaminosulfurtrifluoride 
DBU   1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC   Dicyclohexylcarbodiimide 
DDQ   2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DIBAL              Diisobutylaluminium hydride 
DIEA   Diisopropylethylamine 
DMAP   4-Dimethylaminopyridine 
DMDO               3,3-Dimethyldioxirane 
DMF   N,N-dimethylformamide 
DMSO   Dimethylsulfoxide 
DTBP   Di-tert-butylpyridine 
EDC   N’-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
ELISA   Enzyme-linked immunosorbant assay 
Fmoc   Fluoren-9-ylmethoxycarbonyl 
HATU N-[(dimethylamino)-1H-1,2,3-triazole[4,5-b]-pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate 
HMPA   Hexamethylphosphoramide 
HOAt   7-Aza-1-hydroxy-1H-benzotriazole 
Ig   Immunoglobulin 
IR   Infrared 
IIDQ 2-(2-Methylpropoxy)-1(2H)-quinoline carboxylic acid-(2- 
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methylpropyl)ester 
KLH   Keyhole limpet hemocyanin 
LHMDS  Lithium hexamethyldisilazide 
mAb   Monoclonal antibody 
MBS   m-maleimidobenzoyl-N-hydroxysuccinimide 
mCPBA  Meta-chloroperbenzoic acid 
MHC   Major histocompatibility complex 
Mp   Melting point 
MS   Molecular sieves 
NMR   Nuclear magnetic resonance 
NOE   Nuclear Overhauser effect 
Pam3Cys  Tripalmitoyl-S-glycerylcysteinylserine 
PMB   Para-methoxybenzyl 
PPTS   Pyridinium-p-toluenesulfonate 
pTsOH   Para-toluenesulfonic acid 
SAMA-OPfp   S-acetylthioglycolic acid pentafluorophenyl ester 
Ser   Serine 
TBAF   Tetrabutylammoniumfluoride 
TBS   Tert-butyldimethylsilyl 
TEA   Triethylamine 
TES   Triethylsilyl 
Tf   Trifluoromethanesulfonyl 
TFA   Trifluoroacetic acid 
THF   Tetrahydrofuran 
Thr   Threonine 
TIPS   Triisopropylsilyl 
TMG   Tetramethylguanidinium 
TMS   Trimethylsilyl 
UV   Ultraviolet 
Z   Benzyloxycarbonyl 
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1 Carbohydrate  based vaccines 
1.1 The Carbohydrate 
1.1.1 What are the Carbohydrates? 
The term carbohydrate was originally derived in the nineteenth century from the French 
(hydrate de carbon) for the family of compounds possessing the empirical formula Cn(H2O)n. 
however, subsequently, the term has been greatly extended to encompass many other 
materials. In general, carbohydrates are polyhydroxylated aldehydes containing a number of 
carbon atoms, varying between 3 and 9. some, such as glucose should be very familiar. 
Others, such as sialic acid, may look rather esoteric, but are in fact crucial throughout 
biology. 
1.1.2 Carbohydrate in nature 
One thing is certain, that is, carbohydrates are everywhere, not just in the supermarket in 1 kg 
bags. Glucose is the most abundant organic molecule on the planet. For example cellulose is 
simply a polymer of glucose (actually β(1-4) linked). DNA and RNA are of course also made 
of sugar. Ribose is a sugar containg 5 carbon atoms that is a component of each of bulding 
block used to make these two nucleic acid, which are fundamental to life it self. 
The roles that sugars played in biological systems were thought to be limited to either acting 
as sources of energy, for example, D-glucose is glycolysis to form ATP, or as good structural 
bulding blocks, for example, α(1-4) linked D-glucose as a polymer in starch 
 
1.1.3 Biological Properties of Carbohydrates 
Carbohydrates have a number of important biological roles which fall into three major 
functions :  important foodstuffs and energy source, structurally important compound , and 
considered as a key code molecules in biological communication and interaction. Each of 
 12 
 
these biological properties is related to the physical and chemical properties of the 
carbohydrates. 
 
1.1.4 Energy Storage 
The first of these roles, energy storage, is the major function of starch in plants and glycogen 
in animals. These highly branched, glucose-based polysaccharides serve as efficient means in 
the high density storage of energy for rapid utilisation through enzymatic hydrolysis to the 
monosaccharide, glucose, when required to maintain the energy balance of cell function. 
 
1.1.5 Structural Roles 
Linear polysaccharides that contain highly ordered secondary structures are important in 
making up structural components in both plant and animal tissues. Cellulose and pectins are 
the major structural components of plant tissue while the glycosaminoglycan chains of 
proteoglycan molecules, the major component of the extracellular matrix, serve a similar role 
in animal tissue. 
 
1.1.6 Cell-Cell Interaction and Cellular Communication 
For many decades, carbohydrate molecules were regarded as energy-storage compounds and 
support structures with no significant biological function, despite their ubiquitous presence 
on the proteins and membranes of all eukaryotic cells. 
 
The discovery in 1969 that cell-surface oligosaccharides were profoundly altered in cancer 
cells, and may be related to cancer cell diffusion, marked the beginning of the third 
revolution in biology, with carbohydrate molecules joining the ranks of proteins and nucleic 
acids as determinants of biological activity.1 
During the next 30 years, the biological functions of carbohydrate molecules came under 
intense scrutiny, resulting in the discovery of their roles in mediating such diverse cell-cell 
recognition phenomena as viral and bacterial infection,2 tumor cell metastasis,3 and leukocyte 
                                                     
1 Inbar, M.; Sachs, L.  Nature 1969, 223, 710. M. Inbar, L. Sachs, Proc. Natl. Acad. Sci. USA, 1969, 63, 1418. 
2 Paulson, J. C. "Interaction of animal viruses with cell surface receptors." In The Receptors. Vol. II.  P. M. Conn, Ed. 
Academic Press : New York, 1985, 131. 
3 Sell, S. Human Pathology 1990, 21, 1003 and references cited therein. 
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adhesion during inflammation4 (Figure1.1).5 It is now clear that the mystery of 
carbohydrates, with their enormous structural complexity, is only just becoming to unravel. 
 
 
 
Figure 1.1 Surface Carbohydrates on a cell serve as points of attachment for other cells, infectious bacteria, viruses, toxins, 
hormones and many other molecules. 
 
 
                                                     
4 Brandley, B. K.; Sweidler, S. J.;  Robbins, P. W. Cell 1990, 63, 861. 
5 Sharon, N.; Lis, H. Sci. Am. 1993, 268, 74. 
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1.2 Synthetic Carbohydrate-Based Vaccines 
 
1.2.1 Introduction  
The first successful immunization was carried out by Edward Jenner in the late 18th century. He 
demonstrated that the purposeful inoculation of a young boy with cowpox provided later protection 
against the related and more deadly pathogen smallpox. He dubbed the process vaccination after the 
Latin word vacca for cow. Jenner’s medical breakthrough and subsequent investigations set the 
stage for the development of modern vaccines to treat numberous diseases such as rabies, 
diphtheria and polio.  Today, scientists continue to research new vaccines that recruit the body’s 
own immune system to treat diseases such as HIV and cancer as well as to treat infections 
caused by bacteria, viruses, and parasites.  
 
First-generation vaccines still in use today include those of the live-attenuated, killed, and toxoid 
variety. With the advent of molecular biology and improvements in synthetic and analytical 
methodologies, the preparation of next-generation vaccines based on purified subunits and the 
production of attenuated strains containing programmed genetic modifications have recently 
become possible. Such a strategy of using fully synthetic immunogens with defined compositions 
affording highly reproducible biological properties marks an important advance in immunology. One 
important new direction in vaccine research is the use of conjugate vaccines which are vaccines in 
which a mild antigen (one that is weak enough as to not elicit an immune response) is bound to a 
stronger antigen (one that will almost definitely elicit an immune response) in order to force the 
body's immune system to recognize it and develop antibodies. The particular focus of our group 
involves the covalent attachment of nonhydrolyzable carbohydrate-based antigens to an immunogenic 
carrier to create a cancer vaccine. Through conjugation with an immunogenic carrier such as a 
peptide or protein, a normally non-immunogenic carbohydrate antigen can be presented to the body’s 
immune system in an effective way.6 
There are many factors to consider when designing a carbohydrate-protein conjugate vaccine 
including the nature of the carrier protein, selection of the carbohydrate antigen, the ratio of 
protein to carbohydrate, the length and flexibility of the linker binding the two components, as 
well as the overall homogeneity of the system.   
                                                     
6 Stacy, J. K. Danishefsky, S. J. Carbohydrate-Based Druge Discovery 2003, 1, 381. 
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The various methods for generating the glycoconjugates and for the synthesis of the non-
hydrolysable carbohydrate domains will discussed in chapter 4. In this chapter we will focus on 
vaccines containing completely synthetic carbohydrate antigens.6 
  
The carbohydrate-based antigens necessary for cancer vaccines must necessarily be produced 
synthetically as they are not readily available from natural sources. Their production in quantities 
sufficient for vaccine research has long been a major hurdle to expansion in the field and it is here 
that recent advances in glycosylation methods play a pivotal role.7-9  Recently developed synthetic 
methodologies afford access to complex oligosaccharides with precisely known structure and 
stereochemistry and high purity and offer the advantage of being able to introduce new chemical 
modifications to the carbohydrate domain during the optimization of the vaccine construct. Thus, 
conjugate vaccines that contain completely synthetic carbohydrate domains are now emerging as 
an increasingly feasible and powerful way of producing new vaccines targeted to cancer, as well 
as bacteria and parasites. 
 
1.2.2 Cancer Vaccines 
Cells express a multitude of different carbohydrate epitopes on their surfaces.  Cancerous cells 
can often be identified by patterns of aberrant glycosylation and there is typically a direct 
correlation between the cancer’s progression and the level of expression of the antigens 
associated with it.  These can be in high abundance on the surface of cancerous cells, often as 
high as 107 per cell for certain antigens.  Tumor antigens are classified into four groups: 
gangliosides, glycophorins, blood group determinants, and the globo series.10 Most have been 
discovered through the use of monoclonal antibodies (mAb), but a few have been isolated by direct 
extraction from tumors. 
Antibodies are the primary mechanism by which the immune system eliminates pathogens from 
the bloodstream. Thus, the use of vaccines based on synthetic carbohydrate antigens to stimulate the 
production of antibodies to tumor antigens might be ideally suited for the targeting and elimination of 
                                                     
7 Schmidt, R. R. in Comprehensive organic synthesis: selectivity, strategy and efciency in modem organic 
chemistry, Trost, B. M., Fleming, I., Eds.; Pergamon Press, Inc., 1991, Vol. 6, pp. 33-64. 
8 Danishefsky, S.J.; Bilodeau, M.T. Angew. Chem., Int. Ed. Engl. 1996, 35, 1380. 
9 Seeberger, P.H.J. Carbohydr. Chem. 2002, 21, 613. 
10 Hakomori, S.-I. Adv. Cancer Res. 1989, 52, 257. 
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circulating tumor cells and mecrometastases11 There are many factors to be taken into account in 
considering such a strategy. 
Carbohydrates are characterized as T-cell-independent antigens and give rise primarily to IgM 
antibodies, which are effective for complement activation in the intravascular space. Even with 
repeated vaccinations, class switching to IgG antibodies (which are the most important complement 
activators extravascularly) is rarely observed. Complement activation at the cellular surface 
mediates inflammatory reaction, opsonization for phagocytosis, clearance of antibody complexes 
from the circulation, and membrane-attack-complex mediated lysis. Conjugating a carbohydrate 
antigen with an immunogenic carrier protein is critical in surmounting this lack of T cell help. 
Appropriate conjugation can induce higher IgM antibody counts and partial class switching to IgG 
antibodies thereby inducing helper T cell activation. The antibodies generated are ideally suited for 
action in the adjuvant setting where the targets are micrometastatic and circulating tumor cells. 
The critical objectives of preclinical cancer vaccine programs can be separated into four 
stages: 
(1) The development of strategies and methodologies for the chemical synthesis of antigen 
constructs bearing complex oligosaccharide domains. 
(2) The selection of an appropriate spacer domain to be introduced between the carbohydrate 
antigen and the protein domain. 
(3) The selection and attachment of the immunogenic carrier protein or other immunostimulant 
by a covalent bond. 
(4) Studies using murine hosts to evaluate the immunogenicity of the construct. Should the 
results from preclinical studies prove to be positive, petition can then be made for advancing 
the vaccine to human clinical trials. A detailed review of these approaches developed in the 
Danishefsky laboratory is available.12 
 
 
1.2.3 Carrier Proteins 
As mentioned previously, the use of a suitable carrier is crucial to the development of 
carbohydrate-based cancer vaccines.  While moieties including dendrimers, lipids, and peptidic 
T-cell epitopes have been explored, most carbohydrate conjugate vaccines rely on the use of 
carrier proteins. Among the many different carrier proteins that have been investigated in this 
regard are bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), and bacillus 
                                                     
11 Livingston, P.O.; Zhang, S. L.; Lloyd, K.O. Cancer Immunol. Immunother. 1997, 45, 1. 
 
12 Danishefsky, S. J.; Allen, J. R. Angew. Chem., Int. Ed. Engl. 2000, 39, 836. 
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Calmette-Guérin (BCG). The use of KLH, a very large protein (5 x 106 Da) isolated from a marine 
gastropod,13 has thus far proven to be superior to others in the majority of cases.14 
Figure 1.2 shows several gangliosides (GM2, GD2, GM3) that are considered attractive 
targets for anticancer vaccines since the acidic glycosphingolipids are overexpressed in various 
cancer types such as melanoma, glioma, seminoma, lung cancer, colon cancer, renal cancer, and 
prostate cancer.15-17 GM2 is immunogenic in humans as evidenced by the presence of naturally 
occurring serum antibodies to GM2 which are cytotoxic to GM2+ cancer cells. Human GM2 mAbs 
are easily isolated after stimulating their production in melanoma patients by vaccination with 
GM2-containing vaccines. Those melanoma patients possessing GM2 antibodies appear to have a 
more favorable prognosis regardless of whether they were induced by vaccination or a natural 
occurrence. No negative effects have been observed upon vaccination with GM2-based vaccines 
and early clinical studies of GM2 with different carriers showed that the GM2-KLH conjugate, with 
QS-21 as an adjuvant,18 was highly immunogenic, more so than GM2-BCG conjugates with 
Detox or GM2Lipid A liposomes. The phase III clinical trials with GM2-KLH plus QS-21 
currently in progress do not use synthetic GM2. However, a practical and total synthesis of GM2 
has been published,19 and preclinical data from mouse models have shown the synthetic GM2-
KLH conjugate to be equally effective. Clinical trials in melanoma patients with the synthetic 
construct are ongoing.20 
The first tumor-associated carbohydrate antigens to be discovered were found in epithelial cell 
mucins10 which possess extensive serine/threonine α-linked-O-glycosylated domains in clustered 
form (i.e., glycosylated serine/threonine repeats). The Thomsen-Friedenreich (TF) antigen was first 
described as a tumor-associated antigen by Springer in 1984.21 The increased expression of the TF 
antigen as well as the Tn and sialyl-Tn (STn) antigens is thought to result from changes in the 
regulation of certain glycosyltransferases.22 The less studied and more complex glycophorins 2,3-
STF, 2,6-STn, and glycophorin represent another interesting group of carbohydrate antigens. 
The STn antigen is expressed in more than 80% of cancers of the breast, prostate, and ovaries while 
its expression in normal tissues is much reduced and restricted to a handful of epithelial tissues at 
                                                     
13 Markl, J.; Lier, B.; Gebauer, W.; AltenHein, B.; Meissner, U.; Harris, J. R. J. Cancer Res. Clin. Oncol. 2001, 127, R3. 
14 Musselli, C.; Livingston, P.O.; RaguPathi, G. J. Cancer Res. Clin. Oncol. 2001, 127, R20. 
15 Ragupathi, G. Cancer Immunol. Immunother. 1996, 43, 152 
16 Livingston, P.O.; Ragupathi, G. Cancer Immunol. Immunother. 1997, 45, 10. 
17 Zhang, S.; Cordon-Cardo, C.; Zhang, H. S.;Reuter, V E.; Adluri, S.; Hamilton, W. B.; Lloyd, K.O.; Livingston, P. 
O. Int. J. Cancer 1997, 73, 42. 
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secretory borders.23 Overexpression of STn in certain carcinomas is associated with an aggressive 
phenotype and worsened prognosis.24 Immunization with STn has been shown to be effective in 
inducing anti-STn antibodies thereby protecting mice from subsequent tumor risk with syngeneic 
cancer cell lines expressing STn.25 The STn antigen has been identified as an attractive target for 
antibody-mediated cancer immunotherapy by both active and passive immunotherapy studies. 
This is consistent with a growing body of evidence of the capability of antibodies against 
defined tumor antigens to protect against circulating tumor cells and micrometastases.11,16 
Subjects with a variety of epithelial cancers have been immunized with an STn-KLH 
conjugate with various additional adjuvants resulting in high-titer IgM and IgG anti-bodies against 
STn. Phase III clinical trials in breast cancer patients with the Theratope® vaccine and Detox as 
the adjuvant are currently underway.26 The two domains of the conjugate are linked by ozonization of 
the STn crotyl monomer to introduce an aldehyde followed by reductive amination with the ε-
amino groups of lysine residues on KLH (see Fig. 1.3 for structures). 
Monoclonal antibodies against STn have been shown to recognize not only STn monomers, but 
also STn clusters (STn(c)), indicating the STn antigen is identified in at least two distinct 
configurations at the cancer cell surface.27 The STn(c) studied consisted of a linear tripeptide 
containing serine or threonine residues bearing the carbohydrate antigen attached to the hydroxyl 
side chain. STn-KLH and STn(c)-KLH conjugates were prepared containing either a two carbon linker 
or the recently developed heterobifunctional 4-(4-maleimido-methyl)cyclohexane-1-carboxylic acid 
hydrazide 28 (MMCCH) linker, and their corresponding immunogenicities in mice were evaluated 
and compared. Conjugation with MMCCH gave a better conjugation efficiency (yield) and 
higher titers against OSM and STn-positive tumor cells and is currently the method of choice for the 
preparation of STn(c) vaccines.29 
 
                                                     
23 Zhang, S.; Zhang, H. S.; Cordon-Cardo, C.; Reuter, V. E.; Singhal, A. K.; Lloyd, K.O.; Livingston, P.O.  Int.J. 
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25 Fung, P. Y. S.; Madej, M.; Koganty, R.R.; Longenecker, B. M. Cancer Res. 1990, 50, 4308. 
26 Holmberg, L.A.; Sandmaier, B. M. Expert Opin. Biol. Th. 2001, 1, 881. 
27 Zhang, S.L.; Walberg, L. A.; Ogata, S.; Itzkowitz, S. H.; Koganty, R. R.; Reddish, M.; Gandhi, S. S.; 
Longenecker, B. M.; Lloyd, K.O.; Livingdton, P.O. Cancer Res. 1995, 55, 3364. 
28 Ragupathi, G.; Koganty, R. R.; Qiu, D. X.; Lloyd, K.O.; Livingston, P.O. Glycoconjugate J. 1998, 15, 217. 
29 Ragupathi, G.; Howard, L.; Cappello, S.; Koganty, R.R.; Qiu, D. X.; Longenecker, B.M.; Reddish, M.A.; Lloyd, 
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Figure 1.2 Structures of the gangliosides used or considered for use in human cancer vaccines 
 
In an effort to mimick the clustered motifs of the glycophorin carbohydrate antigens recognized 
by the immune system, Danishefsky et al. developed a general method for the construction of 
glycoamino acids and their incorporation into glycopeptides. In their "cassette" strategy, essentially a 
modular rather than a convergent approach, the basic building block, an N-acetylgalactosamine 
(Ga1NAc) synthon is stereospecifically linked to a serine, threonine, or hydroxynorleucine, with a 
differentiable acceptor site on the Ga1NAc as shown in Scheme 1.1. This construct serves as a 
general insert or ‘cassette’ to be used in subsequent glycosylations with other saccharides.30 In 
this way, the synthetically difficult O-linkage step is accomplished early in the synthesis on a 
simple monosaccharide. Following deprotection of the monosaccharide, a new acceptor site is 
then exposed for subsequent glycosylations. This method has successfully been used to 
synthesize various clustered antigen structures built on a peptide backbone.31-33 
Using the cassette methodology, the synthesis of the clustered epitope of Tn, shown in Fig. 1.4, was 
realized.31 A heterobifunctional linker, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 
was used to crossconjugate the Tn(c) to KLH or BSA to give the desired vaccine constructs. Results 
from preclinical ELISA studies showed that the conjugates in combination with QS-21 as the 
adjuvant were able to generate both IgM and IgG antibodies in mice following three 
immunizations, with the KLH construct vaccine proving to be the more immunogenic.31 Tn(c) 
positive LS-C colon cancer cells and Tn(c) negative LS-B colon cancer cells were used to evaluate 
the cell surface reactivities of the anti-Tn(c) antibodies. Sera from mice vaccinated with either of the 
conjugates plus adjuvant showed clear IgM reactivity and significant IgG reactivity by flow 
                                                     
30 Chen, X.T; Sames, D.; Danishefsky, S. J. J. Am. Chem. Soc. 1998, 120, 7760. 
31 Kuduk, S. D.; Schwarz, J. B.; Chen, X.T.; Glunz, P.W.; Sames, D.; Ragupathi, G.; Livingston, P.O.; Danishefsky, 
S. J. J. Am. Chem. Soc. 1998, 120, 12474. 
32 Glunz, P. W; Hintermann, S.; Schwarz, J. B.; Kuduk, S. D.; Chen, X.T.; Williams, L.J.; Sames, D.; Danishefsky, S. 
J.; Kudryashove, V.; Lloyd, K.O. J. Am. Chem. Soc. 1999, 121, 10636.  
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cytometry assays and complement-dependent cytotoxicity assays. A recently completed Phase I 
clinical trial in patients with prostate cancer using the KLH conjugate yielded positive serological 
results accompanied by stabilizing or declining prostate specific antigen (PSA) levels.34 
The cassette approach has also been used to prepare other glycophorin clusters, including TF,31 STn 
33, and 2,6-STF 35 (Fig. 1.5), as well as a Lewisy (Ley) cluster. Immunological evaluations of the TF(c)-
MBS-KLH and STn(c)-MBS-KLH constructs produced similar results and the evaluation of other 
glycophorin antigens is currently being pursued. 
Ley is a blood group determinant that has been identified as a critical epitope for eliciting antibodies 
against cancers of the colon and liver and has also been implicated in breast, prostate, and ovarian 
tumors. In the first Ley-containing vaccine, shown in Fig. 1.6, the pentasaccharide Ley allyl glycoside 
monomer was linked to the carrier protein by reductive amination while later constructs employed 
MBS-derivatized KLH for conjugation. Based on preclinical results in mice confirming the increased 
formation of antibodies that recognized tumor cells expressing the antigen,36 a Phase I clinical 
trial in ovarian cancer patients was initiated using the conjugate vaccine in combination with the 
adjuvant QS-21.37 The trial was successful at the serological level in that the vaccine induced an 
antibody response in 75% of the patients. 
                                                                                                                                                                    
33 Schwarz, J. B.; Kuduk, S. D.; Chen, X.T; Sames, D.; Glunz, P.W.; Danishefsky, S. J. J. Am. Chem. Soc. 1999, 
121, 2662.  
34 Keding, S; J.; Danishefsky, S. J. Carbohydrate-Based Drug Discovery 2003, 1, 381.  
35 Sames, D.; Chen, X.T; Danishefsky, S. J. Nature 1997, 389, 587. 
36 Kudryashov, V.; Kim, H. M.; Ragupathi, G.; Danishefsky, S.J.; Livingston, P.O.; Lloyd, K.O. Cancer Immunol. 
Immunother. 1998, 45, 281.  
37 Sabbatini, P.; Kudryashov, V.; Ragupathi, G.; Danishefsky, S.; Livingston, P.; Bornmann, W.; Spassova, M.; 
Zatorski, A.; Spriggs, D.; Aghajanian, C.; Solgnet, S.; Peyton, M.; O’Flaherty, C.; Curtin, J. ; Lloyd, K. Clin. 
Cancer Res. 2000, 6, 450. 
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Figure 1.3 Structures of STn monomer and its corresponding conjugate vaccine 
 
 Furthermore, the vaccine was well tolerated and no adverse effects related to autoimmunity were 
reported. In an effort to further promote IgG antibody production in addition to the observed IgM 
antibodies, a clustered Ley epitope was explored.38 Though the Ley(c)-peptide-MBS-KLH conjugate 
was indeed capable of eliciting both IgM and IgG responses, the specificity of those responses was 
limited to the immunizing epitope (ELISA). However, FACS analysis with OVCAR-3 cells did 
detect moderate activity (-25% positive cells). 
The KH-1 antigen contains both the Ley tetrasaccharide and the Lex trisaccharide epitopes and its 
overexpression has been observed in a variety of human adenocarcinomas. The KH-1 
nonasaccharide antigen has been synthesized39 and incorporated into vaccines by conjugation to 
KLH via the reductive amination procedure or through use of the MMCCH linker as shown in 
Fig. 1.7.40  Evaluation of the two constructs in mice showed high titers of both IgM and IgG 
antibodies for the MMCCH-construct, while the other generated only IgM antibodies.41 Both 
constructs elicited antibodies that recognized not only the KH-1 antigen, but also the Ley antigen, 
                                                     
38 Kudryashov, V.; Glunz, P.W.; Williams, L.J.; Hintermann, S.; Danishefsky, S. J.; Lloyd, K.O. Proc. Natl. Acad. 
Sci. USA. 2001, 98, 3264. 
39 Deshpande, P. P.; Danishefsky,S. J. Nature 1997, 387, 164 
40 Deshpande, P. P.; Kim, H. M.; Zatorski, A.; Park, T K.; Ragupathi, G.; Livingston, P.O.; Danishefsky, S. J. J. 
Am. Chem. Soc. 1998,120, 1600. 
41 Ragupathi, G.; Deshpande, P. P.; Coltart, D. M.; Kim, H. M.; Williams, L. J.; Danishefsky, S.J.; Livingston, P.O.  
Int. J. Cancer 2002, 99, 207. 
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which resembles the four saccharides at the non-reducing end of the KH-1 nonasaccharide. 
Based on these results, clinical trials are in preparation for the KH-1-KLH vaccine plus adjuvant.  
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Scheme 1.1 Synthesis of cassette: (a) X = OCNHCCl3, R = H, TMSOTf, THF, -78 oC, (b) X = F, R = Me, Cp2ZrCl2, 
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Figure 1.4 Structure of clustered Tn vaccine 
AcHN
H
N
N
H
H
N
RO
O
O
O
H
N
S
RO
RO
O
N
O
O
O
*KLH
TF(c)-MBS-KLH
AcHN
CO2H
HO
O
HO OH
OH
O
O
AcHN
HO
OH
AcHN
CO2H
HO
O
HO OH
OH
O
O
AcHN
O
OH
OH
O
OH
HO
OH
OH
O
AcHN
O
OH
OH
O
OH
HO
OH
n
STn(c)-MBS-KLH 2,6-STF(c)-MBS-KLH  
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First isolated in sub-milligram quantities from a human breast cancer cell line, Globo-H is a 
hexasaccharide that is expressed at the cancer cell surface as a glycolipid. Subsequent 
 23 
 
immunocharacterization by means of the monoclonal antibody MBrl and an immunohistological 
analysis revealed that Globo-H is also expressed in colon, lung, ovary, prostate, and small cell lung 
cancers. Its structure was later fully elucidated by total chemical synthesis and quantities 
sufficient for use in vaccine development can now be produced synthetically.42 
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Figure 1.6 Ley KLH conjugate vaccine 
 
Specifically, both the allyl- and pentenyl-glycosides43 have been synthesized for attaching the linker 
to the protein carrier. Again, the KLH conjugate showed greater immunogenicity than the BSA 
conjugate when administered with QS21 as adjuvant and produced high titer Igm and IgG 
responses against the Globo-H antigen. The antibodies reacted with MCF-7 cancer cells (Globo-
H positive) but not with B78.2 cells (Globo-H negative),44 and were highly effective at inducing 
                                                     
42 Park, T. K.; Kim, I.J.; Hu, S.H.; Bilodeau, M.T.; Randolph, J.T.; Kwon, O.; Danishefsky, S.J. J. Am. Chem. Soc. 
1996, 118, 11488. 
43 Allen, J. R.; Allen, J. G.; Zhang, X.  F.; Williams, L. J.; Zatorski, A.; Ragupathi, G.; Livingston, P.O.; 
Danishefsky, S. J. Chem. Eur. J. 2000, 6, 1366 
44 Ragupathi, G.; Park, T. K.; Zhang, S. L.; Kim, I. J.; Graber, L.; Adluri, S.; Lloyd, K.O.; Danishefsky, S. J.; 
Livingston, P.O. Angew Chem., Int. Ed. Engl. 1997, 36, 125. 
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complement-mediated cytotoxicity (48% lysis). Clinical trials with the Globo-H-KLH vaccine 
are in progress in breast cancer patients.45 
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Figure 1.7 KH-1 nonasaccharide vaccine with variable linkage to carrier protien KLH 
 
 
OH
O
OH
O
HO
OH
O
AcHN
O
O
OH
O
O
HO
HO
HO
O
OH
HO
O
OH
O
OH
HO
HO
OH
O
OH
HO O * *KLH
nGlobo-H-KLH  
Figure 1.8 Globo-H-KLH vaccine used in clinical trials for  treatement of breast, ovarian, and prostate cancer 
 
 
Completed Phase I trial involving 18 patients with progressive and reoccurring prostate cancer 
gave promising results,46,47 Good IgM responses against Globo-H were observed in all immunized 
patients. The antibodies that were produced recognized Globo-H-expressing cell lines, and in 
some cases induced complement-mediated lysis. An analysis of the patients’ PSA levels was also 
carried out and showed that the vaccine may have caused a decline in the slope of the plot of log 
PSA concentration. Furthermore, in those patients initially presented in a non-metastatic state, 
                                                     
45 Gilewski, T; Ragupathi, G.; Bhuta, S.; Williams, L. J.; Musselli, C.; Zhang, X. F.; Bencsath, K. P.; Panageas, K. S.; 
Chin, J.; Huis, C. A.; Norton, L.; Houghton, A. N.; Livingston, P.O.; Danishefsky, S.J. Proc. Natl. Acad. Sci. 
USA 2001, 98, 3270. 
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 25 
 
follow up observations conducted six to nine months after vaccine treatment suggested the 
possibility of favorable changes in PSA slopes having occurred though further studies were 
needed to confirm these claims. Promising data continues to be obtained from patients who 
continue to receive booster injections and are disease free though the connection between PSA 
slopes and early biological efficacy is, at best, anecdotal at this point in time. 
Fucosyl GM1 is a complex carbohydrate antigen that has been identified as a highly specific 
marker associated with small cell lung carcinoma (SCLC) cells. Using methodologies 
originally developed for the synthesis of the Globo-H antigen, the first total synthesis of this 
sialyl-containing hexasaccharide was accomplished by the Danishefsky group.48 By introducing a 
pentenyl glycoside at the reducing end, more efficient syntheses of potential conjugation 
precursors could be achieved. The antigen was conjugated with KLH to yield the vaccine 
shown in Fig. 1.9, and studies in mice are currently ongoing to compare its immunogenicity to 
earlier non-synthetic fucosyl GM1 vaccines.49,50 
All of the abovementioned carbohydrate-based cancer vaccines were designed to target one antigen 
per vaccine. However, it has been well established that several different carbohydrate antigens 
can be associated with any given cancer type and that these antigens may be expressed at 
different levels during the various phases of cellular development. Therefore, it is believed 
strategies that are monovalent in nature may not be sufficient for targeting tumor cells. For 
these reasons there is an increasing interest in polyvalent strategies that target more than one 
antigen that could well provide a heightened and more varied immune response. Two different 
approaches have been taken in this regard. In one, a polyvalent vaccine is produced by the mixing of 
existing monovalent conjugate vaccines. Alternatively, a multivalent conjugate vaccine is 
constructed, in which a single molecule contains the full set of antigens to be targeted. 
Immunological evaluation of a polymolecular method involving four KLH conjugate vaccines 
(GD3-KLH, Ley-KLH, and two peptidic antigens MUC1-KLH and MUC2-KLH, with adjuvant QS-
21) showed promising results in mice. There was no observed decrease in the immunogenicities of 
the individual components in the polyvalent vaccine as evidenced by high titer IgM and IgG 
antibody induction regardless of the method of administration (singly in separate mice, separate 
sites in same mouse, or the same site in mouse).51 The antibodies showed high specificity and 
reactivity toward their respective antigens in tumor cells lines expressing the antigens. 
                                                                                                                                                                    
47 Slovin, S.F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kibornmann, W G.; Fazzari, M.; Dantis, L.; 
Olkiewicz, K.; Lloyd, Danishefsky, S.J.; Scher, H. I. Proc. Natl. Acad. Sci. USA 1999, 96, 5710. 
48 Allen, J. R.; Danishefsky, S.J. J. Am. Chem. Soc. 1999, 121, 10875. 
49 Cappello, S.; Liu, N.X.; Musselli, C.; Brezicka, F.T; Livingston, P.O.; Ragupathi, G. Cancer Immunol. 
Immunother.1999, 48, 483. 
50 Dickler. M. N.;  Ragupathi, G.; Liu, N.X.; Musselli, C.; Martino, D.J.; Miller, V. A..; Kris, M. G.; Brezicka, F. T.; 
Livingston, P.O.; Grant, S. C. Clin. Cancer Res. 1999, 5, 2773. 
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Following these promising results, a series of Phase II clinical trials in breast, ovarian, and 
prostate cancer patients was initiated in which three to seven individual antigen-KLH conjugates 
were used (all of which had been previously investigated in Phase I clinical trials) mixed with 
an immunoadjuvant and administered at a single site. The measured antibody responses will be 
compared to the antibody response elicited by the same conjugates when administered as 
monovalent vaccines. 
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Figure 1.9 Synthetic fucosyl GM-1 conjugate used to investigate development of a SCLC vaccine.  
 
Thanks to various advances in synthetic chemistry, the use of monomolecular multivalent 
conjugate vaccines for the treatment of cancer is now feasible. Two different glycopeptides have 
been synthesized, each one containing three different carbohydrate antigens (Fig. 1.10). One 
construct was based on the natural mucin-type architecture in which the Ley TF, and Tn 
carbohydrate domains are linked to the peptide backbone via serine hydroxyl groups.52 In this 
case the aforementioned serine-Ga1NAc cassette approach was employed. In the other glycopeptide, 
the Globo-H, Lev, and Tn carbohydrate antigens were linked to the peptide backbone via the non-
natural amino acid hydroxynorleucine.53 Based on preliminary investigations of the two 
constructs in which the hydroxynorleucine-based construct was found to be considerably more 
antigenic than the mucin-derived construct, the former was selected for further investigations in 
murine hosts. The hydroxynorleucine-based conjugate vaccine was observed to generate both IgM 
and IgG antibodies, and FACS analysis showed that they react selectively with cancer cells 
expressing those antigens.54 In addition, GPI-0100,55 which is structurally similar to QS-21 but 
considerably less toxic, was tested as an alternative adjuvant and found to be more effective in 
antibody generation. These findings suggest that a single vaccine construct composed of several 
                                                                                                                                                                    
51 Ragupathi, G.; Cappello, S.; Yi, S. S.; Canter, D.; Spassova, M.; Bornmann, W.G.; Danishefsky, S.J.; Livingston, 
P.O. Vaccine 2002, 20, 1030. 
52 Williams, L. J.; Harris, C. R.; Glunz, P. W; Danishefsky, S. J. Tetrahedron Lett. 2000, 41, 9505. 
53 Allen, J. R.; Harris, C. R.; Danishefsky,S. J. J. Am. Chem. Soc. 2001, 123, 1890 
54 Ragupathi, G.; Coltart, D. M.; Williams, L.J.; Koide, F.; Kagan, E.; Allen, Ston, P.O.; Danishefsky, S.J. Proc.  
Natl. Acad. Sci. USA 2002, 99, 13699. 
55 Marciani, D. J.; Press, J. B.; Reynolds, R. C.; Pathak, A. K.; Pathak, V.; Gundy,L. E.; Farmer, J.T.; Koratich, M. S.; 
May, R. D. Vaccine, 2000, 18, 3141. 
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different carbohydrate-based antigens may be capable of stimulating a multifaceted immune 
response.  
 
1.2.4 Lipid Carriers 
The use of lipid carriers is another approach used in the construction of vaccine and offers a number 
of potential advantages. Most lipids carriers are B-cell stimulators that are capable of amplifying the 
proliferation of B-lymphocytes in response to stimulation by antigens. In addition, many lipids are 
completely synthetic and their combination with synthetic carbohydrate antigens can yield 
vaccines that are wholly synthetic, thereby making SAR analyses possible. Fig. 1.11 shows 
several carbohydrate-based vaccines based on lipid carriers. 
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Figure 1.10 structures of two multigenic unimolecular vaccines containing natural and non-natural amino acids in the 
peptide backbone 
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In 1994, an entirely synthetic carbohydrate vaccine was developed containing monomeric, dimeric, 
and trimeric Tn antigens on serine with a 4-aminobutyric acid spacer at the C-terminus.56 These 
were conjugated to ovine serum albumin (OSA) and their immunogenicities were evaluated in 
mice. Conjugates containing dimeric or trimeric Tn antigens elicited a stronger antibody response 
(IgM and IgG) to a Tn-glycoprotein than the conjugate containing the monomeric Tn antigen. 
With the aim of generating a completely synthetic vaccine, the dimeric Tn antigen was also 
conjugated to tripalmitoylglycerylcysteinylserine (Pam3Cys), a potent B-cell and macrophage 
activator, derived from the immunologically active N-terminal sequence of the principal 
lipoprotein of E. coli.57,58 The resulting Di-Tn-Pam3Cys lipopeptide conjugate produced not only a 
high IgM response but also a significant IgG anti-Tn response without the use of a protein 
carrier or additional adjuvants. 59 
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Figure 1.11 Structure of vaccines utilizing lipid carriers. 
 
Pam3Cys, has also been used in the construction of a Ley vaccine.60 The synthetic Ley(c)-peptide-
Pam3Cys exhibited higher immunogenicity compared to the corresponding Le-Pam3Cys and Ley(c)-
                                                     
56 Toyokuni, T; Hakomori, S.-I.; Singhal, A. K. Bioorg. Med. Chem. 1994, 2, 1119. 
57 Bessler, W. G.; Cox, M.; Lex, A.; Suhr, B.; Wiesmuller, K. H.; Jung, G. J. Im munol. 1985, 135, 1900.  
58 Hoffmann, P.; Wiesmuller, K. H.; Metzger, J.; Jung, G.; Bessler, W .G. Biol. Chem. 1989, 370, 575. 
59 Toyokuni, T.; Dean, B.; Cal, S. P.; Bolvin, D.; Hakomori, S.; Singhal, A. K. J. Am. Chem. Soc. 1994, 116, 395.  
60 Glunz, P.W.; Hintermann, S.; Williams, L. J.; Schwarz, J. B.; Kuduk, S. D.; Kudryashov, V.; Lloyd, K.O.; 
Danishefsky, S. J. J. Am. Chem. Soc. 2000, 122, 7273. 
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KLH vaccines when co-administered with adjuvant QS-21, as evidenced by the profile of IgM 
and IgG antibodies produced, and their recognition of cancer cells bearing Ley epitopes.38 
A conjugate molecule containing the ganglioside GM2 antigen linked via a 9-hydroxynonanoate 
spacer to the B-cell stimulatory glycolipid BAYR1005 has been synthesized.20 Rabbits vaccinated 
with this completely synthetic construct in combination with Freund's adjuvant developed IgG 
antibodies against GM2. 
 
1.2.5 T-Cell Epitopes 
 
In place of an immunogenic protein or lipid carrier, researchers have also investigated the 
incorporation of known T-cell epitopes into vaccine constructs in an effort to induce a cytotoxic 
T cell immune response. 
The feasibility of this approach was elegantly demonstrated with a synthetic conjugate of a 
tumor-associated MUC1 glycopeptide antigen and a tetanus toxin epitope connected by a 
spacer.61 Tn-, TF-, and sialyl-Tn-antigen (STn) glycopeptides were incorporated into the tandem 
repeat region of MUC1 at a threonine residue. As only the STn-containing glycopeptide exhibited 
a proliferating effect on peripheric blood lymphocytes, it was chosen for the further development 
of a novel conjugate vaccine. The STn-glycododecapeptide tumor-associated antigen was linked 
with a T-cell epitope of tetanus toxin via a flexible spacer (Fig. 1.12). Proliferation of the vaccine 
was found to proceed only in the presence of antigen-producing cells and not for purified T cells 
and this was taken as evidence of an antigen-specific reactivity. FACS analysis determined that 
the conjugate induced proliferation of up to 100% for CD3+ and 53% for CD8+ T cells. These 
results lend support to the concept of generating a cytotoxic T-cell response to tumor cells by use 
of a synthetic conjugate vaccine bearing T-cell epitopes and tumor-associated MUC glycopeptide 
antigens. 
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Figure 1.12 vaccine containing a B-cell as well as a T-cell epitope to induce a T-cell-dependent immune response. 
 
                                                     
61 Keil, S.; Clus, C.; Dippold, W.; Kunz, H. Angew. Chem., Int. Ed. Engl. 2001, 40, 366. 
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The Tn, TF, STn, and 2,3-STF antigens have also been investigated using this approach. One 
example involved the incorporation of a carbohydrate alkylated homocysteine into a peptide 
sequence known to bind class I MHC molecules on antigen-presenting cells.62,63 In another 
example, four different glycopeptides were synthesized containing variations in both the amino 
acid sequence and the distance between the T-antigen and the peptide scaffold.64  
 
1.2.6 Dendrimers 
Dendrimer have also been investigated as scaffolds for conjugation to carbohydrate domains. 
Like lipids and T cell epitopes, dendrimeric vaccines are completely synthetic and their 
homogeneity can be strictly controlled. Furthermore, there is less likelihood of carrier-induced 
immune suppression when dendrimers are used in place of proteogenic carriers. 
A dendrimeric glycopeptide bearing multiple O-linked Tn carbohydrate antigens along with a 
CD4+ T-cell epitope has been described (Fig. 1.13).65,66 The fully synthetic immunogen possessed 
a high ratio of saccharidic epitope to carrier ratio and was able to induce anti-Tn IgG antibodies 
that recognize human tumor cell lines.67,68 Immunization in tumor-bearing mice significantly 
increased the survival rate. When used in active specific immunotherapy, the dendrimer bearing 
the tri-Tn glycotope was found to be far more effective in promoting mouse survival than both the 
mono-Tn analogue and a linear glycopeptide carrying two copies of the tri-Tn glycotope. A 
similar approach involving a Starburst dendrimer failed to elicit the desired immune response, 
perhaps due to the presence of only dimeric-Tn antigens.56 Well defined synthetic dendrimeric 
systems represent a versatile and efficient tool explore the importance of both the clustering of 
the carbohydrate antigens and the way in which they are presented in trying to generate 
carbohydrate-specific anti-tumor immune responses.  
                                                     
62 George, S. K.; Schwientek, T; Holm, B.; Rets, C.A.; Clusen, H.; Kihlberg, J. J. Am. Chem. Soc. 2001, 123, 11117. 
63 George, S. K.; Holm, B.; Rets, C.A.; Schwientek, T.; Clausen, H.; Kihlberg, J. J. Chem. Soc., Perkin Trans. 1 2001, 
880. 
64 Hilaire, P. M. S.; Cipolla, L.; Franco, A.; Tedebark, U.; Tilly, D.A.; Meldal, M. J. Chem. Soc., Perkin Trans. 1 1999, 
3559. 
65 Bay, S.; Lo-Man, R.; Osinaga, E.; Nakada, H.; Leclerc, C.; Cantacuzene, D. J. Pept. Res. 1997, 49, 620. 
66 Vichier-Guerre, S.; Lo-Man, R.; Bay, S.; Deriaud, E.; Nakada, H.; Leclerc, C.; Cantacuzene, D. J .  Pept. Res. 
2000, 55,173 
67 Lo-Man, R.; Bay, S.; Vichier-Guerre, S.; Deriaud, E.; Cantacuzene, D.; Leclerc, Cancer Res. 1999, 59, 1520. 
68 Lo-Man, R.; Vichier-Guerre, S.; Bay, S.;Eriaud, E.; Cantacuzene, D.; Leclerc, C. J. Immunol. 2001, 166, 2849. 
 31 
 
AcHN
H
N
N
H
H
N
KLFAVWKITYKDT
O
O
O
O
HO
OH
O
AcHN
HO
O
HO
OH
O
AcHN
HO
O
HO
OH
O
AcHN
HO
= R
T-cell epitope
trimeric Tn-antigene
N
NH
O
R
H
NR
HN
O
R
H
N R
OHO
 
Figure 1.13 Dendrimer containing a clustered Tn motif as well as a T-cell epitope used in vaccine development.  
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2 C-GLYCOSIDES 
 
2.1  The C-Glycosides 
It is now well established that cell surface carbohydrates participate in key molecular recognition 
events with protein receptors. Although such interactions are important elements for cell-to-cell 
recognition and binding, they may also be harmful in that they provide the initial steps in bacterial, 
viral infection,69 as well as cell adhesion in inflammation70 and metastasis.71 Strategies for the 
prevention of such diseases include the preparation of soluble carbohydrate-based pharmaceuticals 
which may inhibit this recognition event by preferential binding to the protein receptor. An important 
class of glycomimetics includes the carbon-linked glycosides: C-glycosides in which the oxygen atom 
at the glycosidic linkage has been replaced with a carbon atom (figure 2.1).72  
RX
HO
OH
O
OH
HO
X = CH2, C-glycosid  
Figure 2.1 Carbon-linked glycosides 
 
C-Glycosides are resistant to both chemical and enzymatic hydrolysis of the glycosidic bond, and can 
be readily synthesised from simple sugars. These properties make C-glycosides particularly well 
suited for use as agents and synthetic tools for studying biological events. 
                                                     
69 Paulson, J. C. "Interaction of animal viruses with cell surface receptors." In The Receptors. Vol. II.  P. M. Conn, Ed. 
Academic Press: New York, 1985, 131. 
70 Brandley, B. K.; Sweidler, S. J.; Robbins, P. W. Cell  1990, 63, 861. 
71 Sell, S. Human Pathology 1990, 21, 1003 and references cited therein. 
72 For reviews of the chemistry and biology of C-glycosides see: a) Hacksell,U.; Davies, D. Prog. Med. Chem. 1985, 22, 1. 
b)  Buchanan, J. G. Prog. Chem. Org. Nat. Prod. 1983, 44, 243. c) Goodchild, J. Top. Antibiot. Chem. 1982, 6, 99. d) 
Special issue, Carbohydr. Res. 1987, 171. 
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2.2  Physical Properties of C-Glycosides 
 
The potential for C-glycosides to mediate biological processes involving carbohydrate-protein 
recognition depends upon their structural similarity to the native O-glycosyl derivatives. The 
substitution of a methylene group for an oxygen atom results in a change in both the size and 
electronic properties of the glycosyl linkage (Table 2.1). 
 
Table 2.1: Physical properties of oxygen and carbon linkages. 
Property Oxygen Carbon 
Van der Waals Radius 1.52 Å 2.0 Å 
Hydrogen Bonding Acceptor None 
Electronegativity 3.51 2.35 
Dipole Moment 0.8 D (C-O) 0 D (C-C) 
 
Replacement of the oxygen atom with a methylene group destroy the hydrogen bonding ability of the 
glycosyl side chain, which may reduce the binding affinity of the C-glycoside if specific hydrogen 
bonds to this oxygen atom are involved in recognition. Because oxygen is more electronegative than 
carbon (3.51 and 2.35 respectively on the Pauling scale), the C-O bond has a strong dipole moment 
(ca. 0.8 Debye) whereas the C-C bond does not. Therefore, interactions between local dipoles of the 
receptor and ligand may be affected by substitution of the C-glycoside. Finally, the dipole moment 
and hydrogen bonding ability of the O-linkage render it better solvated in an aqueous environment 
than the C-linkage. In this regard, the more hydrophobic C-glycoside gains a greater entropic 
advantage by interacting with a protein receptor and may bind with higher affinity, an effect that is 
well documented in protein-ligand studies.73 
Although the differences noted above can affect receptor binding activity, perhaps the most important 
consideration is the conformational similarity of C- and O-glycosides in solution. The conformation 
of O-linked glycosides around the glycosidic bond is governed by steric factors and by a 
stereoelectronic phenomenon termed the "exo-anomeric effect". The exo-anomeric effect is the 
antiperiplanar alignment of a lone pair orbital of the glycosidic oxygen and the bond between the ring 
oxygen and anomeric carbon. As a consequence, the aglycon group (R) tends to be away from the 
sugar ring substituents as indicated in the gauche form to reduce the steric hindrance (Scheme 2.1). 
                                                     
73  Jencks, W. P. Catalysis in Chemistry and Enzymology. Dover Publications, Inc.:New York, 1969. 
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Though the exo-anomeric and steric effects are the main factors that govern the glycosidic torsion 
angles, the steric effect of C-linked saccharides has been found to play a major role in maintaining 
the conformation of C-linked saccharides in the gauche form, similar to the conformation in the 
corresponding O-linked sugars. 
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Scheme 2.1: The exo-anomeric and steric effects on the conformation of a glycoside, and energetic consequence of changing 
an O- glycoside to a C-glycoside.74  
 
Kishi and al. demonstraded that "it is possible to predict the conformational behavior around the 
glycosidic bond of given C-saccharides by placing the C1’-C2’ bond antiperiplanar to the Cα-Cn bond 
and then focusing principally on the steric interaction around the non-glycosidic bond." This 
postulate was demonstrated utilising a diamond lattice to arrange the glycosidic conformations of 
various C-disaccharides and of the C-trisaccharide analogue of blood group determinant (figure 
2.2).75  
However, more rigorous studies performed by Jiménez-Barbero have demonstrated that certain C-
glycosides are more flexible, possessing other non-exo-anomeric conformations.76 
 
 
 
                                                     
74 Lemieux, R. U. Acc. Chem. Res. 1996, 29, 373 
75  a) Goekjian, P. G.; Wu,T.-C.; Kishi,Y.; J. Org. Chem. 1991, 56, 6412.b) Goekjian, P. G.; Wu,T.-C.; Kishi,Y.; J. Org. 
Chem. 1991, 56, 6422. c) Wang, Y. ; Babirad, S. A.; Kishi,Y. J. Org. Chem. 1992, 57, 468. d) Wang, Y.; Goekjian, P. G.; 
Ryckman, D. M.; Miller, W. H.; Babirad, S. A.; Kishi, Y. J. Org. Chem. 1992, 57, 482.  
76  Espinosa, J. -F; Dietrich, H.;  Martin-Lomas, M.; Schmidt, R. R; Jiménez-Barbero, J. Tetrahedron Lett. 1996, 37, 1467. 
Espinosa, J. -F.; Cañada, F. J.; Asensio, J. L.; Dietrich, H.; Martin-Lomas, M.; Schmidt, R. R.; Jiménez-Barbero, J. Angew. 
Chem. Int. Ed. Engl. 1996, 35, 303. Espinosa, J. -F.; Cañada, F. J.; Asensio, J. L.; Martin-Pastor, M.; Dietrich, H.; Martin-
Lomas, M.;  Schmidt, R. R.; Jiménez-Barbero, J.  J. Am. Chem. Soc. 1996, 118, 10862.  
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Figure 2.2: C-Trisaccharide of blood group determinants in diamond lattice. 
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2.3 The synthesis of C-glycosides: 
2.3.1 Introduction 
Carbohydrate analogs in which a carbon atom substitutes for the glycosidic oxygen are called C-
glycosides. During the last two decades, the synthesis of C-glycosides has become an area of intense 
study among carbohydrate chemists and biochemists because:  
1) The discovery of naturally occurring C-nucleosides with important pharmacological properties77 
gave impetus to synthetic efforts for preparing active carbohydrate analogs; 
 2) The requirement of C-glycoside chiral building blocks in the synthesis of biologically important 
macromolecules, such as palytoxin,78 spongistatin79,80 and halichondrin B,81 has stimulated the 
development of the new synthetic methodologies;  
3) C-glycosides are potential inhibitors of carbohydrate processing enzymes and are stable analogs of 
glycans involved in important intra- and inter-cellular processes.82-85 
C-glycoside synthesis has been reviewed by Postema,86 Levy,87 Sinay,88 Beau,89 Nicotra,82 Vogel,90 
and McGarvey.91 In this chapter we are going to cover some of the latest development published 
during the last four years and that are not mentioned in the earlier reviews. 
                                                     
77 Suhadolnik, R. J. Nucleoside Antibiotics; Wiley-Interscience: New York, 1970 
78 Lewis, M. D.; Cha, J. K.; Kishi, Y. J. Am. Chem. Soc. 1982, 104, 4976. 
79 Paterson, L.; Keown, L.E. Tetrahedron Lett. 1997, 38, 5727. 
80 Smith, III., A.B.; Zhuang, L.; Brook, C.S.; Boldi, A.M.; McBriar, M.D. et. al. Tetrahedron Lett. 1997, 38, 8667. 
81 Horita, K.; Sakkkurai, Y.; Nagasawa, M.; Hachiya, S.; Yonemitsu, O. Synlett 1994, 43. 
82 Nicotra, F. Topics Curr. Chem. 1997, 187, 55. 
83 Weatherman, R. V.; Mortell, K. H.; Chervenak, M.; Kiessling, L. L.; Toone, E. J. Biochemistry 1996, 35, 3619. 
84 Weatherman, R.; Kiessling, L. L. J. Org. Chem. 1996, 61,534-538. 
85 Sutherlin, D. P.; Stark, T. M.; Hughes, R.; Armstrong, R. W. J. Org. Chem. 1996, 61, 8350. 
86. a) Postema, M. H. D.; Piper, J. L.; Liu, L.; Shen, J.; Faust, M.; Andreana, P.. J. Org. Chem. 2003, 68, 4748. b) Liu, Lei; 
Postema, M. H. D. J. Am. Chem. Soc. 2001, 123, 8602.  c) Postema, M. H. D. C-Glycoside Synthesis; CRC press: Boca 
Raton, 1995 
87 Levy, D. E.; Tang, C. The Chemistry of C-glycosides; Pergamon: Oxford, 1995 
88 a) Caravano, A.; Mengin-Lecreulx, D.; Brondello, J.-M.; Vincent, S. P.; Sinay, P. Chem. Eur. J. 2003, 9, 5888. b) Sinay, 
P. Pure & Appl. Chem. 1997, 69, 459. 
89 a) Abdallah, Z.; Doisneau, G.; Beau, J.-M. Angew. Chem., In. Ed. Engl. 2003, 42, 5209. b) Beau, J.-M.; Gollagher, T. 
Topics Curr. Chem. 1997, 187, 1. 
90 a) Robina, I.; Vogel, P.. Synthesis. 2005, 5, 675. b) Awad, L.; Riedner, J.; Vogel, P. Chem. Eur. J. 2005, 11, 3565. c) 
Steunenberg, P.; Jeanneret, V.; Zhu, Y-H.; Vogel, P. Tetrahedron: Asymmetry. 2005, 16, 337. d) Demange, R.; Awad, L.; 
Vogel, P. Tetrahedron: Asymmetry 2004,15, 3573. e) Navarro, I.; Vogel, P. Helv. Chim. Acta. 2002, 85, 152. f) Vogel, P.; 
Ferritto, R.; Kraehenbuehl, K.; Baudat, A. in Carbohydrate Mimics, Concepts and Methods, Ed. Chapleur, Y.; Wiley-VCH, 
Weinheirn 1998, Chapter 2, p. 19-48. g) Vogel, P. Curr. Org. Chem. 2000, 4, 455. 
91  Schmidtmann, F. W.; Bendum, T. E; McGarvey, G. J. Tetrahedron Lett. 2005, 46, 4681. 
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2.3.2 Ruthenium-catalyzed cross-metathesis 
2.3.2.1 Intramolecular cross-methathesis: 
Postema et al. have prepared a small library of differentially-linked β-C-disaccharides. They used a 
radical allylation-RCM strategy.86a Acids 2 were prepared by Keck allylation of a suitable 
carbohydrate-based radical precursor, followed by oxidative cleavage of the formed alkene. 
Dehydrative coupling of these acids with the known alkenol 1 then gave the corresponding esters 3 in 
excellent yield. Methylenation of 3 and subsequent RCM and in situ hydroboration/oxidation of the 
so-formed glycals furnished the corresponding protected β-C-disaccharides 6 in good overall yield.  
OH O
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R2HO2C
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+ H2O O OR1
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n
X
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3: X = O
4: X = CH2LnM =
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56  
Scheme 2.2: RCM approach to C-saccharides 
 
The method developed is a general approach for the synthesis of C-glycosides92 and a variety of β-C-
disaccharides.93,94(Scheme 2.3). This approach to C-disaccharides synthesis begins with the 
dehydrative coupling of olefin alcohol 8 with a suitable carbohydrate based acid like 7 that gives the 
corresponding ester 9. Methylation,95 followed by RCM96 gives glycal 11. Hydroboration97 of the 
alkene moiety affords the gluco-β-C-disaccharide 12. Optimization was realized by the development 
of the three-step protocol (55% overall yield for the three steps). 
                                                     
92 Postema, M. H. D.; Calimente D. J. Org. Chem. 1999, 64, 1770. 
93 Postema, M. H. D.; Calimente D.; Lui, L.; Behrmann, T. L. J. Org. Chem. 2000, 65, 6061. 
94 Postema, M. H. D.; Calimente D. Tetrahedon Lett. 1999, 40, 4755. 
95 Takai, K.; Kakiuchi,T.; Kataoka, Y; Utimoto, K. J. Org. Chem. 1994, 59, 2668. 
96 Trnka, T.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18. 
97 Hanessian, S.; Martin, M.; Desai, R. C., J. Chem. Soc. Chem. Commun. 1986, 926. 
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Scheme 2.3: Synthesis of C(1’→4) disaccharide using a RCM strategy by Postema and co-workers. 
 
This methodology was also applied to the synthesis of C-(1’→1) disaccharides. Ester 14 was 
methylated and the protocol described above was applied (Scheme 2.3). Finally, deprotection by 
hydrogenolysis gave the fully deprotected β-C-(1’→1)-disaccharide 17 in 64% overall yield (Scheme 
2.4). The use of Grubbs catalyst allows the cyclization to be carried out readily with bench top 
techniques. Together with the one-pot approach this methodology has become quite practical, and, to 
my opinion, can be seen as an equivalent for the synthesis of C-disaccharides to the methodology 
developed for the synthesis of O-disaccharides by Seeberger. 
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Scheme 2.4: Synthesis of C(1’→1) disaccharide using a RCM strategy by Postema et al. 
 
 39 
 
The synthesis of the first branched C-tetrasaccharide give a better insight in the impressive work of 
Postema (Scheme 2.5).98 Alcohol 8 was coupled with the suitable carbohydrate-based triacid 18, to 
provide triester 19 in 80% yield. Methylanation is followed by a triple RCM reaction99 with the second 
generation Grubbs’ catalyst,100 to furnish the tris-C-glycal. Hydroboration of the triple alkene bonds 
afforded the β-C-tetrasaccharide 23 in 44% overall yield. 
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Scheme 2.5: First synthesis of a branched β-C-tetrasaccharide using a triple RCM cyclization. 
 
2.3.2.2 Intermolecular cross-methathesis: 
Robert N. Ben and co-workers have prepared a series of C-linked antifreeze glycoprotein analogues 
for their evaluation as antifreeze agents as a function of the distance separating the carbohydrate 
moiety from the polypeptide backbone.101 The building blocks for these analogues were prepared 
using either an olefin cross-metathesis or a catalytic asymmetric hydrogenation. 
C-Allylated galactose pentaacetate 24 was prepared via a photochemical-mediated allylation in 90% 
yield.102a C-Glycoside 26 was obtained by reducing 24 with borane followed by PCC oxidation and 
                                                     
98 Piper, J. L; Postema, M. H. D. J. Org. Chem. 2004, 69, 7395. 
99 Grubbs, R. H.; Fu, G. C. J. Am. Chem. Soc. 1992, 114, 7324. 
100 Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953. 
101 Liu, S.; Ben R. N. Org. Lett. 2005, 7, 2385 
102 (a) Ponten, F.; Magnusson, G. J. Org. Chem. 1996, 61, 7463.(b) Perkins, M. V.; Sampson, R. A. Org. Lett. 2001, 3, 123-
126. (c) Abad, A.; Agullo´, C.; Cunat, A. C.; Garcı´a, A. B.; Gimenez-Saiz, C. Tetrahedron 2003, 59, 9523.  
 40 
 
Wittig olefination with methyl triphenyl phosphonium bromide. 102b,c C-(1-Propenyl) glycoside 25, a 
key intermediate in the preparation of AFGP analogue, was generated via a palladium-mediated 
isomerization of 24. Vinyl glycine derivative 27 was obtained in 34% yield from the orthogonally 
protected glutamic acid derivative by oxidative decarboxylation.103 With the requisite building blocks 
in hand, olefin cross-metathesis of 27 with 24, 25, and 26 were conducted using the second- 
generation Grubbs catalyst (Scheme 2.6). As anticipated, building blocks 29 and 30 were obtained in 
quantitative yield (Table 2.2). 
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Scheme 2.6: Preparation of C-Linked Building Blocks 31 and 32 blocks 12 and 
 
 
Unfortunately, cross-metathesis between 27 and 25 furnished building block 28 in only trace 
quantities. Presumably, this is due to the fact that the carbon-carbon double bond in 25 is too close to 
the pyranose ring resulting in significant steric interactions during the OCM. A similar effect has been 
observed by McGarvey et al.104 The carbon-carbon double bonds in enamide esters 29 and 30 were 
reduced by hydrogenation with palladium over carbon. Under these conditions, the Cbz and benzyl 
protecting groups were simultaneously removed necessitating reprotection of the amino terminus as 
an Fmoc carbamate to afford building blocks 31 and 32 in 55% and 85% yield, respectively.  
 
 
 
 
                                                     
103  Bacha, J. D.; Kochi, J. K. Tetrahedron 1968, 24, 2215. 
104  McGarvey, G. J.; Benedum, T. E.; Schmidtmann, F. W. Org.Lett. 2002, 4, 3591.  
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Table 2.2: Olefin Cross-Metathesis To Prepare C-Linked Building Blocks 29-30 
entery C-alkene glycoside product Yield % 
1 24 29 98 
2 25 28 traces 
3 26 30 100 
 
In a second example McGarvey choses to examine a series of substrates with various olefin 
substitutions and proximal functionalities105 (Figure 2.3). Thus C-aminoglycoside substrates A–C 
were constructed.106 In addition to the commercially available dihydroalanine F, allyl and vinyl 
glycines, D and E, were prepared using methods reported by Myers107 and Hanessian,108 respectively. 
 
R2O
OR2
O
AcHN
R2O
R1O
OR1
O
AcHN
R1O
R2O
OR2
O
AcHN
R2O
R3O
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Figure 2.3: Substrates used in the metathesis study and Grubbs second generation catalyst. 
 
The possible cross- and self-metatheses of these substrates was examined using Grubbs second 
generation catalyst (Fig. 2.3). The results are summarized in Table 2.3. The cross-metathesis reactions 
combining C-glycosides A–C with two equivalents of unnatural amino acids D–F are indicated in the 
dashed boxes.109 It was found that allyl glycine D is an effective reaction partner for all three C-
glycosides, giving the various corresponding products 38 and 39 in good yields. It is noteworthy that 
reactions leading to benzyl protected products 38a,b and 39a,b and acetates 38c–e and 39c–e required 
                                                     
105 Maishal, T. K.; Sinha-Mahapatra, D. K.; Paranjape, K.; Sarkar, A. Tetrahedron Lett. 2002, 43, 2263.  
106 McGarvey, G. J.; Schmidtmann, F. W.; Benedum, T. E.; Kizer, D. E. Tetrahedron Lett. 2003, 44, 3775. 
107 (a) For the Fmoc protected form: Myers, A. G.; Gleason, J. L.; Yoon, T.; Kung, D. W. J. Am. Chem. Soc. 1997, 119, 656; 
For the Boc protected form: (b) Myers, A. G.; Gleason, J. L. Org. Synth. 1999, 76, 57; See also: Dominique, R.; Liu, B.; 
Das, S. K.; Roy, R. Synthesis 2000, 6, 862.  
108 Hanessian, S.; Sahoo, S. P. Tetrahedron Lett. 1984, 25, 1425–1428. 
109 Unless otherwise noted, all cross-metathesis reactions were allowed to proceed until consumption of the starting C-
glycoside as noted by TLC analysis. For the case where R1, R2 = Bn, 10 mol % of catalyst was used, whereas 20 mol % of 
catalyst was required for R1, R2 = OAc (see Table 2.3). 
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24 and 48 h respectively. This suggests a significant functional group effect on reactivity. In contrast 
to the allyl amino acids, vinyl glycine E was found to be reactive with only allyl C-glycoside A and 
afforded 40. Unfortunately, attempts to access to a product with a linker length corresponding to 
natural glycoamino acids,41, proved unsuccessful as vinylic C-glycosides B and C did not react with 
E.  
 
Table 2.3: Olefin metathesis study 
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2.3.3 Samarium Iodide-Mediated C-Glycosylation 
Sinaÿ and Beau have shown that glycosylsamarium(III) derivatives, generated from glycosyl chloride 
or sulfones, undergo Barbier-type condensation with carbonyl compounds to form C-glycosides.110,111 
this realizes a very powerful method for the synthesis of C-glycosides. 
Beau and co-workers have obtains an advanced precursor of STn antigen89a using the samarium-
Reformatsky coupling procedure112 with sulfide 42 (1.5equiv) and aldehyde 43. This afforded the 
carbon-linked dimeric product 44a in high yield (93%) as a 1:1 diastereomeric mixture (Scheme 2.7). 
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AcO
S(2-Py)
OMe
O
AcHN
BnO
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O
+
42 43
1) SmI2, THF
2)(Imid)2CS
3) Ph3SnH, C6F5OH, 
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O
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OAcAcO
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Scheme 2.7: Preparation of the carbon-linked sialyl-N-acetylgalactosaminyl donor 44b. 
 
Alcohols 44a were converted into thiocarbonates by treatment with a large excess of N,N’ 
thiocarbonyldiimidazole in refluxing acetonitrile and were then deoxygenated by employing 
triphenyltin hydride a catalytic amount of AIBN and pentafluorophenol.113 This yielded the required 
C-disaccharide 44b as a single compound (65% for the two steps). Desilylation, hydrogenolysis, and 
acetylation provided the peracetylated C-dimer.  
Stereoselective preparation of β-C-glycosides has been developed by Beau and co-workers from 
acetylated glycopyranosyl 2-pyridyl sulfones, involving a samarium-Barbier coupling procedure–
oxidation–isomerization sequence (Scheme 2.8).114 
                                                     
110 de Pouilly, P.; Chenede, A.; Mallet, J.-M.; Sinaÿ, P. Bull Soc. Chim. Fr. 1993, 130, 256.  
111 Mazeas, D.; Skrydstrup, T.; Beau, J.-M. Angew. Chem. Int. Ed. Engl. 1995, 34, 909. 
112 For the reductive samariation of glycyl sulfide derivatives, see Ricci, M.; Madariaga, L.; Skrydstrup, T. Angew. Chem. 
2000, 112, 248; Angew. Chem. Int. Ed. 2000, 39, 242; Ricci, M.; Blakskjaer, P.; Skrydstrup, T. J. Am. Chem. Soc. 2000, 
122, 12413.  
113  Jarreton, O.; Skrydstrup, T.; Beau, J.-M. Chem. Commun. 1996, 1661; Jarreton, O.; Skrydstrup, T.; Beau, J.-M. Chem. 
Eur. J. 1999,5, 430.  
114 Palmier, S.; Vauzeilles, B.; Beau, J.-M. Org.  Blomol. Chem.,2003, 1, 1097. 
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Scheme 2.8: Synthesis of β-C-glycosides 
 
Appling samarium iodide coupling methodology the synthesis of C-linked STn antigen was achieved 
by Linhardt115 in one enzymatic and 17 chemical steps starting from diisopropylidene galactopyranose 
and sialic acid (Scheme 2.9). 
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Scheme 2.9: Synthesis of STn C-glycoside derivatives. 
 
Skrydstrup has used the same methodology to prepare the main building block for a cyclic C-
oligomer containing repeating units of C-dimer. The key step in his synthesis uses a SmI2-mediated 
coupling of 51 with 52, affording the C-disaccharide precursor (Scheme 2.10).116 
                                                     
115  Kuberan, B.; Sikkander, S. A.; Tomiyama, H.; Linhardt, R. J. Angew. Chem. Int. Ed. 2003, 42, 2073. 
116 Mikkelsen, L. M.;Skrydstrup, T. J. Org. Chem. 2003, 68, 2123. 
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Scheme 2.10: Synthesis of STn C-glycoside derivatives. 
 
Linhardt prepared a C-glycoside linking neuraminic acid to serine by using the SmI2 methodology. 
The neuraminic acid derivative 56 was coupled with aldehyde 57 affording the C-glycoside 58 in 
45% yield. Acetylation of the newly generated hydroxymethano linker afforded the fully protected C-
glycoside 59. Removal of THP with pyridinium p-toluenesulfonate (PPTS), followed by oxidation of 
the resulting hydroxyl group, generated L-homoserine C-glycoside derivative 60 (Scheme 2.11).117  
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Scheme 2.11: Synthesis of a serine-based neuraminic acid C-glycoside 
 
 
                                                     
117  Wang, O.; Linhardt, R.  J. J. Org. Chem. 2003, 68, 2668. 
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2.3.4 Radical C-glycosidation: 
Vogel and co-workers have prepared C-disaccharides using enantiomerically pure 7-
oxabicyclo[2.2.1]hept-5-en-2-one (61: a naked sugars of the first generation).118 Reaction of 61 are 
highly diastereoselective. For instance sequence of reactions 61→62→63 have been use to generate 
C-glycosides that are converted into C-disaccharides,119 and analogues.120 Under modified conditions, 
the radical C-mannosidation of 62 between 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl bromide (70) 
is possible in benzene using Ph3SnH as hydrogen donor. This gives 63 in 56% yield (Scheme 2.12). 
This compound can be transformed under standard conditions into the fully deprotected C-linked 
disaccharide 69.121  
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Scheme 2.12: Synthesis of a C-glycoside using the naked sugar methodology. 
 
Guindon and co-workers have shown that the reaction between an anomeric-centered fucosyl-derived 
radical 72 and a galactosylated hydroxytaconate 71 provides an easy access to C,O-diglycosides as 
mimics of sLeX. In this case, two 1,3-distant stereocenters were created with high diastereoselectivity 
using free radical intermediates in a tandem process (Scheme 2.13).122 
                                                     
118 a) Vieira, E.; Vogel, P. Helv. Chim. Acta 1983, 66, 1865. b) Black, K. A.; Vogel, P. Ibid. 1984, 67, 1612. c) Reymond, J.-
L.; Vogel, P. Tetrahedron: Asymmetry 1990, 1, 729. d) Vogel, P.; Fattori, D.; Gasparini, F.; Le Drian, C. Synlett 1990, 173. 
e) Vogel, P. Bull. Soc. Belg. 1990, 99, 295. f) Forster, A.; Kovac, T.; Mosimann, H.; Renaud, P.; Vogel, P. Tetrahedron: 
Asymmetry 1999, 10, 567; see also: g) Saf, R.; Faber, K.; Penn, G.; Griengl, H. Tetrahedron 1988, 44, 389. h) Ronan, B.; 
Kagan, H. B. Tetrahedron: Asymmetry 1991, 2, 75. I) Corey, E. J.; Loh, T.-P. Tetrahedron Lett. 1993, 34, 3979. 
119 Cossy, J.; Ranaivosata, J.-L.; Bellosta, V.; Ancerewicz, J.; Ferritto, R.; Vogel, P. J. Org. Chem. 1995, 60, 8351. 
120 Ferritto, R.; Vogel, P. Synlett 1996, 281. 
121 Pasquarello, C.; Picasso, S.; Demange, R.; Malissard, M.; Berger, E. G.; Vogel, P. J. Org. Chem. 2000, 65, 4251. 
  
 
 
122 Guindon, Y.; Bencheqroun, M.; Bouzide, A. J. Am. Chem. Soc. 2005, 127, 554. 
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Scheme 2.13: Synthesis of C,O-diglycosides under radical conditions 
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2.3.5 C-Glycosidation via Lithiated Anions 
 
Addition of BuLi and lithiated dithianes 77 generated a polar species that added to 2,3- O-
isopropylidene-D-erythronolactone 76 affording lactols 78. The latter are reduced first with Raney 
nickel and then with Et3SiH into the corresponding C-glycosides 80. The use of a D-ribose-derived 
lithiated dithiane nucleophile in this chemistry allows for the convenient construction of a furanose C-
disaccharide (Scheme 2.14).123 
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O O
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Scheme 2.14: Synthesis of furanose C-disaccharide by lithiated dithianes. 
 
Schmidt and co-workers have used a general strategy toward the synthesis of C-ketosides of N-
acetylneuraminic acid (Neu5Ac).124 It has been successfully applied to the synthesis of methylene-
bridged Neu5Ac-α-(2,3)-Gal C-disaccharide 94 (Scheme 2.16). The key strategic element of this 
novel approach is a stereoselective, 6-exo-trig selective, electrophilic cyclization of the appropriate 
open chain precursor 89 by means of phenylselenyl triflate.125,126 The open chain precursor was 
formed by the addition of lithiated iodide 81 accessible from D-galactose to open chain aldehyde 83 
obtained from D-glucono-δ-lactone by chain elongation. Subsequent methylation using Tebbe-
reagent, subsequent formation of a cyclic carbonate and deprotection of the two isopropylidene ketals 
afforded tetrol 89 which, upon treatment with phenylselenyl triflate, was stereoselectively cyclized in 
a 6-exo-trig selective manner (Scheme 2.15). 
                                                     
123 McCartney, J. L.; Meta, C. T.; Cicchillo, R. M.; Bernardina, M. D.; Wagner, T. R.; Norris, P. J. Org. Chem. 2003, 68, 
10152. 
124  Notz, W.; Hartel, C.; Waldscheck, B.; Schmidt, R. R. J. Org. Chem.,2001, 66, 4250. 
125 a) Nicolaou, K. C.; Petasis, N. A. Selenium in Natural Products Synthesis; CIS: Philadelphia, 1984. b) Sharpless, K. B.; 
Gordon, K. M.; Lauer, R. F.; Patrick, D. W.; Singer, S. P.; Young, M. W. Chemica Scripta 1975, 8A, 9-13. c) Wirth, T. 
Angew. Chem. 2000, 112, 3890; Angew. Chem., Int. Ed. Engl. 2000, 39, 3740. 
126 Schmidt, R. R.; Vlahov, I. V. Tetrahedron Asymmetry 1993, 4, 293. 
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Scheme 2.15: Electrophilic Cyclization 
 
A selena-Pummerer rearrangement, oxidation, and esterification readily led to methyl ester 92a 
which, after deacetylation, could be regioselectively tetrabenzoylated with benzoyl cyanide. Triflate 
activation of the axial hydroxyl group in 92d and nucleophilic displacement by azide ion with 
inversion of configuration afforded azide 93, which was reduced with hydrogen and Pearlman’s 
catalyst. Concomitant removal of the benzyl ethers and subsequent saponification of all ester moieties 
successfully completed the de novo synthesis of the desired methylene bridged Neu5Ac-α-(2,3)-Gal 
C-disaccharide 94 (scheme 2.16). 
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Scheme 2.16: Completion of Neu5Ac-C-disaccharide 94 
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2.4 Attempts towards the Synthesis of a Non-Hydrolysable Analogue of 
the (Thomsen-Friedenreich) TF Antigen 
2.4.1 The First Attempt of the Synthesis of a C-Disaccharide Part of the TF Antigen 
The first synthesis of a C-disaccharide analogue of the sugar part of the TF antigen was reported in 
our group by Y.-H. Zhu.127 Persilylated aldehyde 95 and isolevoglucosenone 96 were reacted with 
Et2AlI. Aldol 97a was obtained as the major product of condensation (61%). Addition of N,O-
dibenzyl hydroxylamine gave ketone 98 (41%) which was reduced with LiBH4 to give the 
galactosamine derivative 99 with good diastereoselectivity in (70%) yield. On treatment with 
Me3SiSPh and ZnI2, 99 was converted into the phenyl thiogalactopyranoside 100. It was thus treated 
with K2CO3 in MeOH to provide triol 101 which is a partially protected C-disaccharide analogue of 
the glucan portion of the TF antigen (Scheme 2.17). 
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Scheme 2.17:  First approach of the C-disaccharide part of T antigen. 
 
                                                     
127 Zhu, Y.-H.; Vogel, P. Synlett 2001, 79. 
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In this approach the elegant 1,4-addition of N,O-dibenzyl hydroxylamine furnished a precursor of 
GalNAc with good stereoselectivity. Unfortunately the yield of the latter reaction remained low.  
The approach remained uncertain concerning the possibility to use 99-101 and derivatives in α-
glycosidation of L-serine derivatives. 
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2.4.2 The Second Attempt of the Synthesis of a C-Disaccharide Part of the TF- 
Antigen 
2.4.2.1 1,4-Addition of Azide Anion to a bicyclic enone  
Although isolevoglucosenone 96 is known to add NaN3/AcOH giving the corresponding β-
azidoketone,128 enones 97a and 97b failed to react with HN3 (-40→0 oC). Attempt to add azides to 
97b was reported in our group by R. Demange. He used a 1:1 mixture of Me3SiN3 and AcOH 
containing a catalytical amount of DBU.129 Under these conditions 97b gave a mixture of unstable 
azide after aqueous treatment. The crude reaction mixture obtained at 0 oC was treated with 
NaBH4/MeOH to give a mixture of azido-diols that were not isolated, but directly converted into the 
corresponding acetonides under standard conditions (Scheme 2.18). Flash chromatography on silica 
gel provided the three products 102, 103 and 104 (52 % yield, 3 steps) with the proportion 1:1.6:1.6. 
Unfortunately, none of these azides had the desired 1,6-anhydro-D-galacto configuration. Their 
structures were given by their spectral data, in particular by their 1H-NMR (coupling constants 
between vicinal proton pairs) and 13C-NMR spectra (1’,4-cis vs. 1’,4-trans relative configuration).130 
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Scheme 2.18 Structure of acetonides products related 1H-NOE effects 
 
 
                                                     
128 Horton, D.; Roski, J. P.; Norris, P. J. Org. Chem. 1996, 61, 3783. 
129 Guerin, D. J.; Horstmann,T. E.; Miller, S. J. Org. Lett. 1999, 1, 1107. 
130 Rychnovsky, S. D.; Rogers, B. N.; Richardson, T. I. Acc. Chem. Res. 1998, 31, 9. 
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2.4.2.2 Lemieux’s Azidonitration of Galactal Derivatives: 
Protected D-galactals131 as well as peracetate of β-D-Galp-(1→3)-D-galactal132 of type 105a undergo 
Lemieux’s azidonitration (NaN3/Ce(NH4)2(NO3)6) giving the corresponding α-and β-D-
galactopyranosyl nitrates as major products. Our group reported recently the synthesis of the 
peracetate of β-D-Galp-(1-CH(OH)-3)-D-galactal 105a.133 This compound reacted with 
Ce(NH4)2(NO3)6 and NaN3 in CH3CN giving a single α-nitrate 106 in 87 % yield. Reaction of 106 
with LiBr in CH3CN gave α-bromide 107 (78%) which underwent Königs-Knorr glycosidation of 
MeOH furnishing a separable 4.5:1 mixture of α-and β-galactopyranosides 108α (63%) and 
108β (14%). As already reported,133 iodoglycosidation of semi-protected forms of L-Serine (Cbz-Ser-
OBn, Fmoc-Ser-OBn) with 105a produced 2-deoxy-2-iodo-talo-pyranosides 109 and 110. 
Unfortunately, SN2 displacement attempts of the iodides 109 and 110 by all kinds of azides led to 
decomposition or/and elimination of HI with the formation of enopyranosides 111 and 112, 
respectively (Scheme 2.19). 
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2. NaBH4/ MeOH
3. Raney Ni
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6. Ac2O/ CF3COOH
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Scheme 2.19: attempts of displacement by azides 
 
Vogel and Demange have also prepared triflate 115 from the talopyranoside 114 derived from 113. 
But all attempts to displace the triflate in a SN2 process failed as the product of elimination 116 were 
formed readily(Scheme 2.20).134,135 These failures are in contrast with successes encountered for 
similar reactions with related monosaccharide derived triflates. 
                                                     
131 Lemieux, R. U.; Ratcliffe, R. M. Can. J. Chem. 1979, 57, 1244. 
132 a) Look, G. C.; Ichikawa, Y.; Shen, G. –J.; Cheng, P. –W.; Wong, C. –H. J. Org. Chem. 1993, 58, 4326. b) Bay, S.; 
Berthier-Vergnes, O.; Cantacuzene, D. Carbohydr. Res. 1997, 298, 153. 
133 Demange, R.; Awad, L; Vogel, P. Tetrahedron: Asymmetry 2004, 15, 3573. 
134 (a) Marra, A.; Gauffeny, F.; Sinaÿ, P. Tetrahedron 1991, 47, 5149. (b) Tipson, R., S. Adv. Carbohydr. Res. Chem. 1953, 
8, 107. 
135 Karpiesiuk, W.; Banaszek, A; Zamojski, A. Carbohydr. Res. 1989, 186, 156. 
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Scheme 2.20: Attempts of SN2 displacement by trifluoromethanesulphonate derivatives by azides 
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2.4.2.3 Schmidt’s Glycosidation via 2-nitro-D-galactal.  
 
Schmidt and co-workers136 have prepared perbenzylated T antigen 120 by Michael-type addition of 
Boc-Ser-O-t-Bu to 2-nitro-galactal 118 derived from D-galactal 117 (Scheme4.5). Applying the same 
reaction sequence to the perbenzylated β-Galp-(1-CH(OH)-3)-D-galactal 105b (derived from enone 
97b90d), the nitro-galactal 119 was obtained in (50%) yield which reacted with the semi-protected L-
serine (Boc-Ser-O-t-Bu). Unfortunately again, only the α-talopyranoside 121 was formed. Attempts 
to epimerize the 2-deoxy-2-nitro-D-talopyranoside 121 into the corresponding 2-deoxy-2-nitro-D-
galactopyranoside failed (Et3N, DBU, DABCO) also (Scheme 2.21). 
O
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O
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Scheme 2.21: Synthesis of the 2-deoxy-2-nitro-talopyranoside 121. 
 
                                                     
136 Das, J.; Schmidt, R. R. Eur. J. Org. Chem. 1988, 1609. Winterfeld, G. A.; Ito, Y.; Ogawa, T.; Schmidt, R. R. Eur. J. Org. 
Chem. 1999, 1167. Winterfeld, G. A.; Schmidt, R. R. Angew. Chem. Int. Ed. 2001, 40, 2654. 
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2.4.2.4 Azidonitration of a Conformationally Constrained D-galactal Derivative.  
Vogel and Demange envisioned that Lemieux’s radical azidonitration of a 3-C-glycoside of D-
galactal, azide may selectively attack from the alpha-side if its 4,6-diol unit could be included in a 
ring a such as an acetonide. As shown by several authors,137 the stereoselectivity of this reaction 
depends strongly on substitution of the galactal and on its conformational mobility. They further 
envisioned that an acetonide involving the hydroxy groups at C-4 of the galactal moiety and at C-1’ 
of the hydroxymethylene linker might impede radical addition onto the β face of the galactal alkene 
moiety. Thus, the protected β-C-galactopyranosyl-(1→3)-galactal 127 was prepared as shown in 
Scheme 6. Its azidonitration under Lemieux’s conditions gave a 1:3 mixture of 2-azido-2-deoxy-D-
galacto-pyranosyl nitrates 128α and 128β in mediocre yield (27 %). Nitrate 128 was then converted 
into bromide 129 that was used for the Königs-Knorr glycosidation of Fmoc-Ser-OBn. This led to a 
1.5:1 mixture of the desired α and undesired β-galactosides 130α and 130β respectively, with 
mediocre yield (36 %) also (Scheme 2.22). 
128α X = ONO2
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97b
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Scheme 2.22: Synthesis of a non-hydrolysable analogue of TF (Thomsen-Friedenreich) antigen. 
                                                     
137 Kinzy, W.; Schmidt, R. R. Tetrahedron Lett. 1987, 28, 1981. see also a) Tabeur, C.; Machetto, F.; Mallet, J. –M.; 
Duchaussoy, P.; Petitou, M.; Sinaÿ, P. Carbohydr. Res. 1996, 281, 253-276.  b) Seeberger, P. H.; Roehrig, S.; Schell, P.; 
Wang, Y.; Christ, W. J. Carbohydr. Res. 2000, 328, 61. c) Geiger, J.; Barroca, N.; Schmidt, R. R. Synlett 2004, 836. 
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3 AIM OF THE WORK 
3.1 Synthesis of a Non-hydrolysable Mimic of Thomsen-Friedenreich 
(TF) Antigen: 
 
It can be summarised that oligosaccharides are present at the surface of cellular membranes in the 
form of glycoconjugates (glycoproteins or glycolipids) and serve as sites of attachment for other cells, 
bacteria, viruses, toxins and hormones. Mucin-type glycophorin family share a common structural 
motif possessing an α-glycosidic linkage between Gal-β-(1→3)-GalNAc and the side chain hydroxyl 
group of serine or threonine (TF antigen, figure 3.1). The T structure in normal cells is further 
glycosylated to construct complex O-linked glycans on mucin-type glycoproteins, whereas in most 
human carcimonas, this structure is exposed at the cell surface due to the incomplete synthesis of the 
saccharide chains. 
 
Malignancy is often associated with profound alterations in cell surface bound carbohydrate 
components of glycoconjugates.138,139 Such structural changes are due to incomplete glycosylation or 
novel glycosylation by tumor cells. Among the tumor associated carbohydrate antigens, the Thomsen-
Friedenreich antigen (TF antigen) a disaccharide: Gal-β-1→3-GalNAcα→O linked to serine or 
threonine (Figure 3.1) is found in carcimona-associated mucins (Chapter 1).  
 
O
HO
HO
OH
O
OH
O
HO
ACHN
O
OH
OH
R
NH2
OR = H, CH3  
 
Figure 3.1: Structure of Thomsen-Friedenreich (TF) antigen. 
                                                     
138  Gray, G. R. Methods Enzymol. 1978, 50, 155. 
139  Springer, G. F. Science 1984, 224, 1198. Campbell, B. J.; Finnie, E. F.; Hounsell, E. F.; Rhodes, J. M. J. Clin. Invest. 
1995, 95, 571. 
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The TF-antigen immunogenicity in conjugate vaccines has been confirmed.140 The clustered antigen 
motifs prepared by Danishefsky and coworkers (Chapter 1)12 have demonstrated the potential for 
antitumor vaccines based on TF antigen conjugates. 141-143  
Synthetic approaches towards the synthesis of TF antigen and related mucin-type glycosyl amino 
acids were reported.144-147 Because of their hydrolysis catalysed by glycosidases in vivo, disaccharide 
conjugates are relatively short-lived in the blood stream. Disaccharide mimetics such as C-linked 
disaccharide analogues (Figure 3.2) offer an improved stability towards hydrolysis as required for a 
disaccharide-based vaccine. 
 
R' = R' = H
R' = H, R'' = OH, F
R' = OH, F,  R'' = H
O
HO
HO
OH
OH
O
HO
AcHN
O
OH
OH
R
NH2
O
R = H, CH3
R''R'
 
Figure 3.2: C-Disaccharide analogues of TF antigen.  
                                                     
140  Springer, G. F. Clin. Rev. Oncogenesis 1995, 6, 57. MacLean, G. D.; Reddish, M. A.; Bowen-Yacyshyn, M. B.; 
Poppema, S.; Longenecker, B. M. Cancer Invest. 1994, 12, 45. Jennings, H. J.; Ashton, F. E.; Gamian, A.;. Michon, F. in 
Towards Better Carbohydrate Vaccines (Eds.: Roy, R.; Bell, R.; Torrigiani, G.), Wiley, London, 1987, 11. 
141  MacLean, G. D.; Reddish, M. A.; Bowen-Yacyshyn, M. B.; Poppema, S.; Longnecker, B. M. Cancer Investigat. 1994, 
12, 46. Toyokuni, T.; Singhal, A. K.; Chem. Soc. Rev. 1995, 24, 23. Lo-Man, R.; Bay, S.; Vicher-Guerre, S.; Deriaud, E.; 
Cantacuzene, D.; Leclerc, C. Cancer Res. 1999, 59, 1520 and references therein. 
142 Fung, P. Y. S.; Madej, M.; Koganty, R.; Longenecker, B. M. Cancer Res. 1990, 50, 4308. 
143 MacLean, G. D.; Boyen-Yacyshyn, M. B.; Samuel, J.; Meikle, A.; Stuart, G.; Nation, J.; Poppema, S.; Jerry, M.; 
Koganty, R.; Wong, T.; Longenecker, B. M. J. Immunother. 1992, 11, 292. 
144 For examples of previous Tn syntheses, see: Tokoyuni, T.; Hakomori, S.; Singhal, A. K. Bioorg. Med. Chem. 1994, 11, 
1119, and references therein. For examples of Tn glycopeptide clusters, see: Bay, S.; Lo-Man, R.; Osinaga, E.; Nakada, H.; 
Leclerc, C.; Cantacuzene, D. J. Pept. Res. 1997, 49, 620, and references therein. 
145 For selected interesting examples of glycoprotein synthesis, see: Bill, R. M.; Flitsch, S. L. Chem. Biol. 1996, 3, 145. 
Witte, K.; Sears, P.; Martin, K.; Wong, C.-H. J. Am. Chem. Soc. 1997, 119, 2114. Tsuda, T.;. Nithimura, S. Chem. Commun. 
1996, 2779. 
146 Mono- and diclusters of the T antigen have been reported: Kunz, H.; Birnbach, S.; Wering, P. Carbohydr. Res. 1990, 
202, 207. 
147 Inbar, M.; Sachs, L.; Nature 1969, 223, 710. Inbar, M.; Sachs, L. Proc. Natl. Acad. Sci. USA, 1969, 63, 1418. 
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3.2 Retro-synthetic analysis: 
 
Our group has become interested in preparing non-hydrolysable analogues of TF epitope whose 
immunogenicity in synthetic vaccines has been demonstrated.148,149 The synthesis relies on a 
methodology for the synthesis of C(1→3)-disaccharides developed in the group: condensation 
between a D-galactose derived carbaldehyde and isolevoglucosenone. 
From the earlier attempts of synthesis of TF antigen analogues we have seen that the galactal 
methodology was not convenient for our synthesis: firstly the yield was not suitable for multi-step 
synthesis especially from product 124 to 130a; secondly the number of steps is too high; thirdly this 
methodology led to non compatible protection group (TBDPS, acetonide, OBn) of 130α; fourthly the 
poor selectivity in the glycosidation reaction step could not be improved.  
All the unsatisfactory results forced us to come back to the Zhu studies during which the 2-amino-2-
deoxy-D-galactal moiety was obtained under the protected form of a N-benzyl-O-(benzyloxy)amino 
group. We also chose to use the silyl ether protected enone 97a instead of the benzyl protected 
derivative 97b, as the silyl group can be exchanged for acetates more readily than benzyl ethers.  
The amine was changed for MeONHBn since this amine, less bulky than the BnONHBn, was 
expected to improve the yield of the 1,4-addition step. The opening of the 1,6 anhydrosugar unit 
should be done under adequate conditions to realize α-galactosides with good selectivity. This might 
require to exchange the MeONBn substitutent for an azide group before the opening of the 1,6 
anhydrosugar. A peracetylated intermediate is required since we need to generate clusters of the C-
disaccharide. The clustering step required stable protective groups that can be cleaved readely in the 
last step. At this stage, acetates looked to be the suitable protective groups.  
The synthesis start with a Baylis-Hillmann type of condensation between the persilylated 
carbaldehyde 95a and isolevoglucosenone (96) induced with a dialkylaluminium salt. Then we shall 
use MeONHBn as amine in a 1,4-addition to enone 97a, hopefully getting better yield than when we 
using BnONHBn. Subsequent reduction of the adduct into the corresponding alcohol will then be 
followed by the transformation of the alcohol into a suitable glycosyl donor. Glycosidation of a semi-
protected serine will then be carried out.  
 
                                                     
148  Fung, P. Y. S.; Madej, Koganty, M. R.; Longenecker, B. M. Cancer Res. 1990, 50, 4308. 
149  MacLean, G. D.; Boyen-Yacyshyn, M. B.; Samuel, J.; Meikle, A.; Stuart,, G.; Nation, J.; Poppema, S.; Jerry, M.; 
Koganty, R.; Wong, T.; B. M. Longenecker, B. M. J. Immunother. 1992, 11, 292. 
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Scheme 3.1: Retro-synthetic analysis toward a TF-antigen analogue 
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4 RESULTS AND DISCUSSION 
4.1 The First Synthesis of C-Disaccharide Analogues of the Thomsen-
Friedenreich (TF) Antigen 
4.1.1 The Synthesis of a Hydroxymethano-Linked C-disaccharide  
 
After all the failures encountered by Zhu and Demange in our group with the route making use of 
galactal intermediates, we decided to develop the route based on the 1,4-addition of a suitable amine 
to enone 97a (See section 2.4.1). 
 
For the synthesis of 97a, we envisaged to apply the chemistry developed by Zhu which uses 
isolevoglucosenone (96) and aldehyde 95a. Under previous conditions 127 (0.1 mmol of 95a, -78 oC) 
the yield of the condensation of aldehyde 95a and isolevoglucosenone 96 was 61%. On scaling up 
and using high concentration, and on controlling the slow addition of Et2AlI at -90 oC, conditions 
were formed under which 97a was isolated as a single diasterioisomer in 95 % yield (Scheme 4.2). 
O
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O
O
O
+
Et2AlI
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(95 %)
O
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TBSO
OTBS
OTBS
97a
O
O
O
HO
1'
 
Scheme 4.2: Oshima-Nozaki coupling reaction. 
 
Table 4.1: Conditions and yield in the coupling reaction  
 mmole Conc. Temperature yield 
Zhu  0.1 mmole 0.08 M -78 oC 61 % 
This work 9.4 0.25 -90 oC 95 % 
 
In the condensation reaction between isolevoglucosenone (96) and carbaldehyde 95a in the presence 
of Et2AlI, the Zimmerman-Traxler model explains the configuration of C(1’) of 97a (Figure 3).150 
 
                                                     
150  Zimmerman, H. E.; Traxler, M. D. J. Am. Chem. Soc. 1957, 79, 1920. 
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Figure 4.3: Representation of the closed transition state adopted by the aluminium enolate and aldehyde (minimization of 
steric effects). 
 
 
For the conjugate addition of amines to enone 97a, we have chosen hydroxylamine derivatives. 
Because of the α-effect, their nucleophilicities are much higher than those of similar amines.151 
Initially, a Lewis acid such as Me2AlCl was used to activate the enone. Unfortunately no reaction 
occurred when MeONHBn was added to a mixture of 97a and Me2AlCl between -78 oC and 0 oC. In 
fact, we found that a Lewis acid is not necessary for this addition. The best results were obtained 
using no solvent and no catalyst (Table 4.2). 
This is a manifestation of the mass law effect for equilibrium 97a+ MeONHBn 131. 
 
Table 4.2: Conjugated addition of methoxybenzylamine to enone 97a 
entry catalyst solvent temperature Yield152 131a 
1 Me2AlCl CH2Cl2 -78 → 0 oC No reaction 
2 Me2AlCl CH2Cl2 25 oC 20 % 
3 ⎯ CH2Cl2 25 oC 18 % 
4 ⎯ No solvent 25 oC 82 % 
 
It was discovered by Dr. Jens Riedner that MeONHBn and enone 97a give a 1:1 mixture of 
stereomeric adducts 131a and 131b that are isomerized during their slow chromatography on silica 
gel at room temperature. Thus conditions were found under which adduct 131a could be obtained 
pure in 82% yield (Scheme 4.3). 
                                                     
151 a)  Dixon, J. E.; Brucine, T. C. J. Am. Chem. Soc. 1971, 93, 6592. b) Heo, C. K. M.; Bunting, J. W. J. Chem. Soc., Perkin 
Trans  1994, 2, 2279. c) Bunting, J. W.; Mason, J. M.; Heo, C. K. M. Perkin Trans 1994, 2, 2291. 
152 This value present the isolated yield 
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Scheme 4.3: Conjugation addition of methoxybenzylamine to enone 97a. 
 
When pure 131a was dissolved in THF with MeONHBn, an 8:1 mixture of 131a and 131b was 
obtained upon standing at 25 oC for 2-3 hours. Fast column chromatography on silica gel of 1:1 
mixture of 131a and 131b gave the first fraction containing mixture of 131a and 131b (major), and a 
second fraction of pure 131a (minor). Slow elution led to smaller fraction of 131a and 131b and 
increased amounts of pure 131a (second fraction). This demonstrated that 131a and 131b are in 
equilibrium in the presence of an amine and that the equilibrium shifts in favor of 131a when 
adsorbed on silica gel. Thus a slower elution allows the conversion of absorbed 131b into absorbed 
131a which is finally recovered pure from the column (Figure 4.4). The structure was confirmed in 
this stage by the structure of compound 132 obtained after the reduction of the ketone moiety. 
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Figure 4.4: Isomerization of 131b to 131a during flash chromatograph.  
 
The mechanism of isomerization 131a 131b is proposed to involve reversible E1cb-like 
eliminations 131a  97a + MeONHBn and 131b  97a + MeONHBn, both catalyzed by 
MeONHBn. 
 In the preliminary work of Zhu153 he had shown that the reaction of isolevoglucosenone 96 with 
Me2AlNBn2 gave an aluminium enolate that could be reacted directly with sugar-derived aldehydes 
giving, in the same pot, the corresponding 2-amino-2-deoxy-3-C-linked disaccharide derivatives. We 
thus attempted to obtain 131a in a similar fashion by reacting isolevoglucosenone 96 with 
Me2AlN(OMe)Bn, followed by the addition of aldehyde 95a. Based on related Oshima-Nozaki 
reactions with 96, we expected (Zimmerman-Traxler, steric factors)150 that the preferred double 
adduct should be 131a under conditions of kinetic control (Scheme 4.4). After several unfruitful 
assays we found that the reaction of 96 and Me2AlN(OMe)Bn in THF at -78 oC gives the expected 
enolate 96a. After the addition of 95a to this solution, a slow reaction occurred at -78 oC. Subsequent 
aqueous work-up and purification by chromatography on silica gel gave 131a in 19 % yield only and 
the unreacted aldehyde was recovered (Scheme 4.4). Attempts to run the reaction at higher 
temperature and/or for longer time led to decomposition only.  
                                                     
153 Zhu, Y. -H.; Demange, R.; Vogel, P. Tetrahedron: Asymmetry   2000,  11,  263. 
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Scheme 4.4: One pot double addition 
 
Reduction of ketone 131a with LiBH4 furnished diol 132 in 90 % yield. Hydride addition to the exo 
face of the bicyclo[3.2.1]octenone system is preferred for steric reasons. When the reduction reaction 
was run at -78 oC we observed C-3 epimerization. However when run at 0 oC this reduction gave the 
glucose precursor product. The best way to do this reduction is to add LiBH4 at -78 oC, then let the 
temperature raise to -30 oC within less than 5 min. This gave product 132 as unique product.  
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3.0503.1003.150
2.276
9.348
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O
H
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H
H
H
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HO
1
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4
1'
3J=9.6 Hz
3J=2.3 Hz
O
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TBSO
OTBS
OTBS
3J(H-C(2), H-C(3)) = 9.6 Hz
3J(H-C(3), H-C(4)) = 2.3 Hz
3J(H-C(3), H-C(1')) = 6.8 Hz
H-2 H-3
Figure 4.5: the H-NMR (400 MHz) spectrum of diol 132.  
The cross-peaks of the 2-D-NOESY 1HNMR spectrum and the coupling constants of 
bicyclo[3.2.1]octanol 132 show 3J(H-2, H-3)= 9.6 Hz, 3J(H-3, H-1’)= 6.8 Hz and 3J(H-3, H-4) =2.3 
Hz which is expected for the galactose configuration. 
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Treatment of 132 with Bu4NF (TBAF) in THF (20 oC, 3h) and then with Ac2O/pyridine and a 
catalytic amount of 4-dimethylaminopyridine (DMAP) provided the peracetate 133 quantitatively 
(Scheme 4.5). 
O
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RO
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(90 %)
132 R = Si(t-Bu)Me2, R1 = H
133 R = R1 = Ac
1. TBAF, THF
2. Ac2O, Py, DMAP
(quant.)  
Scheme 4.5: Reduction of ketone 131a 
 
Ring opening of the 1,6-anhydrogalactose moiety of 133 was done using ZnI2 in CH2Cl2.154 Thus, the 
crude product so-obtained was not isolated but immediately desilylated (TBAF, THF) and 
peracetylated under standard conditions to produce thiogalactopyranoside 134 in 93 % yield (Scheme 
4.6). 
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Scheme 4.6: Synthesis of the thio-glycosyl 134. 
                                                     
154 Sakairi, N.; Hayashida, M.; Kuzuhara, H. Tetrahedron Lett. 1987, 28, 2871.  
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Glycosidation of Fmoc-Ser-OBn 135 with 134 under the conditions of Imamura et al.155 led 
exclusively to the β-D-galactoside 136 (92 % yield). The structure of 144 was deduced from its 1H-
NMR spectrum which showed 3J(H-1, H-2)= 7.4 Hz, and 3J(H-2, H-3)=12.3 Hz (see Figure 4.6). The 
high β selectivity during the glycosidation reaction seems to arise from the participation of the amine. 
Thus, participation of the 2-(N-benzyl-N-methoxy)amino group cannot be avoided (Scheme 4.7). 
TMSOTf, NIS, 4 oA MS
0 oC, (92 %)
O
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OAc
OAc
O
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O
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COOBn
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O
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O
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N
OMeBn
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H
H
H
3J=7.7
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Scheme 4.7: Imamura glycosidation of 134 
 
                                                     
155 Imamura, A.; Ando, H.; Korogi,S.; Tanabe, G.; Muraoka, O.; Ishida, H.; Kiso, M.Tetrahedron Lett. 2003, 44, 6725. 
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Figure 4.6: the 1H-NMR(400 MHz) spectrum of 136β.  
 
The bulky and participating 2-BnNOMe subsistituent prohibited the α-glycosidation. Therefore, a 
non-participating and non-bulky group at C-2 that can be readily converted into a 2-acetamido 
moiety. Inspired by the work of Wong and co-workers,156 we converted the N-benzyl-N-
methoxyamino group of 132 into the corresponding primary amine 137. Under Birch’s conditions157 
the methoxy amine group was cleaved and subsequent catalytic (Pd/C, H2) hydrogenation cleaved the 
benzylamine group (Scheme 5).158  The amine 137 so-obtained was not isolated but directly treated 
with trifluromethanesulfonyl azide, cupric sulfate, and triethylamine in a mixture of  H2O / MeOH / 
CH2Cl2. Desilylation of 138 followed by acetylation provided azide 139 that was isolated in 81 % 
yield (based on 132). 
 
                                                     
156 Nyffeler, P. T.; Liang, C.-H.; Koeller, K. M.; Wong, C.-H. J. Am. Chem. Soc. 2002, 124, 10773. 
157 Jr. Dryden, H. L.; Webber, G. M.; Burtner, R. R.; Cella, J. A. J. Org. Chem. 1961, 26, 3237. 
158 Direct azidation of enone 97b failed. See section (4.1.3.1) for more details see R. Demange, Ph. D. Thesis, EPFL, 2002. 
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Scheme 4.7: Transformation of amine into azide. 
 
Smooth ring opening of the 1,6-anhydrogalactose moiety of 139 using TMSOTf in Ac2O gave 140 in 
98 % yield and 23:1 α/β selectivity. Conversion of galactosyl acetate 140 into the corresponding 
bromide 141 (92 %) was done with TiBr4 in CH2Cl2 (25 oC, 12h) (Scheme 4.8). 
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OAc O
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139
N3
 TMSOTf, Ac2O
-40 oC, (98 %)
140α    X = OAc + 140β (α : β 23 : 1)
141α    X = Br + 141β (α : β 98 : 2)
TiBr4, CH2Cl2 (92 %)
 
Scheme 4.8: synthesis of glycosyl bromide. 
 
 Königs-Knorr glycosidation (AgClO4 / CH2Cl2 , 2,4,6-collidine, 4 Å molecular sieves)159 of N-Fmoc-
serine tert-butylester 142 gave a 5:1 mixture of α-143α and β-galactoside 143β in 93 % yield. Flash 
chromatography does not provided pure 143α. The preferred formation of the α-galactoside is 
ascribed to a kinetic anomeric effect (no participating group at C-2) (Scheme 4.9).160 
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Scheme 4.9: Synthesis of a C-disaccharide analogue of TF-antigen precursor. 
                                                     
159 a)Paulsen, H.; Adermann, K. Liebigs Ann. Chem. 1989, 8, 751; b) Rothman, D. M.; Vazquez, M. E.; Vogel, E. M.; 
Imperiali, B. J. Org. Chem. 2003, 68, 6795. 
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Figure 4.7: The 400 MHz 1H-NMR spectra of 143α,β mixture. 
 
The structure of 143 was confirmed by its 1H-NMR spectrum. For the major anomer 143α 3J(H-1, H-
2) =3.0 Hz and 3J(H-2, H-3) =12.2 Hz were measured, what is typical for α galactopyranosides. For 
the minor product 3J(H-1, H-2) =7.7 Hz and 3J(H-2, H-3) =12.2 Hz were found, what is typical for β-
galactosides (Figures 4.7, 4.8). 
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Figure 4.8: 1H-NMR Analysis of α and β glycosides of 143. 
                                                                                                                                                                    
160 a) Maura, A.; Shun, L. K. S.; Gauffeny, F.; Sinay, P. Synlett 1990, 445. b) Maura, A.; Gauffeny, F.; Sinay, P. 
Tetrahedron 1991, 47, 5149. c) Cheshev, P. E.; Kononov, L. O.; Tsuekkov, Yu. E.; Shashov, A. S.; Nifantiev, N. E. Russ. J. 
Bioorg. Chem. 2002, 28, 419. 
 72 
 
By MALDI-HRMS the molecular weight of 143 was confirmed (Figure 4.9). The purity of the mixture 
of 143 was confirmed as well by elemental analysis (for more details see the experimental part). 
 
Figure 4.9: MALDI-HRMS Analysis of 143. 
Treatment of a 5:1 mixture of 143α and 143β with thioacetic acid, collidine and Ac2O161 furnished a 
5:1 mixture of 144α and 144β in 89 % yield. When 143α and 144β were treated with zinc AcOH, 
THF, and Ac2O the yield climbed up to 92 %. Compound 144α is a key intermediate of a protected 
C-linked analogue of TF epitope α-O-conjugated to L-serine. It should be suitable for the 
construction of clusters via peptide synthesis and further conjugation to immunogenic proteins. We 
have verified that disaccharide 144α and 144β can be fully deprotected (Scheme 4.10). When 144α 
and 144β were treated with morpholine in DMF followed by CF3COOH, and then by MeONa/MeOH, 
disaccharide 145α was obtained in 52 % yield after preparative HPLC purification. 
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Scheme 4.10: Synthesis of fully protected and deprotected C-analogue of  TF-antigen.   
                                                     
161 a) Macindoe, W. M.; Nakahara, Y.; Ogawa, T. Carbohydr. Res. 1995, 271, 207; b) Kuberan, B.; Sikkander, S. A.; 
Tomiyama, H.; Linhardi, R. Angew. Chem. Int. Ed. 2003, 42, 2073. 
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4.1.2 The Synthesis of a C-Disaccharide analogue of the Thomsen-Friedenreich (TF) 
Antigen Containing a Methano Linker 
 
Attempts to introduce suitable radical leaving group in position C(1’) in order to deoxygenate the 
alcohol under radical conditions all failed. Only degradation products or dienone 146 were obtained 
(Table 3). The geometric configuration of the double bond present in product 146 has not been 
established unambiguously. 
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Scheme 4.11: Thioesterification Attempts  
 
Table 4.3: attempt to introduce radical leaving group 
entry solvent XG Temperature yield 
1 CH3CN CS(Im)2 70 oC 78 % of 146 
2 Pyridine ClOSCOPh 0 oC 25 % of 146 
3 THF S2C, then MeI 0 to 25oC 10 % of 146 
4 Pyridine TfCl 0 oC degradation 
 
So far the unique reaction which allowed us to protect the hydroxyl group at C(1’) has been Vogel’s 
triethylsilyl 2-methylprop-2-ene-1-sulfinate. The latter reagent is a very active silylation agent under 
neutral and mild conditions (Scheme 4.18).162 Unfortunately silyl ether 147 was not useful for our 
synthesis because the selective cleavage of triethylsilylether in later steps could be difficult in the 
presence of four (t-butyl)dimethylsilylether moieties. 
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162 Huang, X.; Craita, C.; Awad , L.; Vogel, P. Chem. Commun. 2005, 10, 1297. 
 74 
 
Scheme 4.12: Silylation of alcohol at C(1’) 
 
4.1.2.1 Hydrogenation of enones 
In the presence of Raney nickel in THF, the TBS-protected C-galactoside 97a was reduced 
quantitatively into a mixture of aldols from which 148 and 149 were isolated (flash chromatography) 
in 57% and 43% yield, respectively. When the crude mixture of 148 and 149 was treated with 
CH3SO2Cl/pyridine and a catalytical amount of DMAP, this led to the formation of a mixture of 
unstable enones 150. The latter were not isolated but treated directly with Raney nickel in THF at 25 
oC. This produced a mixture of ketones from which pure 151 and 152 were isolated in 44% and 43% 
yield, respectively. Attempts to isomerize 151 into 152 failed applying different isomerization 
conditions (Et3N, DBU, KOH, KOt-Bu) (Scheme 4.13).  
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Scheme 4.13: Reduction / elimination / reduction / sequence.  
 
4.1.2.2 Azidonitration of galactal derivatives 
 
Reduction of 152 with LiBH4 in THF gave alcohol 153 in 79% yield, the structure of which (1,6-
anhydro-2-deoxy-D-lyxo configuration) was given by its1H-NMR and the cross-peaks of 2-D-
NOESY 1H-NMR spectrum. Treatment of 153 with TESOTf and acetic anhydride lead to the ring 
opening of 1,6-anhydro moiety and acetylated D-lyxose derivative 154 was obtained without 
formation of furanosides. The mixture of α- and β-pyranosides 154 thus obtained, was not purified 
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but directly treated with silica gel in benzene heated under reflux. This produced the C-linked 
analogue of β-D-galactopyranosyl-(1→3)-D-galactal 155 in 60% yield (Scheme 4.14). 
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Scheme 4.14: Synthesis of galactal 155 
 
One of the method for the introduction of azido functionality at C-2 is the conversion of glycals into 
2-azido-2-deoxyglycosyl nitrates functioning as 2-amino-2-deoxy glycoside precursors. This 
conversion is commonly effected by the azidonitration reaction developed by Lemieux and Ratcliffe 
in 1979.131 
 
Azides can be considered as masked amino groups and can thus serve as N protection in a sense. As 
non participating groups, they also allow the synthesis of 2-amino-2-deoxy-α-D-glycosides. This is 
not the case with 2-N-acetyl-2-deoxy derivatives and analogues for which β-glycosides are 
exclusively formed due to the neighbouring group participation at C-2 as shown in scheme 4.15. 
O
HN X
O
O
HN
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HN
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O
HN
O
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Scheme 4.15: Neighbouring group participation at C-2: complete control over anomeric configuration. 
 
Schmidt has reported that reaction of protected D-galactal 156 with ceric ammonium nitrate (CAN) 
and sodium azide results in the formation of a mixture of anomers of the desired 2-azido-2-deoxy-D-
galactose derivative 157 as well as varying amounts of D-talose side product 158 containing the axial 
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2-azido moiety (Scheme 4.16). Stereoselectivity of this useful transformation was found to be greatly 
dependent upon the steric hindrance. In the case of galactal 156, the axial C-4 substituent guarantees 
good selectivity for the installation of an equatorial C-2 azido moiety, but selectivities vary 
considerably depending upon the protecting group (15-40:1 of 157 (D-galacto) to 158 (D-talo)).131 
In the case of D-glucal 159, which carries an equatorial C-4 substituent, unpredictable ratios of 
products containing an equatorial or an axial C-2 azido group have been obtained. Selectivities 
ranging from 3:1 in favour of the manno-derivative 161 to a 5:1 ratio in favor of gluco-derivative 160 
have been reported.163 
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Scheme 4.16: Selectivity of the azidonitration reaction depending on glycols (Schmidt and co-workers). 
 
The anomeric nitrate group can later be readily converted into a hydroxyl, halide or acetyl 
functionalty and thus gives access to a variety of glycosyl donors containing a non-participating 2-
azido group. 
Wong164 and Cantacuzene165 reported that azidonitration of peracetylated Gal-β-(1→3)-galactal 162 
afforded exclusively the galacto-product 163. Bromination of nitrate 163 by LiBr provided bromide 
164 in 67% overall yield (Scheme 4.17). 
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Scheme 4.17: Azidonitration of Gal-β-(1→3)-Galactal 162 by Wong and Co-worker. 
                                                     
163 Schmidt, R. R.; Rembold, H. Carbohydr. Res. 1993, 246, 137. Kinzy, W.; Löhr, A. Carbohydr. Res. 1993, 245, 193. 
164 Look, G. C.; Ichikawa, Y.; Shen, G.-J.; Cheng, P.-W.; Wong, C. H. J. Org. Chem. 1993, 58, 4326. 
165 Bay, S.; Berthier-Vergnes, O.; Cantacuzene, D. Carbohydr. Res. 1997, 298, 153. 
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With Gal-β-C(1→3)-galactal 155 in our hands, the reaction of azidonitration can be achieved. 
Surprisingly, in our case, inseparable complex mixture was obtained (Scheme 4.18); one can explain 
this because of the steric effect of TBS groups in azidonitration reaction, and concurrent formation of 
D-talopyranoside, and D-galactopyranoside. The difficulty to reach galactal 155 in sufficient quantity 
led us to abandon this route. 
O
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OTBS
OAc
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155
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 mixture
(NH4)2Ce(NO3)6
NaN3
 
Scheme 4.18: Azidonitration of Gal-β-(1→3)-Galactal 155. 
 
This unexpected result can be attributed to the conformation of the galactal moiety. To over-come this 
problem, 4,6 diol protection of the galactal part was thought necessary in order to give some rigidity 
to the galactal moiety and thus favour the equatorial attack of the azide radical. 
Thus, we returned to the azidonitration reaction to construct the α-glycosidic bond of 2-azido-2-
deoxy-D-galactopyranoside keeping in mind that steric effects and the conformation of galactal are of 
great influence on the selectivity of this reaction.137 Indeed, the unexpected mixture obtained in the 
former experiment of azidonitration of Gal-β-C(1→3)-galactal 155 suggested that the selectivity 
could be obtained by fixing the structure of 155 by 4,6 diol protection group.  
 
A sterically less-hindered α-face would favour the attack on the galactal onto the bottom face, thus 
leading to the desired equatorial azide. To this end, the use of conformationally constrained galactal 
should be adequate. Molecular modelling of structure containing a 4,6-O-isopropylidene acetal 
suggested that the top face was significantly more crowded that the bottom face of the molecule. 
These remarks prompted us to elaborate the following retrosynthetic scheme (Scheme 4.19). 
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Scheme 4.19: Retrosynthetic scheme of a galactal 167 
 
We thus treated 153 with trimethylthiophenylsilane (TMSSPh) in dichloromethane in the presence of 
ZnI2. Further desilylation at C(6) and acetonide formation provided a α,β mixture of 166, in a poor 
yield.166 
 
The thioglycosides 166 were converted into the corresponding sulfone donors 168 by oxidation with 
m-CPBA. Then the mixture of 168 was dissolved in toluene and heated under reflux but unfortunately 
we did not obtain the desired galactal 167 (scheme 4.20).167  
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Scheme 4.20: Approach toward the synthesis of galactal 167 
 
                                                     
166  Roth, W.; Pigman, W. Meth. Carbohydr. Chem. 1963, 2, 405. 
167 The mixture of 166 shown in Scheme 4.20 could not be separated by chromatography.   
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The failure of the later elimination must be put onto the account of conformational constraints that 
make the syn elimination too difficult.  
4.1.2.3 Deoxygenation of –CH(OH)- Linker by an Addition-Elimination-Reduction Sequence. 
We have seen in Chapter 4.1.2.2 that attempts to deoxygenate the free alcohol at C(1’) was possible 
by elimination. 
Thus, we returned to the product of addition 131a and tried to eliminate the free alcohol as (Scheme 
4.21) keeping in mind the high possibility of the elimination of methoxybenzyl amine at C(2). We 
tried to find a very small and good leaving group. Trifluroacetate appeared to be the correct choice. 
Elimination to enone 169 was then effected by trifluoroacylation ((CF3CO)2O, Et3N, CH2Cl2, 0oC) 
followed by addition of DBU. The overall yield for the elimination sequence was 80%.  
Attempt to generate mesylate instead of trifluoroacetate led to considerable decomposition. Enone 
169 was formed and isolated in 30 % yield only (Scheme 4.21).168 
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Scheme 4.21: Formation of enone 169 
The geometric configuration of the double bond present in product 169 has not been established 
unambiguously.169. 
With 169 in our hands, the enone was reduced using Raney Nickel and 50 atm of hydrogen gas in 
ethanol to give a 3:1 mixture of 170a and 170b. Fortunately by treating this mixture with KOH, only 
epimer 170a was obtained in 87 % yield (Scheme 4.22). The drawback for this approach is the long 
reaction time and problems with the scale-up. Smooth conditions for the reduction were found for 3.0 
mmol scale. Further scale-up becomes problematic due to considerable amounts of degradation 
product. The use of CuH as reducing agent led to non-reproducible results and considerable 1,2 
reductions. 
 
                                                     
168 Smith, A. B; Nolen, E. G.; Shirai, G. J. R; Blase, F. R.; Ohta, M.; Chida, N.; Hartz, R. A.; Fitch, D. M.; Clark, W. M.; 
Sprengeler, P. A. J.Org. Chem. 1995,60, 7837. 
169 It is propose to be Z configuration as above in scheme 4.21. Prelimary NMR studies did not show NOE interaction 
between H-1’ and H-2. 
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Scheme 4.22: Reduction of enone 169 
 
Attempts to exchange the silyl protection groups for methoxymethyl groups (MOM) did not lead to 
satisfactory results. In order to improve selectivily of the reduction of conjugated carbon-carbon 
double bond, compound 169’ was treated with triethylsilane and a catalytic amount of 
tris(triphenylphosphine)rhodium(I) chloride 170 in THF at 65 oC, followed by the addition of K2CO3. 
This provided 170’ in 40 % yield together with the mixture of products 171’ in 45 % yield (Scheme 
4.23).  
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Scheme 4.22: Reduction of enone 169’ 
 
Applying the same reagent at 25 oC gave diene 172’ as unique product (Figure 4.10) in 74 % yield. 
There results forced us to use the reduction of enone 169 as the route of choice to our target.  
                                                     
170 Liu, H. J.; Browne, E. N. C. Can. J. Chem. 1981, 59, 601. 
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Scheme 4.23: Reduction of enone 169’at room temperature 
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Figure 4.10: The 1H-NMR (400 MHz) spectra for enone 172’ 
 
4.1.2.4 Preparation of a 2-azido-galactosyl donor 
 
Reduction of ketone 170a with LiBH4 furnished alcohol 171 in 92 % yield. Hydride addition to the 
exo face of the dioxabicyclo[3.2.1]octonone system is preferred for steric reasons. Then the 2-
BnNOMe substituent, which prohibits α-glycosidations, was converted into the corresponding 
primary amine 172 under Birch’s conditions and subsequent catalytic (Pd/C, H2) hydrogenation 
(Scheme 4.24).  The amine 172 so-obtained was not isolated but directly treated with 
trifluromethanesulfonyl azide, cupric sulfate, and triethylamine in a mixture of  H2O / MeOH / 
CH2Cl2 to give the azide 173 in 81 % yield. Desilylation of 173 followed by acetylation provided 
azide 174 in 89 % yield. 
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(89 %)  
Scheme 4.24: Synthesis of azide 174. 
 
The NMR spectra did not confirm the structure of 174 unambiguously because of signal overlapping 
nevertheless, its structure was confirmed by the structure of product 179α and 180α derived from 174 
and described below. 
Ring opening of the 1,6-anhydrogalactose moiety of 174 was realized with ZnI2/TMSSPh in CH2Cl2. 
The crude product so-obtained was not isolated but immediately desilylated (HF, pyridine) and the 
primary alcohol was reprotected as a triisopropylsilyl ether under standard conditions. This produced 
thiogalactoside 175 in 88 % yield as an inseparable 1:1 mixture of α and β anomers (Scheme 4.25). 
  
O
OAc
AcO
OAc
OAc O
OAcO
N3
O
AcO
AcO
OAc
OAc
O
AcO
N3
SPh
OTIPS
1. TMSSPh / ZnI2, CH2Cl2
2. HF, Py
3. TIPSOTf, 2,6-lutidine
(88 % from 174, one-pot)
174 175  
Scheme 4.25: Synthesis of the galactopyranosyl donor175 
 
Glycosidation of Fmoc-Ser-Ot-Bu 142 with 175 under the conditions of Imamura et al. led to a 1:1 
mixture of the α- and β-galactopyranosides 176 and 177 these compounds could not be separated 
(Scheme 4.26).  
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Scheme 4.26: Imamura glycosidation with 175. 
 
The structures of compound 176 and 177 were deduced from their 1H-NMR spectra which showed in 
particular 3J(H-1, H-2)= 3.3 Hz, 3J(H-2,H-3)=12.2 Hz for the α-epimer and 3J(H-1, H-2)= 7.2 Hz, 
3J(H-2,H-3)=11.9 Hz for the β-epimer (see Figure 4.11).  
 
 
ppm (t1)
1.02.03.04.05.06.07.08.0
3.321 12.223
7.271
11.853
ppm (t1)
3.1003.1503.2003.2503.300
3J(H-1, H2) = 3.3
3J(H-2, H3) = 12.2
3J(H-1, H2) = 7.3
3J(H-2, H3) = 11.9
H-2αH-2β
 
Figure 4.11: The 1H-NMR (400 MHz) spectra of 1:1 mixture of 176 and 177  
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Smooth ring opening of the 1,6-anhydrogalactose moiety of 174 using TESOTf in Ac2O gave a 15:1 
mixture of α-(178α) and β-galactoside (178β) in 95 % yield. Conversion of galactosyl acetate 178 
into the corresponding bromide 179 (92 %) was carried out with TiBr4 in CH2Cl2 (25 oC, 12h). Under 
these conditions only the α anomer was formed (Scheme 4.27).  
O
AcO
AcO
OAc
OAc
O
AcO
N3
OAc
X
O
AcO
AcO
OAc
OAc O
O
AcO
174
N3
 TESOTf, Ac2O
-40 oC, (95 %)
178α    X = OAc + 178β (α : β 15 : 1)
179α    X = Br
TiBr4, CH2Cl2 (91 %)
 
Scheme 4.27: Synthesis of galactosyl bromide 179α 
The structure of 179α was confirmed by 1H-NMR which showed 3J(H-1, H-2) =3.1 Hz, 3J(H-2, H-3) 
=12.3 Hz, 3J(H-4, H-3) and 3J(H-4, H-5) less than 2 Hz. This is typical for α-galactopyranosides. 
Further more the chemical shift of H-4 (5.4 ppm) confirmed the pyranoside structure (figure 4.12, for 
more details the experimental part) and is not consistent with a furanoside structure. 
 
3J(H-1, H-2) = 3.1 Hz
3J(H-2, H-3) = 12.3 Hz
H-2
1.01.52.02.53.03.54.04.55.05.56.06.57.0
3.4903.5003.5103.5203.5303.5403.550
J=3.083 J=12.330
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Figure 4.12: The H-NMR spectra of 179α  
 
 Königs-Knorr glycosidation (AgClO4 / CH2Cl2 , 2,4,6-collidine, 4 Å molecular sieves) of N-Fmoc-
serine tert-butylester 142 gave a 3:1 mixture of α-(180α) and β-galactoside (180β in 73 % yield. 
Flash chromatography provided pure 180α. The preferred formation of the α-galactoside is ascribed 
to a kinetic anomeric effect (no participating group at C-2) (Scheme 4.28). 
O
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AcO
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N3
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179
O
COOt-Bu
NHFmoc
HO
COOt-Bu
NHFmoc
142
α : β 
3: 1
AgClO4, Collidine
4 A MS, 0 oC, (93 %)
o
 
Scheme 4.28: Synthesis of a precursor of a C-disaccharide analogue of the TF-epitope. 
 
3J(H-1, H-2) = 3.2 Hz
3J(H-2, H-3) = 12.2 Hz
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
3.063.083.103.123.143.163.183.203.225.325.345.365.385.405.425.445.465.48
J=3.199J=12.156
H-5' H-4
H-2
 
Figure 4.13: the 1H-NMR (400 MHz) spectrum of 180α.  
The structure of 180 was confirmed by its 1H-NMR spectrum (Figure 4.10). The major product shows 
3J(H-1, H-2) =3.2 Hz, 3J(H-2, H-3) =12.2 Hz, and 3J(H-4, H-3) and 3J(H-4, H-5) less than 1 Hz. 
Additionally 2-D-NOESY 1H-NMR spectrum show cross peak between H-(C3) and H-(C5) which  
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confirms α-galactopyranoside structure. Further-more the chemical shift of H-4 (5.34 ppm) confirmes 
the pyranoside structure (Figure 4.13 and 4.14) (for more details see the experimental part). 
 
3J=3.0 Hz
3J=12.2 Hz
O
AcO
AcO
OAc
OAc
O
AcO
N3
OAc
180 α
O
COOt-Bu
NHFmoc
H
H
H
Typical α galactose  
Figure 4.14: 1H-NMR analysis of 180α. 
 
By MALDI-HRMS the molecular weight of 180α was confirmed (Figure 4.15). The purity of 180α 
was confirmed by elementary analysis (for more details see the experimental part). 
 
 
Figure 4.15: MALDI-HRMS of 180α. 
 
Treatment of 180α with zinc in acetic acid, THF, and Ac2O furnished 181 in 90 % yield, a protected 
form of a C-linked analog of the TF epitope α-conjugated to L-serine. This form should be suitable 
for the construction of clusters via peptide synthesis and further conjugation to immunogenic 
proteins. We have verified that the key intermediate 181 can be fully deprotected. When the TF-
antigen analogue 181 was treated with morpholine in DMF followed by TFA and then with 
MeONa/MeOH disaccharide 182 was obtained in 65 % yield after HPLC purification (Scheme 4.29). 
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3. MeONa
     (65 %)
 
Scheme 4.29: Synthesis of fully protected and deprotected TF-antigen. 
The molecular weight of the fully protected TF-antigen analogue 181 was confirmed by MALDI-
HRMS (Figure 4.16). The purity of 181 was confirmed by elementary analysis (for more details see 
the experimental part). 
 
 
 
Figure 4.16: MALDI-HRMS of 181. 
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4.2 Clustering of C-Disaccharide Analogues of the TF-epitope 
4.2.1 Introduction 
It was determined that multiple repeats or clustering of the carbohydrates was required for a robust 
and efficient immune response to be generated.171 The cassette approach to the synthesis of these 
antigenic glycosylamino acids allowed facile construction of the requisite glycopeptides. Single-
antigen vaccines, derived from both clustered (multiple copies of the same antigen displayed on a 
peptide backbone) and nonclustered (single copy of an antigen).172 
The strategy envisioned for the construction of vaccines would require the fashioning of a pool of 
glycosylamino acids in which the carbohydrate entities would be completely protected and the amino 
terminus blocked with the fluorenylmethyl carbamate (Fmoc) group. Solution-phase Fmoc-based 
peptide chemistry173 would be used to assemble the glycopeptide, and to attach a linker domain. 
Exhaustive deprotection as the last step would provide a final cluster readly for conjugation with 
KLH.174 
                                                     
171 Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L. J., Musselli, C., Zhang, X. F., Bencsath, K. P., Panageas, K. S., Chin, 
J., Hudis, C. A. Proc. Natl. Acad. Sci. USA 2001, 98, 3270. 
172 Keding S. J; Danishefsky S. J. Proc. Natl. Acad. Sci. USA 2004, 101,11937. 
173 1) The coupling steps for the two C-disaccharide antigen amino acids will mediated by HOAt/ HATU coupling reagents 
2) cleavage of the Fmoc group using 20 % piperidine in DMF 3) acetylation of the last deprotected N-terminus of the third 
building block in the cluster is required.  
174 So-Yeop, H.; Young-Ah, K. Tetrahedron 2004, 60, 2447.  
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4.2.2 The First Synthesis of a Cluster of a –CH(OH)– C-Disaccharide Analogue of the 
TF Antigen 
4.2.2.1 Using a Diamine Linker 
The 5:1 mixture of α-and β-galactopyranosides of protected serine 143 was treated with CF3COOH 
and Et3SiH in CH2Cl2 at 25 oC to give the free carboxylic acid 183. Treatment of 183 with (3-amino-
propyl)-carbamic acid tert-butyl ester 197a in the presence of HATU, HOAt, and collidine afforded 
amide 184 in 87 % yield for two steps.175 Selective removal of Fmoc protection group with 20 % 
piperidiene in DMF 176 gave the corresponding primary amine that was not isolated but directly 
treated with with carboxylic acid 183, HATU, HOAt, and collidine. This produced dipeptide 185 in 
81 % for two steps. Repeating the same sequence of reaction (Fmoc cleavage with piperidine, 
amidification with 183) led to the tripeptide 186a in 75 % yield. Removeal of Fmoc protective group 
of 186a on treatment with 20 % piperidine in DMF gave the corresponding primary amine which was 
not isolated but treated directly with excess of AcSH/Ac2O/collidine at 25 oC giving 186b. The latest 
operation converted all the three C(2)triazi-azido group in disaccharide moieties into the 
corresponding C(2)-acetamido system. This compound possesses a terminal NHBoc that was 
converted into the corresponding amino group on treatment with CF3COOH. Followed by  acylation 
with SAMA-OPfp in the presence of Hünig’s base ((i-Pr)2NEt) gave 187a. Zemplen’s deacetylation 
(NaOMe/MeOH, 25 oC) liberated fully deprotected C-disaccharide furnishing cluster 187b in 21 % 
overall yield based on 143. Compound 187b possesses a terminal thiol group ready for conjugation 
with an adequate modified immunogenic protein such as KLH.   
 
                                                     
175 Mono- and diclusters of the natural (O-linked) TF antigen have been reported: see e.g.: Kunz,H.; Birnbach, S.; Wernig, P. 
Carbohydr. Res. 1990, 202, 207. 
176 a) Carpino, L. A. J. Am. Chem. Soc. 1993, 115, 4397. b) Carpino, L. A.; Ionescu, D.; El-Faham, A. J. Org. Chem. 1996, 
61, 2460. 
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Scheme 4.30: Clustering of the CH(OH)–linked-disaccharide analogue of the TF-epitope  
4.2.2.2 Analysis of the Clustering Intermediate Products 
As expected, the signals observed in 1H-and 13C-NMR spectra of compounds 185, 186a, 186b, and 
187a were difficulty to attitude to any particular structure fragment due to the molecular complex of 
these products. 
However, the integration of separate groups of signals in 1H-NMR spectra of above mentioned 
products showed expected ratio. 
Thus, this groups of products was characterized exclusively by MALDI-HRMS and elementary 
analysis (Figures 4.17, 4.18). 
Additionally, transformation of 186a→186b was clerly observed by IR spectra of starting material 
and product. Triazide 186a was characterized by the presence of strong absorption band at 2115 in its 
IR spectrum which vanished completely after reduction to 186b. Instead, relatively strong C=O (st) 
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characteristic to amides was seen at 1685 cm-1 together with classical C=O (st) absorbtion band at 
1750 cm-1for acetate.  
 
product 184
[M+Na]+ [M+Na]+
product 185
[M+Na]+
product 186a
Calcd:1163.4284, 
Found: 1163.4208
Calcd: 1907.6622
 Found: 1907.6612
Calcd 2651.8959
 Found 2651.8909
 
Figure 4.17: MALDI-HRMS of 184, 185, 186a. 
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The molecular weight of tripeptide 187b, was confirmed by MALDI-HRMS (Figure 4.18). Fully 
deprotected peptide 187b was purified by HPLC177. The fractions were collected according to their 
MALDI-HRMS analysis (for more details see the HPLC chromatogram in the experimental part). 
[M-18]-
[M-32]-
Calcd 1569.5994
Found 1569.6000
 
 
Figure 4.18: MALDI-HRMS of 187b. 
 
4.2.2.3 Using an Aminothio Linker 
 
In a parallel study the fully protected (CH)OH-linked- disaccharide analogue of the TF-epitope 144 
was converted into cluster 192 bearing a 2-carboxamidothiol moiety, also ready for conjugation with 
an adequately modified immunogenic protein. For that, 144 was first treated with CF3COOH/ Et3SiH 
in CH2Cl2 at 25 oC to liberate the free carboxylic acid 188. The latter was not isolated but directly 
submitted to amidification (HATU, HOAt, collidine) with 2-tritylthioethaneamine (197b). providing 
189 in 90 % yield. Treatment of 189 with 20% piperidiene in DMF at 25 oC liberated the free amine 
of the L-serine moiety. It was reacted in situ with one equivalent of carboxylic acid 188 and HATU, 
HOAt and collidine  at 25 oC, giving dipeptide analogue 190 in 85 % yield. Repeating the same 
reaction sequence, a third unit of 188 was condensed with 190 giving an intermediate product that 
was treated with 20 % piperidiene in DMF. Subsequent detrytilation with CF3COOH/Et3SiH/CH2Cl2 
at 25 oC liberated the thiol that was not isolated but acetylated with Ac2O and Hünig’s base in CH2Cl2 
at 25 oC. Zemplen’s deacetylation of so-obtained thioacetate 191 with MeONa/MeOH at 25 oC 
provided the fully deprotected cluster 192 in 40 % overall yield (based on 189). 
 
                                                     
177 (100 % water → 0, and 0% CH3CN → 100 % ) used as eluant, reversed-phase column have C-18 stationary phase, and 
the Rt = 3.05min 
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Scheme 4.31: Clustering of the CH(OH) disaccharide analogue of the TF-epitope using 2-Amino-ethanethiol linker.  
4.2.2.4 Analysis of the Clustering Intermediate Products 
As expected like befor, the signals observed in 1H-and 13C-NMR spectra of compounds 190, and 191 
were difficults to attitude to any particular structure fragment due to the molecular complex of these 
products. 
However, the integration of separate groups of signals in 1H-NMR spectra of above mentioned 
products showed expected ratios. 
Thus, this group of products was characterized exclusively by MALDI-HRMS and elementary analysis 
(Figures 4.19, 4.20). 
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product189 product190 product191
[M+Na]+[M+Na]
+
[M+Na]+
Calcd:   1324.4511
Found:  1324.4510
Calcd:   2084.7049 
Found;  2084.7023
Calcd:   2464.8023
Found:  2464.8069
 
 Figure 4.19: MALDI-HRMS of 189, 190, 191. 
 
The molecular weight of mono-, di-, and tripeptides 189, 190 and 191, was confirmed by MALDI-
HRMS (Figure 4.18). Fully deprotected peptide 192 was purified by HPLC.178 The fractions were 
collected according to their MALDI-HRMS analysis, additionally elementary analysis of tripeptide 
was obtained (for more details see the HPLC chromatogram in the experimental part). 
[M]+
 
Figure 4.20: MALDI-HRMS of 192. 
 
In a model study, the purpose of which was to find suitable conditions for the conjugation of KLH 
with a thiol, we used the β-galactoside 136 and converted it into 195, 2-carboxamidoethanethiol 
attached to a CH(OH)-disaccharide analogue of TF epitope. 
 
Thus, 136 was hydrogenated (H2/Pd/C) to liberate the free carboxylic acid 193. Amidification of 193 
with 2-tritylthioethaneamine using HATU/HOAt and collidine at 25 oC provided 194 in 92 % yield. 
                                                     
178 (100 % water → 0, and 0% CH3CN → 100 % ) used as eluant, reversed-phase column have C-18 stationary phase, and 
the Rt = 3.9min 
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Treatment of 194 with 20 % piperidene in DMF cleaved away the Fmoc protective group. The free 
amine so-obtained was not isolated but directly acetylated with pure Ac2O. The intermediate product 
so-obtained was then detritylated by treatment with CF3COOH/Et3SiH/CH2Cl2 at 25 oC. Subsequence 
deacetylation with MeONa/MeOH gave 195 in 72 % overall yield based on 136. 
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Scheme 4.32: the preparation of the thio-linker β-glycoside 195.  
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4.2.3 The First Synthesis of a Cluster of a –(CH2)–Linked-Disaccharide Analogue of 
the TF Antigen 
The fully protected (CH2)-disaccharide analogue of the TF-epitope 181 was converted into cluster 
199 bearing a 4-carboxamidothiol moiety, also ready for third coupling with carboxylic acid 196. For 
that, 181 was first treated with CF3COOH/ Et3SiH in CH2Cl2 at 25 oC to liberate the free carboxylic 
acid 196. The latter was not isolated but directly submitted to amidification (HATU, HOAt, collidine) 
with 2-tritylthiobutylamine (197c) producing 198 in 82 % yield. Treatement of 198 with 20% 
piperidiene in DMF at 25 oC liberated the free amine of the L-serine moiety. It was then reacted in 
situ with one equivalent of carboxylic acid 196,HATU, HOAt, and collidine at 25 oC, giving 
dipeptide in which the S-trityl group of the 4-tritylthiobutylamine liker was cleaved during the 
chromatographical purification on silica gel which then treated by TIPSOTf/lutidine 0 oC, gave 
dipeptide 199 in 30 % yield.179  
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Scheme 4.33: Clustering of the (CH2)-linked-disaccharide analogue of the TF-epitope using 4-amino-butanethiol linker.  
Di-peptide 199 should undergo in the same manner to get tri-peptide of the (CH2)-linked-disaccharide 
analogue of the TF-epitope.  
                                                     
179 The synthesis is still in progress and the protocol still under further investigation. 
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4.3 Preparation of Conjugates of KLH with C-disaccharide Analogues of 
TF-epitope: 
4.3.1 Preparation of Peptide-MBS-KLH 
As described in chapter 1.2.1 keyhole limpet hemocyanin180 has produced up to now the best anti-
tumor conjugates with vaccines sugar epitopes. Therefore we chose this immunogenic protein as 
carrier for our TF-epitope analogues 187b, 192, and 195. The KLH protein was first coupled with 
MBS (m-maleimidobenzoyl-N-hydroxysuccinamide ester) by transamidification of lysine terminal 
NH2 group. After this transformation the maleimido-modified-KLH is ready to serve as a Michael 
accepter for following conjugation step. 
The thiol 195 bearing a CH(OH)-linked disaccharide β-linked to L-serine was reacted with the 
maleimide moieties of KLH-MBS by 1,4-addition reaction.181 This generates conjugate 195-MBS-
KLH. By considering the weight increase of KLH used in the experiment the ratio 195: KLH was 
determined to be 360:1 (Scheme 4.34) 
                                                     
180 (KLH, Molecular weight: 6-8 million) 
181 Zhang, S. L.; Graeber, L. A.; Helling, F.; Ragupathi, G.; Adluri, S.; Lloyd, K. O.; Livingston,P. O. Cancer Res. 1996, 56, 
3315. 
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Scheme 4.34: Preparation 195-MBS-KLH  
 
The same procedure was applied to MBS-KLH using the trimeric cluster 187b. The ratio of 
glycopeptide-to-protein for the conjugate (187b:KLH) was determined to be 45:1 by considering the 
weight increase of KLH used in the experiment (Scheme 4.35). 
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Scheme 4.35: Preparation 187b-MBS-KLH  
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4.3.2 Preparation and purification  methods of the KLH-Conjugates and Discussion  
As the preparation and purification of such kind of KLH-conjugates is not common for the synthetic 
organic chemists, we would like to focus here on the experimental details of this final key step of our 
project. 
 Keyhole limpet hemocyanin KLH182 (5 mg) was dissolved in phosphate buffer (0.01M, pH 7.0, 0.5 
mL). Then m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (1mg, 0.0032 mmol) was 
dissolved in DMF(70µL) and added to the KLH solution. The resulting mixture was stirred for 1 h at 
20 oC, and MBS-KLH conjugate was submitted to pre-equilibrated Sephadex G-25 column with 
phosphate buffer (0.05M, pH 6.0).183 The mixture was eluted with phosphate buffer (0.05M, pH 6.0), 
and the first 3.5 ml of elute were collected in 7 Eppendorfs tubes (0.5 ml/Eppendorf). The fractions 
containing MBS-KLH conjugate were put in dialysis tube,184 let to equilibrate for 3h and lyophilized.  
Synthetic peptide 187b (5 mg, 0034 mmol) was dissolved in phosphate buffer solution (0.01 M, pH 
7.3, 1ml) and added to the resulting MBS-KLH conjugate from the step above. The pH of the 
resulting solution was adjusted to 7.3,185 and the reaction mixture was stirred for 3h at 20 oC. Then it 
was submitted to pre-equilibrate Sephadex G-25 column with double distilled water, and 3.5 ml of 
elute was collected in 7 Eppendorf tubes (0.5 ml/Eppendorf). The fractions containing peptide-MBS-
KLH conjugates were collected and purified by dialysis tube, let to equilibrate for 3h and lyophilized.  
Bradford reagent t 186 was used to determine the presence of peptide-MBS-KLH conjugate in the 
collected fractions. 
Thus in each of 7 wells187 of microwell plate Bradford reagent ( 100µL) was diluted with double 
distilled water ( 100µL) and after 1min of equilibration, aliquot ( 10µL) of every chromatography 
fraction were added respectively in above mentioned 7 wells. 
The color change from brown to blue indicated the presence of peptide-MBS-KLH conjugates. The 
corresponding fractions were collected, submitted to dialysis for 3h at 20 oC and lyophilized (Scheme 
4.21).  
 
                                                     
182 Megathura crenulata, High Purity, Endotoxin-free, Glycerol, Cat. No 374813 from CALBIOCHEM 
183 Pre-equilibrated mean elute the solvent for 3 times (5ml each time), wait minimum for 15 min befor using the column. 
184 30,000 cut off dialysis tube 
185 the pH of the solution was adjusted using 0.1M HCl or 0.1M NaOH, 
186 The solution was prepared by dissolving 100 mg Coomassie Brilliant Blue G-250 (100 mg) in 50 ml 95% ethanol 
followed by addition of 100 ml 85% (w/v) phosphoric acid. The resulting mixture was dilute to 1 liter using double distilled 
water. When the dye has completely dissolved the final solution was filtered through Whatman #1 paper just before the use 
(the color of the reagent has to be brown). 
187 The number of wells corresponds to the number of collected fractions.  
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1. add 100µl Bradford solution, and100µl of double distilled water
2. add 10µl of the collected fractions.
3. the blue color is indicatating the presence of protein exist in 
corresponding fractions.
H
G
F
A
B
C
D
E
1 2 3 4 5 6 7 8 9 10 11 12  
Figure 4.21: microwell plate  
. 
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4.4 Perspectives 
4.4.1 Toward a 2,6 ST-antigen analogue  
As we have seen in section 1.2.1 several important sugar epitopes containing the 2,6-Sialyl moieties. 
With the isolation of C-disaccharide 175 we have the possibility, following chemistry developed by 
Beau and co-workers,109 to transform it into a C,C-trisaccharide of type 204 (Scheme 4.36). For that, 
liberation of the hydroxylmethyl group in 175 by treatement with Bu4NF and subsequent Swern 
oxidation should generate aldehyde 201. one carbon homologation with ylide Ph3P=CHOMe will 
provide key aldehyde 202a which ready for samarium-Reformatsky coupling with a protected sialyl 
acid 202b. a mixture of diastereomeric alcohols 203a should be deoxygenated under standard 
conditions to generate the protected C,C-trisaccharide 203c. This compound should be suitable for α-
O-glycosidation of semi- protected L-serine. Compound 205 obtained after the reduction of azide 
moiety should be used to generate clusters and their conjugates with KLH.  
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Scheme 4.37: Proposal toward the synthesis of 2,6 ST-antigen analogue C 
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4.4.2 Toward a Gal-β-C(1→3)-GalNAc-α-C-aminoacid 
Danishefsky and co workers172 have shown that the vaccines made out of O-disaccharide conjugated 
with KLH have similar activity independently from the length of linker connecting the disaccharide 
and the peptide mimetic.171 We have thus envisioned to use our C-disaccharide 178 in a C-
glycosidation with an allylsilane under acidic conditions (Me3SiOTf, BF3·OEt2). This experiment has 
been done and generated the expected α-C-glycoside 206. Unfortunately its purification has been 
problematic up to now, most probably because of the rapid intermolecular dipolar cycloaddition 
between the propene moiety and the 2-azido substituent. Once the condition will be found to avoid 
this intermolecular cycloaddition, well established routs are available to convert alkene 206 into 207 
and then further into 208 (Scheme 4.38). 
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Scheme 4.38: Proposal Toward a Gal-β-C(1→3)-GalNAc-α-C-aminoacid 
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5 CONCLUSION AND SUMMARY  
 
Our work was initiated on the hypothesis that, the C-linked disaccharide would constitute 
better cancer vaccines as they would be expected to be more stable towards hydrolysis via 
glycosidase in the blood stream. Given the conformational similarity between C- and O-
disaccharide, and the expected higher biological activity of C-linked disaccharide, we sought 
to design and synthesize potential cancer vaccines based on C-linked disaccharide analogue 
of prostate cancer antigens. Towards achieving this goal, we have been able to accomplish 
the following: 
 
We have reported an efficient synthesis of C-linked disaccharide α-conjugate with L-Serine 
for the first time. Our flexible synthetic strategy allows us to produce two non-hydrolysable 
C-disaccharide analogues of Thomsen-Friedenreich antigen. The fully protected  TF-antigens 
analogues N-[(9H-Fluoren-9-yl-methoxy)carbonyl]-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-
dideoxy-α-D-galactopyranosyl}-L-serine tert-butyl ester (144), and N-[(9H-fluoren-9-
ylmethoxy)carbonyl]-{4,6-O-Acetyl-3-C-[2,6-anhydro-1-deoxy-3,4,5,7-tetra-O-acetyl-D-
glycero-L-manno-heptitol-1-C-yl]-2-Acetamido-2,3-dideoxy-α-D-galacto-pyranosyl}-L-
serine tert-butyl ester (181) have been employed in the preparation of cluster  form.  
 
We have employed TF-antigen analogue (144) successfully in preparation of  a fully 
deprotected thio-glycotripeptide N-acetyl-O-{α-D-glyco}-D-seryl-O-{α-D-glyco}-D-seryl-
rac-N-(3-[(acetylthio)amino]propyl)-O-{α-D-glyco}-D-serinamide (187b), the latter was 
conjugates to the KLH carrier via MBS by Michael addition.  The ratio of glycopeptide-to-
protein for conjugate 187b-MBS-KLH was determined to be 45:1. The conjugate molecule 
derived during the study reported here, will find use as anti-prostate cancer vaccine 
candidates, molecular probes for epitope mapping of anti-prostate cancer antibodies and for 
other biological studies, to reveal the minimal structural requirements that convey protection 
from prostate cancer. 
 
We developed an efficient synthetic strategy of the a key intermediate 4-O-acetyl-6-[O-(tri-
isopropylsyliyl)]-3-C-[2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-acetyl-D-glycero-L-manno-
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heptitol-1-C-yl]-2-azido-2,3-dideoxy-α,β-D-galacto-hexopyranose thiophenol (175) which 
can be applied to the further synthesis of a C,C-trisaccharide analogue of the 2,6 ST-antigen 
which does not require any complicated synthetic step. The possibility of rapid convergent of 
intermediate into C, C-linked trisaccharide 2,6-ST-antigen analogue should facilitate the 
construction of a host of glycopeptide conjugates for biological evaluation. 
 
The fully deprotected TF-antigen analogues 3-C-[2,6-anhydro-1R-D-glycero-L-manno-
heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galacto-pyranosyl-L-serine 145 and 3-
C-[2,6-anhydro-1-deoxy-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-
dideoxy-α-D-galacto-pyranosyl-L-serine 182 were prepared and will be used in 
conformational studies to make a comparison between C-disaccharide TF-antigen analogue 
and native TF-antigen, this studied will give us in the future an idea about the possible 
required change on these analogues in order to reach to maximum biological activity.   
 
We have used successfully for the first time methoxybenzylamine as Michael donor without 
using any catalyst. Additionally Michael adduct   1,6-anhydro-3-{(1R)-2,6-anhydro-3,4,5,7-
tetrakis-O-[(tert-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}–2-[(N-benzyl-N-
methoxyl)amino]2,3-dideoxy-β-D-xylo-hexopyran-4-ulose (131a) has been obtained pure 
after isomerization during the chromatography on silica gel and, we have employed 
successfully  this amine as azide precursor. 
 
The biological activity of conjugate 187b-MBS-KLH on prostate cancer is currently under 
investigation in collaboration with Prof. P. O. Livingston group, USA; Current studies will 
examine the production of prostate cancer antibodies upon treatment with 187b-MBS-KLH. 
We hope that these studies will shed some light on the activities of these compounds and the 
possibilities of developing effective vaccine based therapeutic strategies using our approach.  
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EXPERIMENTAL SECTION 
General Remarks 
Reagents were purchased from Acros, Fluka, Senn, Aldrich or Merk and used without further 
purification. All solvents for extraction and chromatography were distilled prior to use. Anhydrous 
THF and Et2O and toluene were distilled from sodium and benzophenone, CH2Cl2 from CaH2 and 
methanol magnesium. Reactions were monitored by TLC (Merk Kiesegel 60F254) silica gel plates; 
detection with UV(254 nm) light or molybdic reagent (21g of (NH4)6Mo7O24.4H2O, 1g of Ce(SO4)2, 
31 ml H2SO4 and 470 ml of H2O). Flash chromatography (FC) used 230-400 mesh silica gel (Merk 
No.9385). Melting points were measured with a Mettler FP52 and were uncorrected. Optical rotations 
were measured with a JASCO DIP-370 digital polarimeter. UV spectra were recorded on a Kontron 
Uvikon 810 CW spectrophotometer. IR spectra were recorded on Perkin Elmer Paragon 1000 FT-IR 
spectrometer. Mass spectra were recorded on a Nermag R 10-10C in chemical ionisation mode. 
Electron spray mass analyses were recorded on a Finnagan MAT.SSQ 710C spectrometer in positive 
ionisation mode.1H-NMR spectra were recorded on Bruker DPX-400 FT, Bruker ARX-400 FT, or 
AMX-600 spectrometers; all 1H signal assignments were confirmed by COSY spectra. 13C-NMR 
spectra were recorded on Bruker DPX-400 FT (100.61 MHz), Bruker ARX-400 FT (100.61 MHz) 
machines; all 13C signal assignments were confirmed by HMQC spectra. Chemical shifts in ppm, 
relative to internal standard such as residual signals of solvents, coupling constants in hertz. High 
resolution FAB mass spectra were recorded on a FAB-LSIMS (Uniservidad de Sevilla – Spain). 
Microanalyses were performed by the Ilse Beetz Laboratory, Kronach (Germany). 
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1,6-Anhydro-3-{(1R)-2,6-anhydro-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-glycero-hex-2-enopyran-4-ulose 
(97a). 
O
TBSO
TBSO
OTBS
OTBS
97a
O
O
O
HO
1
23
4
5
6
1'2'
3'4'
5' 6'
7'
 
A solution of Et2AlI 1M in toluene  ( 12 mL, 12.0 mmol) was added dropwise to a mixture 
of aldehyde 95 (6.0 g, 9.4 mmol) and isolevoglucosenone 96 (2.0 g, 15.9mmol) in CH2Cl2 
(25 mL ) at –78 oC. The solution was stirred at this temperature for 2h and diluted with 
Et2O (500ml). A 2M aq. soln. HCl (50 mL) was added. The aq. phase was extracted with 
Et2O (2 × 200ml). The combined organic phases were washed sequentially with 2M aq. 
soln. HCl (50 mL), H2O (50 mL), and brine (50 mL), dried over (MgSO4) and 
concentrated, FC (9:1, light petroleum ether / EtOAc) afforded 6.89 gm (96 %) of 97a, 
colorless oil.  
 
[α]25589 = +79, [α]25577 = +85, [α]25435 = +334, [α]25405 = +710 (c 0.24, CHCl3). 
 
IR (film) 3400, 2950, 2860, 1695, 1465, 1360, 1260, 1090, 830, 770 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ 
 7.39 (dd, 3J (H-C(1), H-C(2)) = 3.5 , 4J (H-C(2), H-C(1’)) = 1.0 , H-C(2)); 5.83 (d, 3J (H-
1, H-C(2)) = 3.5 , H-C(1)); 4.75 (dd, 3J (H-C(5), H-C(6)) = 6.4 , 3J (H-C(5), H-C(6)) = 1.3 
Hz, H-C(5)); 4.45 (d, 3J( H-C(3’), H-C(4’)) = 8.6, H-C(3’)); 4.26 (d, 2J = 12.4 , Ha-C(7’)); 
4.23 (ddd, 3J (H-C(1’), H-C(2’)) = 7.0, 3J (H-C(1’), OH-C(1’)) = 6.7, 4J (H-C(2), H-C(1’)) 
= 1.0, H-C(1’)); 4.06 (dd, 2J=8.3, 3J (H-C(5), Hexo-C(6)) = 6.4, Hexo-6); 3.99 (d, 3J (H-
C(3’), H-C(4’))= 8.6, H-C(4’)); 3.96 (d, 3J (H-C(5’), H-C(6’)) = 4.1, H-C(5’)); 3.91 (t, 
3J(H-C(1’), H-C(2’)) = 3J (H-2’, H-3’) = 7.0, H-C(2’)); 3.80 (dd, 3J (H-C(5’), H-C(6’)) = 
4.1 , 3J (H-C(6’), Hb-(7’)) = 1.9 Hz, H-C(6’)); 3.75 (dd, 2J=12.7, 3J (H-C(6’), Hb-C(7’)) = 
1.9, Hb-(7’)); 3.65 (dd, 2J= 8.3, 3J (H-C(5), Hendo-C(6)) = 1.3, Hendo-C(6)); 2.94 (d, 3J (H-
C(1’), OH-C(1’) = 6.7, OH-C(1’)); 0.94, 0.93, 0.90, 0.90 (4s, 9H 4, t-Bu × 4), 0.14, 0.12, 
0.10, 0.09, 0.08, 0.07, 0.06, 0.05 (8s, 3H × 8, SiCH3 × 8); 
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13C NMR (100.6 MHz, CDCl3): δ 
194.5 (s, C(4)); 143.6 (d, 1J(C,H) = 165, C(2)); 137.0 (s, C(3)); 96.9 (d, 1J(C,H) = 177, 
C(1)); 79.7 (d, 1J(C,H) = 141, C(2’)); 79.1 (d, 1J(C,H) = 160, C(5)); 73.1 (d, 1J(C,H) = 
143, C(6’)); 70.5 (d, 1J(C,H) = 144, C(5’)); 67.3 (d, 1J(C,H) = 142, C(3’)); 67.1 (d, 
1J(C,H) = 147, C(1’)); 66.9 (d, 1J(C,H) = 138, C(4’)); 62.3 (t, 1J(C,H) = 154, C(6)); 58.2 
(t, 1J(C,H) = 142, C(7’)); 25.9, 25.89, 25.85, 25.7(4q, 1J (C,H) = 125, (CH3)3CSi); 18.2; 
18.1, 17.9; 17.0 (4s, (CH3)3CSi); -4.4; -4.6; -4.7; -4.9, -5.0; -5.1, -5.3; -5.5; (8q, 1J (C,H) = 
118 , CH3Si); 
 
MALDI-HRMS Calcd for (M + Na) C37H74O9Si4Na 797.4307; found 797.4310. 
 
Anal. calcd for C37H74O9Si4 (775.32): C 57.32, H9.62; found: C 57.24, H 9.56. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 97a: 
 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.0
H-2
H-1
H-5
H-3'
Ha-7', H-1' Hexo-6, H-4', H-5', H-2'
H-6', Hb-7', Hendo-6
OH
7.347.367.387.407.427.44
5.8255.8305.8355.8405.8455.8 05.8 5
3.804.004.204.404.60
sm
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1,6-Anhydro-3-{(1R)-2,6-anhydro-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}–2-[(N-benzyl-N-methoxyl)amino]2,3-dideoxy-β-D-
xylo-hexopyran-4-ulose 131a. 
O
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 A solution of 97a (200 mg, 0.258 mmol) in CH2Cl2 (1ml) was stirred at rt. Then 
BnNHOMe (120 mg, 0.876 mmol)  was added. The mixture  was allowed to stir at 
ambient temperature for 12 h. Slow chromatography on silica gel (9:1 , light petroleum 
ether/ether), afforded 193 mg (82 %) of 131a, colorless oil. 
 
[α]25589 = −1.7, [α]25577 = −2, [α]25435 = −21, [α]25405 = −37 (c 0.40, CHCl3). 
 
IR (film): 3550, 2955, 2855, 1720,1470, 1265, 1130, 880, 780, 740 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
 7.46-7.43 (m, 2H,.ArH); 7.38-7.26 (m, 3H, ArH); 6.07 (s, H-C(1)); 4.50 (dd, 3J (H-5, 
Hexo-C(6)) = 5.8, 3J (H-5, Hendo-C(6)) = 0.9 , H-5); 4.27(dd, 3J (H-C(1’), H-C(2’)) = 6.6, 3J 
(H-C(1’), H-C(3)) = 2.6, H-C(1’)); 4.23 (d, 2J = 13.0, Ha-C(NCH2Ph)); 4.19-4.10(m, 3H, 
H-C(6’), Ha-C(7’), H-C(5’)); 3.95 (d, 3J(H-C(3’), H-C(4’)) = 4.2 , H-C(3’)); 3.87 (d, 2J = 
13.0, Hb-C(NCH2Ph)); 3.84 (d, 2J = 7.6, Hendo-C(6)); 3.85-3.80 (m, 2H, H-C(4’), H-C(2’)); 
3.74 (dd, 2J = 7.6, 3J (Hexo-C(6), H-C(5)) = 5.8 , Hexo-C(6)); 3.70 (dd, 2J = 12.9, 3J (Hb-
C(7’), H-C(6’)) = 1.2, Hb-C(7’)); 3.45 (d, 3J (H-C(2), H-C(3)) = 9.83, H-C(2)); 3.25 (m, 
4H, H-C(3), 3H-C(OCH3)); 0.96, 0.93, 0.92, 0.87 (4s, 36H, 36H-C(SiC(CH3)3)); 0.14, 
0.13, 0.13, 0.12, 0.11, 0.10, 0.10, 090, (8s, 24H, 24H-C(SiCH3));  
 
13C NMR (100.6 MHz, CDCl3):δ 
 214.0 (s, C(4)); 137.0 (s, C(arom)); 129.8 (d, 1J(C,H) = 159, C(arom)); 128.1 (d, 1J(C,H) 
= 156, C(arom)); 127.3 (d, 1J(C,H) = 159, C(arom)); 100.3 (d, 1J (C,H) = 179, C(1)); 79.5 
(d, 1J (C,H) = 146, C(2’)); 78.4 (d, 1J (C,H) = 159, C(5)); 73.3 (d, 1J (C,H) = 154, C4’); 
70.2 (d, 1J(C,H) = 141, C(3’)); 67.4 (d, 1J(C,H) = 144, C(1’)); 70.4 (d, 1J(C,H) = 146, 
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C(5’)); 67.0 (t, 1J(C,H) = 154, C(6)); 66.7 (d, 1J(C,H) = 147, C(6’)), 64.9 (d, 1J(C,H) = 
126, C(2)); 62.0 (q, 1J(C,H) = 125, C(OCH3)); 58.5 (t, 1J(C,H) = 143, C(7’)); 46.3 (d, 
1J(C,H) = 143 , C(3)), 25.9, 25.89, 25.85, 25.7(4q, 1J (C,H) = 125, (CH3)3CSi); 18.2; 18.1, 
17.9; 17.0 (4s, (CH3)3CSi); -4.4; -4.6; -4.7; -4.9, -5.0; -5.1, -5.3; -5.5; (8q, 1J (C,H) = 118 , 
CH3Si). 
 
MALDI-HRMS Calcd for (M + Na) C45H85NO10Si4Na 934.5148; found 934.5134. 
 
Anal. calcd for C45H85NO10Si4 (912.50): C 59.23, H9.39, N 1.53; found: C 59.33, H 9.33, 
N 1.55. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 131a: 
 
 
0.0 0.5 1.0 1.52.02.53.03.54.0 4.55.0 5.5 6.0 6.5 7.0 7.5 8.0 
3.203.40 3.60 3.80 4.00 4.20 4.40 4.60 
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1,6-Anhydro-3-{(1R)-2,6-anhydro-3,4,5,7-tetra-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}–2-[(N-benzyl-N-methoxy)amino]-2,3-dideoxy-β-D-
galacto-hexopyranose (132). 
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 A THF solution of LiBH4  (7.0 mL, 14.0 mmol) was added dropwise to a solution of 131a 
(3.50 mg, 3.84 mmol) in 50 ml of THF at –78 oC. The mixture was stirred at - 78 oC to 15 
oC for 4h. An aq. NH4Cl solution (25 ml) was added. The reaction mixture was warmed to 
20 oC. An aq. solution of sodium potassium tartrate (25ml) was added. The aq. phase was 
extracted with CH2Cl2 (100 mL/ 3 times). The combined org. phases were dried, 
concentrated in vacuo. FC(4:1 , light petroleum ether/Et2O) gave 3.22 g (92 %) of 132, 
colorless oil. 
 
[α]25589 = +26, [α]25577 = +28, [α]25435 = +49, [α]25405 = +57 (c 0.28, CHCl3). 
 
IR (film): 3475, 2955, 2855, 1715, 1635, 1470, 1255, 1100, 835, 780, 740 cm-1 
 
1H NMR (400 MHz, CDCl3): δ 
 7.45-7.39 (m, 2H,.ArH); 7.38-7.27 (m, 3H, ArH); 5.84 (s, H-C(1)); 4.84 (m, H-C(4)), 
4.54 (dd,3J(H-5, H-C(4)) = 7.0, 3J (H-C(5), Hexo-C(6)) = 5.4, H-C(5)); 4.43 (dd, 2J = 11.5, 
3J (Ha-C(7’), H-C(6’)) = 9.9, Ha-C(7’)); 4.37-4.30 (m, 2H, Hendo-C(6), H-C(1’)); 4.27 (dd, 
3J(H-C(5’), H-C(6’)) = 6.4, 3J (H-C(5’), HC-(4’)) = 2.6, H-C(5’)); 4.13 (d, 3J(H-C(2’), H-
(1’)) = 9.3, H-C(2’)); 3.64 (d, 2J = 13.1, Ha-C(NCH2Ph)); 3.98-3.89 (m, 3H, H-C(3’), H-
C(6’), Hb-C(NCH2Ph)); 3.72 (dd, 3J(H-C(4’),H-C(3’)) = 3.5, 3J (H-C(4’), H-C(5’)) = 2.6, 
H-C(4’)); 3.80 (dd, 2J = 11.5, 3J (Hb-C(7’), H-C(6’)) = 1.9, Hb-C(7’)); 3.51 (dd, 2J = 7.4, 
3J(H-5, Hexo-C(6)) = 5.4, Hexo-C(6)), 3.3 (s, 3H, H-C(OCH3)); 4.24 (d, 3J(H-C(2), H-C(3)) 
= 9.6, H-C(2)); 2.64 (ddd, 3J(H-3, H-2) = 9.6, 3J(H-3, H-4) = 6.7, 3J (H-C(3), H-C(1’)) = 
2.6, H-C(3)); 0.98, 0.95, 0.94, 0.93 (4s, 36H, 36H-C(SiC(CH3)3)); 0.16, 0.15, 0.14, 0.13, 
0.120, 0.12, 0.11,0.10 (8s, 24H, 24H-C(SiCH3)).  
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13C NMR (100.6 MHz, CDCl3):δ 
 137.6 (s, C(arom)); 129.6 (d, 1J(C,H) = 159, C(arom)); 128.3 (d, 1J(C,H) = 156, C(arom)); 
127.3 (d, 1J(C,H) = 156, C(arom)); 99.6 (d, 1J (C,H) = 179, C(1)); 79.1 (d, 1J(C,H) = 147, 
C(6’)); 73.6 (d, 1J (C,H) = 159, C(5)); 73.4 (d, 1J (C,H) = 154, C4’); 70.7 (d, 1J(C,H) = 
141, C(3’)); 69.0 (d, 1J(C,H) = 144, C(1’)); 67.4 (d, 1J (C,H) = 146, C(2’)); 67.3 (d, 
1J(C,H) = 146, C(5’)); 66.3 (t, 1J(C,H) = 144, C(4)); 64.2 (d, 1J(C,H) = 143 , C(2)); 61.6 
(t, 1J(C,H) = 154, C(6)); 61.6 (q, 1J(C,H) = 122, C(OCH3)); 58.5 (t, 1J(C,H) = 143, C(7’)); 
58.5 (t, 1J (C,H) = 145, C(NCH2Ph); 34.9 (d, 1J(C,H) = 126, C(3)); 26.0, 25.9, 25.8, 
25.7(4q, 1J (C,H) = 125, (CH3)3CSi); 18.3; 18.0, 17.9; 17.8 (4s, (CH3)3CSi); -4.4; -4.6; -
4.8; -4.9, -5.0; -5.1, -5.3; -5.5; (8q, 1J (C,H) = 118 , CH3Si). 
 
MALDI-HRMS Calcd for (M + Na) C45H87NO10Si4Na 936.5304; found 936.5304. 
 
Anal. calcd for C45H87NO10Si4 (914.52): C 59.10, H9.59, N 1.53; found: C 59.15, H 9.50, 
N 1.62. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 132: 
 
 
0.0 0.5 1.0 1.52.02.53.03.54.04.55.05.5 6.0 6.57.0 7.5 8.0 
2.22.42 .62 .83.03.23.43 .63.8 4.0 4.2 4.4 4 .6 4.8 5.0 
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4-O-Acetyl-1,6-anhydro-3-{(1R)-1,3,4,5,7-penta-O-acetyl-2,6-anhydro-D-glycero-L-
manno-heptitol-1-C-yl}-2-[(N-benzyl-N-methoxy)amino]-2,3-dideoxy-β-D-galacto-
hexopyranose (133). 
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Compound 132 (1.12g, 1.22 mmol) was dissolved in THF (3 mL), a solution of TBAF in 
THF  (8 ml g, 9.76 mmol) was added, and the solution was stirred for 3 h at 20 oC. The 
mixture was evaporated to dryness, then the residue was dissolved in pyridine (5 ml). A 
catalytic amount of DMAP was added, then acetic anhydride (3ml), and the solution was 
stirred for 2 days at 20 oC. MeOH (5 ml) was added, the mixture was evaporated to 
dryness, then dissolved in EtOAc (25 mL). The solution was quenched with aqueous HCl 
(10 ml), washed with a sat. aq. solution of NaHCO3 (5 mL), water and brine and dried 
(MgSO4). Evaporation of the filtrate and FC gave 870 mg (100 %) of 133, colorless oil. 
 
[α]25589 = +73, [α]25577 = +77, [α]25435 = +147, [α]25405 = +176 (c 0.18, CHCl3). 
 
IR (film): 3060, 2985, 2895, 1750, 1665, 1430, 1370, 735, 700 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
 7.47-7.42 (m, 2H, H-C(arom)); 7.33-7.22 (m, 6H, H-C(arom)); 5.87-5.77 (m, 3H, H-
C(1’), H-C(1), H-C(4)); 5.33 (dd, 3J(H-C(6’), H-C(5’)) = 6.2, 3J(H-C(6’), Ha-C(7’)) = 3.1, 
H-C(6’)); 5.25 (dd, 3J(H-C(3’), H-C(4’)) = 4.0,3J(H-C(3’), H-C(2’)) = 3.7, H-C(3’)); 4.84 
(dd, 3J(H-C(4’), H-C(3’)) = 4.0, 3J(H-C(4’), H-C(5’)) = 1.2, H-C(4’)); 4.72 (dd, 3J(H-C(5), 
H-C(4)) = 7.7,3J(H-C(5), Hexo-C(6)) = 4.6,H-C(5)); 4.68 (d, 2J = 12.9, Ha-C(7’)); 4.29-
4.20 (m, 3H, Hb-C(7’), H-C(2’), H-C(5’)); 4.02 (d, 2J = 12.9, Ha-C(NCH2Ph); 3.95 (d, 2J = 
7.4, Hendo-C(6)); 3.79 (d, 2J = 12.9, Hb-C(NCH2Ph); 3.42 (dd, 2J=7.4, 3J(Hexo-C(6),H-C(5)) 
= 4.6, Hexo-C(6)); 3.20 (s, 3H, H-C(OCH3); 2.72 (m, H-C(2); 5.31 (ddd, 3J(H-C(3), H-
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C(2)) = 10.8, 3J(H-C(3), H-C(4)) = 5.5, 3J(H-C(3), H-C(1’)) = 2.6, H-C(3)); 2.13-1.87 (6s, 
18H, H-C(CH3COO)).  
 
13C NMR (100.6 MHz, CDCl3):  
δ 170.7, 170.1, 169.8, 169.4, 169.2, 168.8 (6s, C(CH3COO)); 137.3 (s, C(arom)); 129.9 (d, 
1J(C,H) = 159, C(arom)); 128.0 (d, 1J(C,H) = 156, C(arom)); 127.2 (d, 1J(C,H) = 156, 
C(arom)); 99.3 (d, 1J(C,H) = 179, C(1)); 71.9 (d, 1J(C,H) = 159, C(5)); 71.7 (d, 1J(C,H) = 
146, C(2’)); 67.3 (d, 1J(C,H) = 144, C(1’)); 67.1 (d, 1J(C,H) = 154, C(4’)); 66.6 (d, 
1J(C,H) = 141, C(3’)); 66.3 (d, 1J(C,H) = 144, C(4)); 65.5 (d, 1J(C,H) = 147, C(6’)); 65.4 
(d, 1J(C,H) = 146, C(5’)); 64.5 (d, 1J(C,H) = 143, C(2)); 62.6 (t, 1J(C,H) = 154, C(6)); 62.3 
(q, 1J(C,H) = 122, OCH3); 59.2 (t, 1J(C,H) = 143, C(7’)); 59.2 (t, 1J (C,H) = 145, 
C(NCH2Ph), 33.0 (d, 1J(C,H) = 126, C(3)); 21.0-20.5 (6q, 1J(C,H) = 130, H-C(CH3COO)). 
 
MALDI-HRMS  Calcd for (M + Na) C33H43NO16Na 732.2479; found 732.2469. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 133: 
 
 
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 
5.15 5.205.25 5.30 5.35 5.40 4.554.604.654.704.75 4.80 4.85 4.90 2.48 2.50 2.52 2.542.562.582.602.62
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4,6-Di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-
heptitol-1-C-yl]-2-[(N-benzyl-N-methoxy)amino]-2,3-dideoxy-β-D-galacto-
hexopyranosyl phenylsulfide (134). 
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A mixture of 133 ( 0.316 g, 0.450 mmol), (phenylthio)trimethylsilane (0.254 mL, 1.345 
mmol), and ZnI2 , (0.42 g, 1.333 mmol) in dry CH2Cl2, (7 mL) was stirred at 20 oC for 2 h. 
The mixture was diluted with CH2Cl2 (50 mL) and washed successively with sat. aq 
NaHCO3, (30 mL), water (20 mL, 3 times), and brine (20 mL), dried (MgSO4), and 
evaporated. The residue was dissolved in THF (10 mL), TBAF (0.450ml, 0.450 mmol ) 
was added, the mixture was stirred at 20 oC for 1h. The solvent was evaporated, and the 
residue was dissolved in pyridine (10mL), then DMAP (40 mg) and Ac2O (4mL) were 
added. The mixture was stirred at 20 oC for 18h. The solvent was evaporated, FC gave 370 
mg (96%) of 134, colorless oil. 
 
[α]25589 = +24, [α]25577 = +27, [α]25435 = +47, [α]25405 = +53 (c 0.21, CHCl3). 
 
IR (film): 2965, 1735, 1435, 1370, 1220, 1040, 1025, 940, 890 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ  
7.65-7.55 (m, 4H, H-C(arom)); 7.35-7.25 (m, 6H, H-C(arom)); 6.10 (dd, 3J(H-C(1’), H-
C(3)) = 9.9, 3J(H-C(1’), H-C(2’)) = 1.5, H-C(1’)); 5.61 (s, H-C(4)); 6.34 (d, 3J(H-C(1), H-
C(2)) = 8.6, H-C(1)); 5.31 (dd, 3J(H-C(5’), H-C(6’)) = 6.5, 3J(H-C(5’), H-C(4’)) = 3.1, H-
C(5’)); 5.173 (t, 3J(H-C(4’), H-C(3’)) = 3.4,H-C(4’)); 4.86 (d, 3J(H-C(3’), H-C(4’)) = 3.4, 
H-C(3’)); 4.75 (dd, 2J = 12.9, 3J(Ha-C(7’), H-C(6’)) = 9.9, Ha-C(7’)); 4.59 (d, 2J = 12.6, 
Ha-C(NCH2Ph); 4.50 (d, 3J(H-C(2’), H-C(1’)) = 10.2, H-C(2’)); 4.38 (dd, 2J = 12.9, 3J(Ha-
C(7’), H-C(6’)) = 1.8, Hb-C(7’)); 4.30-4.18 (m, 2H, Hendo-C(6), H-C(6’)); 4.08 (dd, 
2J=11.4, 3J(Hexo-C(6),H-C(5)) = 7.4, Hexo-C(6)); 3.90 (t, 3J(H-C(5), Hexo-C(6)) = 6.8,H-
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C(5)); 3.75 (d, 2J = 12.6, Ha-C(NCH2Ph); 3.11-3.08 (m, 4H, H-C(OCH3), H-C(2)); 2.57 
(d, 3J(H-C(3), H-C(2)) = 12.3, H-C(3)); 2.27-1.83 (7s, 21H, CH3COO). 
 
13C NMR (100.6 MHz, CDCl3): δ Data for the β anomer:  
 170.6, 170.5, 170.3, 169.8, 169.6, 169.1, 169.0 (7s, -COO); 138.7 (s, C(arom)); 134.0 (s, 
C(arom)); 131.9 (d, 1J(C,H) = 162, C(arom)); 130.0 (d, 1J(C,H) = 158, C(arom)); 128.7 (d, 
1J(C,H) = 159, C(arom)); 128.0 (d, 1J(C,H) = 159, C(arom)); 127.4 (d, 1J(C,H) = 159, 
C(arom)); 127.3 (d, 1J(C,H) = 159, C(arom)); 83.4 (d, 1J(C,H) = 159, C(1)); 76.2 (d, 
1J(C,H) = 139, C(5)); 72.9 (d, 1J(C,H) = 150, C(6’)); 67.6 (d, 1J(C,H) = 155, C(1’)); 67.1 
(d, 1J(C,H) = 155, C(3’)); 66.7 (d, 1J(C,H) = 157, C(4’)); 65.6 (d, 1J(C,H) = 149, C(5’)); 
65.4 (d, 1J(C,H) = 150, C(4)); 64.9 (d, 1J(C,H) = 144, C(2’)); 63.2 (q, 1J(C,H) = 130, 
OCH3); 62.5 (t, 1J(C,H) = 149, C(6)); 60.8 (d, 1J(C,H) = 139, C(2)); 59.5 (t, 1J(C,H) = 
148, C(7’)); 41.4 (d, 1J(C,H) = 127, C(3)); 21.3-20.7 (7q, 1J(C,H) = 130, CH3COO); 
 
MALDI-HRMS Calcd for (M + Na) C41H51NO17SNa 884.2775; found 884.2776. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 134: 
 
2.0 2.5 3.03.54.04.55.05.56.0 6.5 7.0 7.5 
5.20 5.40 5.60 5.80 6.00 6.20 
3.804.004.204.404.604.80
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N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro-
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-benzyl-N-
methoxy)amino]-2,3-dideoxy-β-D-galactopyranosyl}-L-serine benzyl ester (136). 
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To a solution of 134 (167 mg, 0194 mmol) and N-Fmoc-serine-OBn (170 mg, 0407 mmol) 
in dry CH2Cl2 (5 mL) was added pre-activated 4 Å molecular sieves (200 mg) under an Ar 
atmosphere, then the mixture was stirred for 1 h. After addition of NIS (44 mg, 0194 
mmol) and TMSOTf (70 µL, 0.388 mmol) at 0°C, the reaction mixture was continuously 
stirred at 0°C until 134 was completely consumed on TLC analysis. The mixture was 
filtered through a pad of Celite, washed with CH2Cl2 (50 mL), and the combined filtrate 
and washings were washed with sat. NaHCO3 aq.(10 mL), sat. Na2S2O3 aq. (10 ml) and 
brine, dried over Na2SO4 and concentrated in vacuo. FC (hexanes:EtOAc, 4:1 3:1) gave 
205 mg (92 %) of 136 (β only), white foam. 
 
[α]25589 = +31, [α]25577 = +32, [α]25435 = +64, [α]25405 = +78 (c 0.211, CHCl3). 
 
IR (film): 3330, 2965, 1735, 1515, 1435, 1365, 1215, 1040, 1025, 910 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ  
 7.81-7.10 (m, 18H, H-C(arom)); 6.84 (d, 3J(H-N, H-C*(Ser)) = 9.2, H-N); 6.12 (dd, 3J(H-
C(1’), H-C(3)) = 9.9, 3J(H-C(1’), H-C(2’)) = 1.2, H-C(1’)); 5.56 (s, H-C(4)); 5.34 (dd, 
3J(H-C(5’), H-C(6’)) = 6.5, 3J(H-C(5’), H-C(4’)) = 3.1, H-C(5’)); 5.29 (t, 3J(H-C(4’), H-
C(3’)) = 3.1,H-C(4’)); 5.23 (t, 2H, 2J = 12.9, H-C(CH2Ph); 6.34 (d, 3J(H-C(1), H-C(2)) = 
7.7, H-C(1)); 4.81 (m, 1H, H-C(3’)); 4.78 (dd, 2J = 12.5, 3J(Ha-C(7’), H-C(6’)) = 9.9, Ha-
C(7’)); 4.67 (dt, 3J(H-C*(Ser),H-N) = 9.2, 3J(H-C*(Ser),H2-C(Ser) = 3.1, H-C*(Ser)  ); 
4.63 (d, 2J = 11.7, H2-C(Ser)); 4.53-4.39 (m, 4H, H2- C(Fmoc), Hb-C(7’), H-C(6’)); 4.36 
(d, 2J = 12.9, Ha-C(NCH2Ph); 4.30-4.15 (m, 3H, H-C(2’), Hendo-C(6), H-C(Fmoc)); 4.03 
(dd, 2J=11.4, 3J(Hexo-C(6),H-C(5)) = 7.1, Hexo-C(6)); 4.63 (dd, , 2J = 11.7, 3J(H2-C(Ser), 
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H-C*(Ser)= 3.1 H2-C(Ser)  ); 3.88 (t, 3J(H-C(5), Hexo-C(6)) = 6.47,H-C(5)); 3.6 (d, 2J = 
12.6, Ha-C(NCH2Ph); 3.08 (s, 3H, H-C(OCH3)); 2.84 (dd, 3J(H-C(2), H-C(3)) = 12.3, 
3J(H-C(2), H-C(1)) = 7.7, H-C(2)); 2.57 (br dd, 3J(H-C(3), H-C(2)) = 12.3, H-C(3)); 2.25-
1.89 (7s, 21H, CH3COO). 
 
13C NMR (100.6 MHz, CDCl3): δ  
170.5, 170.4, 170.2, 170.1, 169.8, 168.9, 168.7 (7s, -COO); 156.3 (s, C(Carbamat); 143.7 
(s, C(arom)); 143.6 (s, C(arom)); 141.2 (s, C(arom)); 141.0 (s, C(arom)); 138.1 (s, 
C(arom)); 135.1 (s, C(arom)); 130.4 (d, 1J(C,H) = 162, C(arom)); 128.4 (d, 1J(C,H) = 158, 
C(arom)); 128.2 (d, 1J(C,H) = 158, C(arom)); 128.1 (d, 1J(C,H) = 158, C(arom)); 128.0 (d, 
1J(C,H) = 159, C(arom)); 128.0 (d, 1J(C,H) = 159, C(arom)); 127.9 (d, 1J(C,H) = 159, 
C(arom)); 127.6 (d, 1J(C,H) = 159, C(arom)); 127.5 (d, 1J(C,H) = 159, C(arom)); 127.1 (d, 
1J(C,H) = 159, C(arom)); 126.9 (d, 1J(C,H) = 159, C(arom)); 124.9 (d, 1J(C,H) = 159, 
C(arom)); 119.8 (d, 1J(C,H) = 159, C(arom)); 103.9(d, 1J(C,H) = 159, C(1)); 74.3 (d, 
1J(C,H) = 139, C(5)); 72.9 (d, 1J(C,H) = 144, C(2’)); 70.4 (t, 1J(C,H) = 153, CH2(Ser)); 
67.4 (t, 1J(C,H) = 149, CH2(Bn)); 67.3 (t, 1J(C,H) = 150, CH2(Fmoc)); 67.3 (d, 1J(C,H) = 
139, C(1’)); 67.0 (d, 1J(C,H) = 155, C(3’)); 66.5 (d, 1J(C,H) = 157, C(4’)); 65.6 (d, 
1J(C,H) = 150, C(4)); 65.4 (d, 1J(C,H) = 149, C(5’)); 64.9 (d, 1J(C,H) = 150, C(6’)); 63.4 
(q, 1J(C,H) = 130, OCH3); 62.5 (t, 1J(C,H) = 149, C(NCH2Ph)); 61.7 (t, 1J(C,H) = 148, 
C(7’)); 61.0 (d, 1J(C,H) = 139, C(2)); 59.5 (t, 1J(C,H) = 149, C(6)); 54.5 (d, 1J(C,H) = 138, 
C∗(Ser)); 47.1 (d, 1J(C,H) = 130, C(Fmoc)); 41.1 (d, 1J(C,H) = 127, C(3)); 21.1-20.5 (7q, 
1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C60H68N2O22Na 1191.416; found 1191.416. 
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1H-NMR (400 MHz, CDCl3) spectrum of 136: 
 
 
2.0 2.5 3.0 3.54.04.55.05.56.0 6.5 7.0 7.5 8.0 
4.604.80 5.00 5.20 5.40 5.60 5.80 6.00 6.20 
3.603.804.004.204.40
2.8002.8102.8202.8302.8402.8502.8602.870 2.480 2.490 2.500 2.510 2.5 0 2.530 
J=7.3 J=12.3
J = 12.3 
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1,6-Anhydro-3-C-{(1R)-2,6-anhydro-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}-2-azido-2,3-dideoxy-β-D-galacto-hexopyranose 
(138) 
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To a stirred mixture of metallic sodium (184 mg, 8.0 mmol, 24 equiv) in liquid NH3 (10 
mL) at -78 oC was added a solution of 132 (300 mg, 0.329 mmol) in dry THF (5 mL). 
After 30 min at -78 oC, NH4Cl (540 mg, 10 mmol, 30 equiv) was added and ammonia was 
allowed to evaporate at 20 oC. After the addition of H2O (20 ml), the aqueous phase was 
extracted with CH2Cl2 (20 ml, 3 times). The combined org. phases were dried, 
concentrated in vacuo. The residue was dissolved in MeOH (10 ml), then 10% Pd on 
charcoal (35 mg) was added. The degassed mixture was stirred under H2 at 20°C for 12 h. 
The catalyst was filtered off, the solvent evapored and the residue was dissolved in 1 ml of 
CH2Cl2, 1 mg of CuSO4 in 2 ml of H2O was added, then triethylamine (131 µl, 0.987 
mmol) was added, followed by MeOH (7 ml). The dichloromethane solution of 
trifluoromethanosulfonyl azide freshly prepared (1 ml, 0.6 M, 0.6 mmol) was added at 
once. The reaction was stirred until TLC showed reaction to be complete. Then the 
mixture was  extracted by CH2Cl2 (15 ml, 3 times). These combined org. phases were 
dried, concentrated in vacuo. FC (7:3, light petroleum ether/ether) afforded 220 mg (81 %, 
3 steps) of 138, colorless oil. 
 
[α]25589 = +28, [α]25577 = +30, [α]25435 = +57, [α]25405 = +68 (c 0.296, CHCl3). 
 
IR (film): 3475, 2955, 2855, 2110, 1635, 1470, 1255, 1100, 835, 780, 740 cm-1. 
 
1H NMR (400 MHz, C6D6): δ  5.43 (s, H-C(1)); 4.81 (t, 3J(H-C(4), H-C(3)) = 7.4, H-
C(4)), 4.72 (dd, 2J = 12.3, 3J (Ha-C(7’), H-C(6’)) = 10.5, Ha-C(7’)); 4.47 (dd, 3J(H-C(5’), 
H-C(6’)) = 6.2, 3J (H-C(5’), HC-(4’)) = 2.5, H-C(5’)); 4.38-4.28 (m, 3H, H-C(5), H-C(1’), 
H-C(2’)); 3.25 (d, 2J = 7.4, Hendo-C(6)), 4.20 (d, 3J(H-C(3’), H-(4’)) = 4.3, H-C(3’)); 4.13 
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(dt, 3J (Ha-C(7’), H-C(6’)) = 10.5, 3J (H-C(6’), H-C(5’)) = 6.2, 3J (H-C(6’), (Hb-C(7’)) = 
2.5, H-C(6’)); 3.99 (dd, 3J(H-C(4’), H-C(3’)) = 4.3, 3J (H-C(4’), HC-(5’)) = 2.5, H-C(4’)), 
3.96 (dd, 2J = 12.3, 3J (Hb-C(7’), H-C(6’)) = 2.5, Hb-C(7’)); 3.63 (d, 3J(H-C(2), H-C(3)) = 
6.2, H-C(2)); 3.63-3.50 (bs,2H, 2H-C(OH)); 3.27 (dd, 2J = 6.8, 3J(H-5, Hexo-C(6)) = 4.9, 
Hexo-C(6)), 2.64 (ddd, 3J(H-3, H-2) = 9.9, 3J(H-3, H-4) = 7.4, 3J (H-C(3), H-C(1’)) = 3.1, 
H-C(3)); 1.05, 1.01, 0.99, 0.96 (4s, 36H, 36H-C(SiC(CH3)3)); 0.28, 0.21, 0.19, 0.17, 0.16, 
0.15, 0.11, 0.06 (8s, 24H, 24H-C(SiCH3)). 
 
13C NMR (100.6 MHz, C6D6):δ 
 102.5 (d, 1J (C,H) = 179, C(1)); 78.9 (d, 1J(C,H) = 147, C(6’)); 74.2 (d, 1J (C,H) = 159, 
C(5)); 74.1 (d, 1J (C,H) = 154, C4’); 71.5 (d, 1J(C,H) = 141, C(3’)); 70.6 (d, 1J(C,H) = 
144, C(1’)); 68.8 (d, 1J (C,H) = 146, C(2’)); 67.9 (d, 1J(C,H) = 146, C(5’)); 66.8 (t, 
1J(C,H) = 144, C(4)); 63.5 (d, 1J(C,H) = 143 , C(2)); 62.7 (t, 1J(C,H) = 154, C(6)); 59.1 (t, 
1J(C,H) = 143, C(7’)); 40.4 (d, 1J(C,H) = 126, C(3)); 26.3, 26.1, 26.0, 25.9 (4q, 1J (C,H) = 
125, (CH3)3CSi); 18.5; 18.2, 18.1; 18.0 (4s, (CH3)3CSi); -4.3; -4.4; -4.4; -4.6, -4.8, -4.9, -
5.0; -5.1 (8q, 1J (C,H) = 118 , CH3Si). 
 
MALDI-HRMS Calcd for (M + Na) C37H77N3O9Si4Na 842.4634; found 842.4631. 
 
Anal. calcd for C37H77N3O9Si4 (920.36): C 54.17, H 9.46, N 5.12; found: C 54.19, H 9.38, 
N 5.12. 
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1H-NMR (400 MHz, CDCl3) spectrum of 138: 
 
 
0.5 1.0 1.52.02.53.03.54.0 4.55.0 5.5 
4.20 4.304.40 4.50 4.60 4.70 4.80 3.503.603.703.803.904.00 4.10 
2.2502.2602.2702.2802.2902.3002.3102.320
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4-O-Acetyl-1,6-anhydro-3-C-[(1R)-2,6-anhydro-1,3,4,5,7-penta-O-acetyl-D-glycero-L-
manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-β-D-galacto-hexopyranose (139). 
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The tert-butyldimethylsilyl-protected 138 (600 mg, 0.733 mmol) was dissolved in THF (4 
mL), a solution of TBAF in THF  (4 mL, 4.0 mmol) was added, and the solution was 
stirred for 3 h at room temperature. The mixture was evaporated to dryness, then dissolved 
in pyridine (5 mL). A catalytic amount of DMAP (10 mg, 0.08 mmol) was added, then 
acetic anhydride (3 mL, 31.80 mmol) was added, and the solution was stirred for 2 days at 
20 oC. Then MeOH (5 mL) was added, the mixture was evaporated to dryness, then 
dissolved in ethyl acetate  (25 mL), the solution was quenched with aqueous HCl (10 ml), 
washed successively with saturated aqueous solution of NaHCO3 (5 mL), water and brine 
and dried (MgSO4). Evaporation of the filtrate, FC (1:1, light petroleum ether/EtOAc) 
gave 355 mg (89 %) of 139, white solid,  
 
m.p. 46-47°C. 
 
[α]25589 = +51, [α]25577 = +56, [α]25435 = +107, [α]25405 = +131 (c 0.124, CHCl3). 
 
IR (film): 3450, 2970, 2150, 1755, 1735, 1440, 1370, 1245, 1140, 1065, 1020, 910 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
5.74 ((dd, 3J(H-C(4), H-C(5)) = 8.0, 3J(H-C(4), H-C(3)) = 5.9, H-C(4)); 5.52 (s , H-C(1)); 
5.43-5.36 (m, 2H, H-C(5’), H-C(1’)); 5.22 (t, 3J(H-C(4’), H-C(5’)) = 4.0,H-C(4’)); 5.03 
(dd, 3J(H-C(3’), H-C(4’)) = 4.3, 3J(H-C(3’), H-C(2’)) = 1.8, H-C(3’)); 4.82-4.74 (m, 2H, 
Ha-C(7’), H-C(5)); 4.39-4.27 (m, 2H, H-C(6’), H-C(2’)); 4.19 (dd, 2J = 12.6, 3J(Hb-C(7’), 
H-C(6’)) = 2.5, Hb-C(7’)); 3.97 (d, 2J=7.4, Hendo-C(6)); 3.43 (dd, 2J=7.4, 3J(Hexo-C(6),H-
C(5))= 4.3, Hexo-C(6)); 3.25 (d, 3J(H-C(2), H-C(3)) = 10.2, H-C(2)); 2.18-2 (7s, 22H,, H-
C(3), CH3COO). 
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13C NMR (100.6 MHz, CDCl3): δ  
167.0, 169.9, 169.8, 169.7, 169.7, 169.4, 168.9 (7s, -COO); 102.9 (d, 1J(C,H) = 175, 
C(1)); 72.3 (d, 1J(C,H) = 149, C(6’)); 72.1 (d, 1J(C,H) = 146, C(5)); 67.5 (d, 1J(C,H) = 
149, C(5’)); 67.2 (d, 1J(C,H) = 148, C(4’)); 66.9 (d, 1J(C,H) = 149, C(3’)); 65.6 (d, 
1J(C,H) = 156, C(1’)); 65.5 (d, 1J(C,H) = 144, C(2’)); 65.0 (d, 1J(C,H) = 151, C(4)); 63.2 
(t, 1J(C,H) = 149, C(6)); 62.1 (d, 1J(C,H) = 129, C(2)); 59.3 (t, 1J(C,H) = 147, C(7’)); 36.4 
(d, 1J(C,H) = 127, C(3)); 21.0- 20.6 (7q, 1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C25H33N3O15Na 638.1809; found 638.1801. 
 
Anal. calcd for C25H33N3O15 (615.54): C 48.78, H 5.40, N 6.83; found: C 48.82, H 5.46, 
N 6.83. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 139 
 
 
2.0 2.5 3.03.54.04.5 5.05.5 6.0 6.57.0 7.5 
4.60 4.80 5.00 5.20 5.40 5.60 5.80 
3.00 3.20 3.403.603.804.004.204.40
 
 
 125 
 
4,6-Di-O-acetyl-3-C-[(1R)-2,6-anhydro-1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-
heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-galacto-hexopyranosyl acetate (140α). 
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139 (0.35 g, 0.57 mmol) was dissolved in Ac2O (10 mL ). After cooling to -40 oC, 
Me3SiOSO2CF3 (0.123 mL, 0.683 mmol) was added (syringe) and the mixture stirred for 1 
h. CH2Cl2 (30 ml ) was added and the reaction quenched with a saturated aqueous solution 
of NaHCO3 (10 mL), the organic phase was collected and extracted with H2O, and then 
with brine and dried (MgSO4). Solvent evaporation and FC (hexanes:EtOAc, 2:1 1:3) 
gave 400 mg (98 %) of a 23:1 mixture of 140α and 140β (400 mg, 98 %), white foam. 
 
[α]25589 = +89, [α]25577 = +94, [α]25435 = +182, [α]25405 = +217 (c 0.3775, CHCl3). 
 
IR (film): 2130, 1750, 1435, 1375, 1235, 1035, 910, 600 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ  
Data for the α anomer: 6.34 (d, 3J(H-C(1), H-C(2)) = 3.4, H-C(1)); 5.58 (s, H-C(4)); 5.38 
(dd, 3J(H-C(1’), H-C(3)) = 10.2, 3J(H-C(1’), H-C(2’)) = 2.5, H-C(1’)); 5.31 (dd, 3J(H-
C(5’), H-C(6’)) = 6.5, 3J(H-C(5’), H-C(4’)) = 3.1, H-C(5’)); 5.17 (t, 3J(H-C(4’), H-C(5’)) 
= 3.1,H-C(4’)); 4.86 (dd, 3J(H-C(3’), H-C(4’)) = 4.5, 3J(H-C(3’), H-C(2’)) = 1.5, H-
C(3’)); 4.77 (dd, 2J = 12.9, 3J(Ha-C(7’), H-C(6’)) = 10.2, Ha-C(7’)); 4.50 (dd, 3J(H-C(2’), 
H-C(1’)) = 10.2, 3J(H-C(2’), H-C(3’)) = 1.5, H-C(2’)); 4.33-4.25 (m, 2H, Hb-C(7’), H-
C(6’)); 4.14 (t, 3J(H-C(5), Hexo-C(6)) = 6.5,H-C(5)); 4.08 (d, 2J=11.1, Hendo-C(6)); 3.91 
(dd, 2J=11.1, 3J(Hexo-C(6),H-C(5)) = 6.5, Hexo-C(6)); 3.61 (dd, 3J(H-C(2), H-C(3)) = 12.3, 
3J(H-C(2), H-C(1)) = 3.4, H-C(2)); 2.45 (dt, 3J(H-C(3), H-C(2)) = 12.3, 3J(H-C(3), H-
C(1’)) = 2.5, H-C(3)); 2.08-1.99 (8s, 24H, CH3COO). 
 
13C NMR (100.6 MHz, CDCl3): δ  
Data for the α anomer: 170.3, 170.2, 169.8, 169.7, 169.3, 168.8, 168.7, 168.6 (8s, -COO); 
90.1 (d, 1J(C,H) = 175, C(1)); 72.7 (d, 1J(C,H) = 149, C(6’)); 69.9 (d, 1J(C,H) = 146, 
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C(5)); 66.6 (d, 1J(C,H) = 156, C(1’)); 66.6 (d, 1J(C,H) = 148, C(4’)); 66.5 (d, 1J(C,H) = 
149, C(3’)); 65.3 (d, 1J(C,H) = 149, C(5’)); 64.8 (d, 1J(C,H) = 151, C(4)); 64.6 (d, 1J(C,H) 
= 144, C(2’)); 61.3 (t, 1J(C,H) = 149, C(6)); 59.3 (t, 1J(C,H) = 147, C(7’)); 54.8 (d, 
1J(C,H) = 129, C(2)); 37.1 (d, 1J(C,H) = 127, C(3)); 20.8-20.4 (8q, 1J(C,H) = 130, 
CH3COO). 
MALDI-HRMS Calcd for (M + Na) C25H33N3O15Na 740.2126; found 740.2128. 
 
Anal. calcd for C29H39N3O18 (717.63): C 48.54, H 5.48, N 6.86; found: C 48.59, H 5.50, 
N 5.78. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 140α 
 
2.0 2.5 3.03.54.04.55.05.5 6.0 6.5 7.0 
4.805.00 5.20 5.40 5.60 
3.40 3.603.804.004.204.404.60
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4,6-Di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-
heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-galacto-hexopyranosyl bromide (141α). 
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 A solution of 140 (0.50 g, 0.697 mmol) and anhydrous TiBr4 (0.99 mg, 1.35 mmol) in 
anhydrous CH2Cl2 (14 mL) was stirred at 20 oC for 12 h. after addition of CH2Cl2 (150 
mL), the solution was washed with ice-cold H2O (50 mL, twice) and dried (MgSO4). 
Solvent evaporation in vacuo and quick FC (hexane: EtOAc, 1:1) gave 472 mg (92 %) of 
141α, contaminated by less than 2% of the β-anomer yellow foam, that was dried and 
stored at -20 oC until its use. 
 
[α]25589 = +116, [α]25577 = +122, [α]25435 = +238, [α]25405 = +287 (c 0.243, CHCl3). 
 
IR (film): 3475, 2965, 2115, 1750, 1370, 1235, 1050 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
Data for the α anomer: 6.69 (d, 3J(H-C(1), H-C(2)) = 3.7, H-C(1)); 5.69 (s, H-C(4)); 
5.413 (dd, 3J(H-C(1’), H-C(3)) = 9.6, 3J(H-C(1’), H-C(2’)) = 1.8, H-C(1’)); 5.36 (dd, 
3J(H-C(5’), H-C(6’)) = 6.5, 3J(H-C(5’), H-C(4’)) = 3.1, H-C(5’)); 5.22 (t, 3J(H-C(4’), H-
C(5’)) = 3.7,H-C(4’)); 4.97-4.89 (m, 2H,Hexo-C(6) , H-C(3’)); 4.53 (dd, 3J(H-C(2’), H-
C(1’)) = 9.9, 3J(H-C(2’), H-C(3’)) = 1.5, H-C(2’)); 4.40 (t, 3J(H-C(5), Hexo-C(6)) = 6.5,H-
C(5)); 4.24-4.16 (m, 2H, Hendo-C(6) , Ha-C(7’)); 4.02 (dd, 2J = 11.7, 3J(Ha-C(7’), H-C(6’)) 
= 7.4, Hb-C(7’)); 3.70 (dd, 3J(H-C(2), H-C(3)) = 12.0, 3J(H-C(2), H-C(1)) = 3.7, H-C(2)); 
2.59 (dt, 3J(H-C(3), H-C(2)) = 12.0, 3J(H-C(3), H-C(1’)) = 1.8, H-C(3)); 2.19-2.00 (8s, 
24H, CH3COO). 
 
13C NMR (100.6 MHz, CDCl3): δ  
Data for the α anomer: 170.7, 170.3, 169.8, 169.6, 169.3, 168.9, 168.8 (7s, -COO); 92.8 
(d, 1J(C,H) = 184, C(1)); 72.9 (d, 1J(C,H) = 153, C(6’)); 72.6 (d, 1J(C,H) = 146, C(5)); 
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66.8 (d, 1J(C,H) = 149, C(5’)); 66.7 (d, 1J(C,H) = 148, C(4’)); 66.6 (d, 1J(C,H) = 149, 
C(3’)); 65.4 (d, 1J(C,H) = 139, C(1’)); 64.7 (d, 1J(C,H) = 151, C(4)); 64.6 (d, 1J(C,H) = 
143, C(2’)); 61.1 (t, 1J(C,H) = 151, C(7’)); 59.2 (t, 1J(C,H) = 155, C(6)); 57.6 (d, 1J(C,H) 
= 142, C(2)); 38.0 (d, 1J(C,H) = 129, C(3)); 20.9-20.5 (7q, 1J(C,H) = 130, CH3COO). 
 
Anal. calcd for C27H36BrN3O16 (738.49): C 43.91, H 4.91, Br 10.82, N 5.69; found: C 
43.81, H 5.05, Br 10.73, N 5.65.  
 
1H-NMR (400 MHz, CDCl3) spectrum of 141α 
2.0 2.5 3.03.5 4.04.55.05.5 6.0 6.5 7.0 
4.805.00 5.20 5.40 5.60 5.80 
3.60 3.804.004.204.404.60
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5:1 Mixture of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-{4,6-di-O-acetyl-3-C-[(1R)-2,6-
anhydro-1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-
dideoxy-α- and-β-D-galactopyranosyl}-L-serine tert-butyl ester (143α , 143β). 
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A mixture of N-Fmoc-Serine-OtBu 142 (408 mg, 1.03 mmol), anhydrous CH2Cl2 (10 mL), 
AgClO4 (370 mg, 1.73 mmol), 2,4,6-collidine (240 µL, 1.73 mmol) and 4 Å molecular 
sieves (dried under vaccum at 200 oC, 1 g) was stirred at 20 oC for 10 min. A solution of 
bromide 141α,β (834 mg, 1.129 mmol) in anhydrous CH2Cl2 (10 mL) was added slowly 
(syringe) to the stirred mixture over 30 min. After stirring at 20 oC for 5h, CH2Cl2 (100ml) 
was added and the mixture filtered through a pad of Celite (washing with CH2Cl2). 
Solvent evaporation, FC (hexanes:EtOAc, 4:1 3:1) gave 1.1 g (93 %) of 143α/143β 5:1, 
white foam. 
 
[α]25589 = +91, [α]25577 = +96, [α]25435 = +187, [α]25405 = +224 (c 0.375, CHCl3). 
 
IR (film): 3660, 2990, 2110, 1735, 1525, 1370, 1220, 1065, 890 cm-1. 
 
1H NMR (400 MHz, CDCl3):  δ  
Data for the α anomer: 7.80-7.26 (4 m, 8H, ArH); 6.04 (d, 3J(H-N, H-C*) = 8.0, H-N); 
5.56 (s, H-C(4)); 5.38 (dd, 3J(H-C(1’), H-C(3)) = 9.6, 3J(H-C(1’), H-C(2’)) = 2.6, H-
C(1’)); 5.32 (dd, 3J(H-C(5’), H-C(6’)) = 6.7, 3J(H-C(5’), H-C(4’)) = 3.2, H-C(5’)); 5.22 (t, 
3J(H-C(4’), H-C(3’)) = 3.5, H-C(4’)); 4.96 (d, 3J(H-C(1), H-C(2)) = 2.9, H-C(1)); 4.83 (d, 
3J(H-C(4’), H-C(3’)) = 3.5, H-C(3’)); 4.75 (dd, 2J = 12.8, 3J(H-C(6exo), H-C(5)) = 9.9, H-
C(6exo)); 4.54-4.44 (m, 2H, H-C(2’) , H-C*(Ser)); 4.43-4.31 (m, 3H, Hendo-C(6) , H2-
C(Fmoc)); 4.30-4.11 (m, 5H, Ha-C(7’) , H-C(6’), H-C(5), H-C(Fmoc), H2-C(Ser)); 4.30-
4.11 (m, 2H, Hb-C(7’) , H2-C(Ser)); 3.33 (dd, 3J(H-C(2), H-C(3)) = 12.2, 3J(H-C(2), H-
C(1)) = 2.9, H-C(2)); 2.59 (d, 3J(H-C(3), H-C(2)) = 12.2, H-C(3)); 2.25-1.94 (7s, 21H, 
CH3COO); 1.48 (s, 9H, (CH3)3C). 
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13C NMR (100.6 MHz, CDCl3): δ  
Data for the α anomer: 170.7, 170.4, 170.3, 169.9, 169.8, 168.9, 168.7, 168.4 (8s, -COO); 
155.8 (s, C(Carbamat); 143.6 (s, C(Fmoc)); 141.2 (s, C(Fmoc)); 127.6 (d, 1J(C,H) = 159, 
C(Fmoc)); 126.9 (d, 1J(C,H) = 159, C(Fmoc)); 125.1 (d, 1J(C,H) = 158, C(Fmoc)); 119.8 
(d, 1J(C,H) = 158, C(Fmoc)); 99.3 (d, 1J(C,H) = 184, C(1)); 82.8 (s, C(CH3)3); 72.9 (d, 
1J(C,H) = 153, C(6’)); 70.7 (t, 1J(C,H) = 153, CH2(Ser)); 68.8 (d, 1J(C,H) = 146, C(5)); 
66.8 (t, 1J(C,H) = 150, CH2(Fmoc)); 66.6 (d, 1J(C,H) = 148, C(4’)); 66.6 (d, 1J(C,H) = 
139, C(1’)); 66.4 (d, 1J(C,H) = 149, C(3’)); 65.8 (d, 1J(C,H) = 151, C(4)); 65.4 (d, 1J(C,H) 
= 149, C(5’)); 64.6 (d, 1J(C,H) = 143, C(2’)); 62.1 (t, 1J(C,H) = 151, C(7’)); 59.4 (t, 
1J(C,H) = 155, C(6)); 55.0 (d, 1J(C,H) = 138, C∗(Ser)); 54.9 (d, 1J(C,H) = 142, C(2)); 47.0 
(d, 1J(C,H) = 130, C(Fmoc)); 37.0 (d, 1J(C,H) = 129, C(3)); 27.7 (q, 3C, 1J(C,H) = 128, 
(CH3)CO); 20.9-20.5 (7q, 1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C49H60N4O21Na 1063.3647; found 1063.3612.  
 
Anal. calcd for C49H60N4O21 (1041.02): C 56.53, H 5.81, N 5.38; found: C 56.56, H 5.79, 
N 5.36. 
MALDI-HRMS spectrum of 143α,β: 
C49H60N4O21Na
 
Calcd:  1063.3647;
Found: 1063.3612.
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1H-NMR (400 MHz, CDCl3) spectrum of 143α,β 
 
1.52.0 2.5 3.03.5 4.04.5 5.0 5.56.0 6.5 7.0 7.5 
4.805.00 5.20 5.40 5.60 5.80 6.00 6.20 3.243.263.283.303.323.343.36 2.660 2.670 2.680 2.690 2.7002.7102.720
 
J=3.199 J=12.2
α-product J=7.7
β-product 
J=12.2 
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N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-
dideoxy-α-D-galactopyranosyl}-L-serine tert-butyl ester (144). 
 
6
1'
2'3'
4'
5' 6'
12
3
4 5O
AcO
AcO
OAc
OAc
O
AcO
AcHN
OAc
AcO
144
O
COOBn
NHFmoc
7'
 
A 5:1 mixture of 143α and 143β (120 mg, 0.115 mmol) was dissolved in 4:4:1 mixture of 
collidine/CH3COSH/Ac2O (6 mL). After stirring at 20 oC for 18 h the mixture was co-
evaporated with toluene under vacuum (10-3Torr). FC (hexanes:EtOAc, 4:1 1:2) gave A 
5:1 mixture of 144α and 144β (107 mg, 89 %) as a white foam. 
 
[α]25589 = +65, [α]25577 = +69, [α]25435 = +129, [α]25405 = +152 (c 0.21, CHCl3).  
 
IR (film): 3660, 3325, 2965, 1740, 1735, 1520, 1370, 1220, 1055, 800 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ  
Data for the α anomer: 7.74-7.23 (4 m, 8H, ArH); 5.89 (d, 3J(H-N, H-C*) = 8.3, H-N); 
5.52 (s, H-C(4)); 5.49 (d, 3J(H-(NAc), H-C(2)) = 8.7, H-N); 5.33-5.27 (m, 2H, H-C(1’), H-
C(5’)); 5.23 (t, 3J(H-C(4’), H-C(5’)) = 3.4,H-C(4’)); 4.75-4.65 (m, 3H, H-C(1), Hexo-C(6), 
H-C(5’)); 4.60 (td, 3J(H-C(2), H-C(3)) = 12.9, 3J(H-C(2), H-(NAc)) = 10.0, 3J(H-C(2), H-
C(1)) = 3.4, H-C(2)); 4.52-4.35 (m, 5H, H2-C(Fmoc), H-C(Ser), H-C(2’), H-C(3’), Hendo-
C(6), ); 4.26-4.17 (m, 3H, H-C(Fmoc), H-C(6’), Ha-C(7’)); 4.14-4.06 (m, 1H, H-C(5)); 
3.97-3.87 (m, 3H, H2-C(Ser), Hb-C(7’)); 2.53 (d, 3J(H-C(2), H-C(3)) = 12.9, H-C(2)); 
2.22-1.87 (8s, 24H, CH3COO); 1.47 (s, 9H, (CH3)3C). 
 
13C NMR (100.6 MHz, CDCl3): δ  
Data for the α anomer: 170.7, 170.3, 170.0, 169.7, 169.5, 169.4, 169.1, 169.0, 168.9 (9s, -
COO); 155.9 (s, C(Carbamate); 143.6 (s, C(Fmoc)); 141.3 (s, C(Fmoc)); 127.7 (d, 1J(C,H) 
= 159, C(Fmoc)); 127.0 (d, 1J(C,H) = 159, C(Fmoc)); 124.9 (d, 1J(C,H) = 158, C(Fmoc)); 
120.0 (d, 1J(C,H) = 158, C(Fmoc)); 98.8 (d, 1J(C,H) = 169, C(1)); 82.8 (s, C(CH3)3); 72.9 
(d, 1J(C,H) = 149, C(6’)); 69.8 (t, 1J(C,H) = 153, CH2(Ser));68.9 (d, 1J(C,H) = 140, C(5)); 
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67.0 (t, 1J(C,H) = 150, CH2(Fmoc)); 67.0 (d, 1J(C,H) = 149, C(3’)); 66.4 (d, 1J(C,H) = 
149, C(4’)); 65.8 (d, 1J(C,H) = 160, C(4)); 65.5 (d, 1J(C,H) = 159, C(5’)); 65.2 (d, 1J(C,H) 
= 148, C(1’)); 64.8 (d, 1J(C,H) = 139, C(2’)); 62.4 (t, 1J(C,H) = 163, C(7’)); 59.7 (t, 
1J(C,H) = 151, C(6)); 55.0 (d, 1J(C,H) = 138, C∗(Ser)); 47.1 (d, 1J(C,H) = 130, C(Fmoc)); 
43.5 (d, 1J(C,H) = 130, C(Ser)); 38.0 (d, 1J(C,H) = 128, C(3)); 28.6 (q, 3C, 1J(C,H) = 128, 
(CH3)CO); 23.4 (q, 1J(C,H) = 129, CH3CON); 21.1-20.6 (7q, 1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS: Calcd for (M + Na) C51H64N2O22Na 1079.3848; found 1079.3843. 
 
Anal. calcd for C51H64N2O22 (1057.05): C 57.95, H 6.10, N 2.65; found: C 57.88, H 6.11, 
N 2.59. 
 
MALDI-HRMS spectrum of 144α,β: 
C51H64N2O22Na
Calcd: 1079.3848
found: 1079.3843.
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1H-NMR (400 MHz, CDCl3) spectrum of 144α,β 
1.52.0 2.5 3.03.54.04.55.05.5 6.0 6.57.0 7.5 
0.74 0.76 0.78 0.80 0.82 0.84 0.86 0.90 0.92 0.94 0.96 0.98 1.00
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(E) or (Z)-1,6-Anhydro-3-{2,6-anhydro-3,4,5,7-tetrakis-O-[tert-butyl(dimethyl)silyl]-
D-galacto-hept-1-en-1-ol-1-C-yl}-2,3-dideoxy-β-D-glycero-hex-2-eno-pyran-4-
(ulose((E) or (Z)-146)  
O
TBSO
TBSO
OTBS
OTBS
146
O
O
O 1
23
4
5
6
1'2'
3'4'
5' 6'
7'
 
Solid N,N’ –thiocarbonyldiimidazole (583 mg, 3.28 mmol) was added to a solution 97a 
(500 mg, 0.66 mmol) in THF (3ml). The reaction mixture was gently heated under reflux 
and nitrogen atm. until TLC indicated complete consumption of the starting material. The 
solution was cooled to rt. and concentrated. Flash chromatography ( 9:1, light petroleum 
ether / EtOAc ), afforded a colorless oil (E) or (Z) 146 (455 mg, 78 %). 
 
Rf =0.50, (9:1, light petroleum ether / Ether). 
 
UV (MeCN): 317 (12625), 244 (4896). 
 
1H NMR (400 MHz, CDCl3): δ 
7.93 (d, 3J (H-(2), H-C(1)) = 3.7, H-(2)); 5.83 (d, 3J (H-(1), H-C(2)) = 3.7, H-(1)); 5.78 (s, 
H-C(1’)); 4.79 (dd, 3J (H-(5), Hexo-C(6)) = 6.2, 3J (H-(5), Hendo-C(6)) = 1.3 , H-5); 4.46 (d, 
3J (H-(5’), H-C(6’)) = 3.2, 3J (H-(5’), H-C(4’)) = 2.1, H-(5’)); 4.19 (dt, 3J (H-(6’), H-
C(7’)) = 5.3 , 3J (H-(6’), H-C(5’)) = 3.2, H-(6’)); 4.03 (d, 2J = 8.0, 3J (Hexo-(6), H-C(5)) = 
6.2 , Hexo-C(6)); 4.02 (d, 3J (H-(3’), H-C(4’)) = 4.3, H-(3’)); 3.81 (m, 2H, Ha-C(7’), Hb-
C(7’)); 3.73 (d, 3J (H-(4’), H-C(3’)) = 4.3,, 3J (H-(4’), H-C(5’)) = 2.1, H-C(4’)); 3.59 (d, 2J 
= 8.9, 3J (Hexo-(6), H-C(5)) = 1.3 , Hendo-C(6)); 0.94, 0.93, 0.90, 0.90 (4s, 36H, 36H-
C(SiC(CH3)3)); 0.14, 0.12, 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, (8s, 24H, 24H-C(SiCH3)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
194 (s, C(4)); 156.3 (s, C(2’)); 141.2 (d, 1J(C,H) = 170, C(2)); 132.0 (s, C(3)), 102.2 (d, 1J 
(C,H) = 159, C(1’)); 97.9 (d, 1J (C,H) = 176, C(1’)); 83.4 (d, 1J(C,H) = 144, C(5’)); 79.3 
(d, 1J (C,H) = 164, C(5)); 74.3 (d, 1J (C,H) = 146, C4’); 74.3 (d, 1J(C,H) = 147, C(3’)); 
66.9 (d, 1J(C,H) = 140, C(6’)); 62.4 (t, 1J(C,H) = 156, C(6)); 62.0 (t, 1J(C,H) = 143, 
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C(7’)); 26.0, 26.0, 25.9, 25.85 (4q, 1J (C,H) = 128, (CH3)3CSi); 18.4; 18.3, 18.1; 18.0 (4s, 
(CH3)3CSi); -4.4; -4.6; -4.8; -4.9, -5.0; -5.0, -5.3; -5.5; (8q, 1J (C,H) = 118 , CH3Si). 
 
HR-FAB-MS: for C37H72O8Si4+Na calcd 779.4202 found 779.4200 
 
 
1H-NMR (400 MHz, CDCl3) spectrum of 146: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
H-2
H-1 H-1'
H-5
H-5'
H-6'
Hexo-6 H-3' Ha-7' Hb-7'
H-4'
Hendo-6
7.847.867.887.907.927.947.967.988.00
5.655.705.755.805.855.90
3.603.804.004.204.404.60
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1,6-Anhydro-3-{(1R) -O-[(tert-butyl)dimediethylsilyl]-2,6-anhydro-3,4,5,7-tetrakis-O-
[(tert-butyl)dimethylsilyl]-1-O-triethylsilyl-D-glycero-L-manno-heptitol-1-C-yl}-2,3-
dideoxy-β-D-glycero-hex-2-enopyran-4-ulose (147). 
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IR (film) 2950, 2855, 1695, 1465, 1360, 1265, 1090, 835, 775 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ  
6.69 (d, 3J (H-C(1), H-C(2)) = 3.4 , H-C(2)); 5.81 (d, 3J (H-1, H-C(2)) = 3.4 , H-C(1)); 
4.82 (br s, H-C(1’)), 4.71 (dd, 3J (H-C(5), H-C(6)) = 6.5 , 3J (H-C(5), H-C(6)) = 1.3 Hz, 
H-C(5)); 4.20 (dd, 3J( H-C(3’), H-C(4’)) = 6.8 , 3J ( H-C(2’), H-C(3’)) = 2.5 , H-C(3’)); 
4.07 (dd, 2J = 12.0 , 3J ( Ha-C(7’), H-C(6’)) = 8.32 , Ha-C(7’)); 3.99 (dd, 2J=8.0, 3J (H-
C(5), Hexo-C(6)) = 6.5, Hexo-(6)); 3.95(d, 3J ( H-C(5’), H-C(6’)) = 4.1 , H-C(5’)); 3.95-3.77 
(m, 4H, H-C(4’), Hendo-C(6), H-C(6’), H-C(2’)); 3.75 (d, 2J = 12.0 , Hb-C(7’)); 1.00- 0.84  
(m, 35 H , t-Bu × 4, SiCH2CH3× 3); 0.53 ( q, 6H, SiCH2 CH3); 0.14, 0.12, 0.10, 0.09, 0.08, 
0.07, 0.06, 0.05 (8s, 3H × 8, SiCH3 × 8). 
  
13C NMR (100.6 MHz, CDCl3): δ 
193.4 (s, C(4)); 141.9 (d, 1J(C,H) = 165, C(2)); 139.1 (s, C(3)); 96.7 (d, 1J(C,H) = 177, 
C(1)); 80.5 (d, 1J(C,H) = 145, C(2’)); 79.2 (d, 1J(C,H) = 163, C(5)); 73.1 (d, 1J(C,H) = 
146, C(6’)); 70.4 (d, 1J(C,H) = 149, C(5’)); 70.1 (d, 1J(C,H) = 141, C(4’)); 67.0 (d, 
1J(C,H) = 145, C(3’)); 65.4 (d, 1J(C,H) = 146, C(1’)); 62.5 (t, 1J(C,H) = 157, C(6)); 58.2 
(t, 1J(C,H) = 144, C(7’)); 26.1, 25.9, 25.8, 25.7(4q, 1J (C,H) = 123, (CH3)3CSi); 18.3; 18.0, 
17.9; 17.8 (4s, (CH3)3CSi); 6.9 (q, 1J (C,H) = 125, CH3CH2Si); 5.7 (t, 1J (C,H) = 118, 
CH3CH2Si); -3.6, -4.3; -4.6; -4.7; -4.8, -5.0; -5.4,  -5.5 (8q, 1J (C,H) = 118 , CH3Si).  
 
MALDI-HRMS Calcd for (M + Na) C43H88O9Si5Na 911.517; found  911.518.  
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Anal. calcd for C43H88O9Si5 (889.58): C 58.06, H9.67; found: C 58.03, H 10.05. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 147: 
6.926.946.966.987.007.027.047.06 5.725.745.765.785.805.825.845.865.88 4.654.704.754.804.854.90
3.703.803.904.004.104.20
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
H-2 H-1
H-1'
H-5
H-3' Ha-7'
Hexo-6
H-5' H-4', H-2', Hendo-6, H-6'
Hb-7'
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1,6-Anhydro-3-{(1S)-2,6-anhydro-3,4,5,7-tetra-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-glycero-hexopyranos-4-ulose (148). 
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103 mg of an aqueous suspension of Raney Nickel was added to a stirred solution of 
compound 97a (103 mg, 0.129 mmol ) in tetrahydrofuran (1.11 mL) and the mixture was 
further stirred at 20 °C until complete conversion of starting material (TLC control). The 
mixture was diluted with Et2O (200 mL), filtrated through a pad of silica gel. FC (9.5:0.5, 
light petroleum ether/EtOAc), afforded 59 mg (57%) of 148 and 45 mg (43%) of 149, both 
as colorless oil. 
 
Data of 148:  
Rf = 0.16, (9.5:0.5, light petroleum ether/EtOAc). 
 
[α]25589 = +4, [α]25546 = +3, [α]25435 = -1, [α]25405 = -10 (c 0.42, CHCl3). 
 
 IR (film) 3405, 2955, 2860, 1715, 1460, 1360, 1265, 1095, 835, 775 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ 
5.73 (br s, H-C(1)); 4.50 (dd, 3J (H-(6’), H-C(7’)) = 9.7 , 3J (H-(6’), H-C(5’)) = 5.8, H-
(6’)); 4.42 (dd, 3J (H-(5), Hexo-C(6)) = 5.4, 3J (H-(5), Hendo-C(6)) = 0.9 , H-5); 4.22 (dd, 2J 
= 12.2, 3J (Ha-C(7’), H-C(6’)) = 9.5, Ha-C(7’)); 4.20 (t, 3J (H-(3’), H-C(4’)) = 3J (H-(3’), 
H-C(2’)) = 2.7, H-(3’)); 4.01 (d, 2J = 8.9, Hendo-C(6)); 3.85 (m, 3H, Hexo-(6), H-(4'), H-
(1')); 3.75 (dd, 3J (H-(2’), H-C(1’)) = 3.2 , 3J (H-(2’), H-C(3’)) = 2.7, H-(2’)); 3.70 (dd, 2J 
= 12.2, 3J (Hb-C(7’), H-C(6’)) = 1.6, Hb-C(7’)); 3.55 (d, 3J (H-(5’), H-C(6’)) = 9.7, H-
(5’)); 3.07 (m, H-C(3)): 2.51 (m, Hendo-C(2)); 2.13 (m, Hexo-C(2)); 1.91 (bs, H-(OH));0.97, 
0.97, 0.91, 0.88 (4s, 36H, 36H-C(SiC(CH3)3)); 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 
0.01, (8s, 24H, 24H-C(SiCH3)).  
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13C NMR (100.6 MHz, CDCl3):δ 
206.0 (s, C(4)); 102.0 (d, 1J (C,H) = 173, C(1)); 79.5 (d, 1J (C,H) = 141, C(2’)); 79.5 (d, 1J 
(C,H) = 163, C(5)); 73.2 (d, 1J(C,H) = 147, C(1’)); 70.2 (d, 1J (C,H) = 146, C4’); 67.3 (d, 
1J(C,H) = 141, C(3’)); 66.8 (t, 1J(C,H) = 154, C(6)); 65.2 (d, 1J(C,H) = 146, C(6’)); 64.7 
(d, 1J(C,H) = 140, C(5’)); 58.5 (t, 1J(C,H) = 145, C(7’)); 44.5 (t, 1J(C,H) = 140 , C(3)), 
32.5 (t, 1J(C,H) = 125 , C(3)); 26.0, 26.0, 25.9, 25.85 (4q, 1J (C,H) = 128, (CH3)3CSi); 
18.4; 18.3, 18.1; 18.0 (4s, (CH3)3CSi); -4.4; -4.6; -4.8; -4.9, -5.0; -5.1, -5.3; -5.5; (8q, 1J 
(C,H) = 118 , CH3Si). 
 
HR-FAB-MS: for C37H76O8Si4+Na calcd 799.4442; found 799.4464. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 148: 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.0
5.665.685.705.725.745.765.78 3.603.804.004.204.40
1.802.002.202.402.602.803.00
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1,6-anhydro-3-{(1R)-2,6-anhydro-3,4,5,7-tetra-O-[(tert-butyl)dimethylsilyl]-D-glycero-
L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-erythro-hexopyran-4-ulose (149). 
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Data of 149:  
Rf = 0.16 (9.5:0.5, light petroleum ether/EtOAc).  
 
[α]25589 = +10, [α]25546 = +9, [α]25435 = +14, [α]25405 = +16 (c 0.44, CHCl3). 
 
 IR (film) 3405, 2955, 2860, 1715, 1460, 1360, 1265, 1095, 835, 775 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
5.76 (d, 3J (H-C(1), Hexo-C(2)) = 5.6,H-C(1)); 4.48 (d, 3J (H-(5), Hexo-C(6)) = 4.8, H-5); 
4.21 (dd, 3J (H-C(5’), H-C(6’)) = 6.7, 3J (H-C(5’), H-C(4’)) = 2.7, H-C(5’)); 4.16 (dd, 2J = 
11.8, 3J (Ha-C(7’), H-C(6’)) = 9.4, Ha-C(7’)); 4.09 (d, 3J (H-(2’), H-C(1’)) = 9.7, H-(2’)); 
3.94-3.86 (m, 2H, H-C(3’), H-C(4’)); 3.80-3.75 (m, 2H, Hendo-C(6), H-C(6’)); 3.73-3.66 
(m, 2H, Hexo-C(6), Hb-C(7’)); 3.53 (dt, 3J (H-(1’), H-(OH)) = 10.5,3J (H-(1’), H-C(2’)) = 
9.7, 3J (H-(1’), H-C(3)) = 2.7, H-(1’)); 3.26 (dt, 3J (H-(3), Hexo-C(2)) = 3J (H-(3), Hendo-
C(2)) = 10.2, 3J (H-(3), H-C(1’)) = 2.7, H-(3)); 2.63 (d, 3J (H-(OH), H-C(1’)) = 10.5, H-
(OH)); 2.57 (ddd, 2J = 14, 3J (Hexo-C(2), H-C(3)) = 10.2, 3J (Hexo-C(2), H-C(1)) = 5.6, 
Hexo-C(2)); 1.80 (dd, 2J = 14, 3J (Hendo-C(2), H-C(3)) = 10.2, Hendo-C(2)); 0.97, 0.97, 0.91, 
0.88 (4s, 36H, 36H-C(SiC(CH3)3)); 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01, (8s, 24H, 
24H-C(SiCH3)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
216.0 (s, C(4)); 100.5 (d, 1J (C,H) = 173, C(1)); 79.4 (d, 1J (C,H) = 141, C(4’)); 78.5 (d, 1J 
(C,H) = 163, C(5)); 72.9 (d, 1J(C,H) = 146, C(6’)); 70.1 (d, 1J(C,H) = 141, C(3’)); 68.6 (d, 
1J(C,H) = 147, C(1’)); 67.3 (d, 1J (C,H) = 144, C(2’)); 66.8 (d, 1J(C,H) = 140, C(5’)); 66.5 
(t, 1J(C,H) = 154, C(6)); 57.6 (t, 1J(C,H) = 145, C(7’)); 42.4 (d, 1J(C,H) = 125 , C(3)); 
 142 
31.7 (t, 1J(C,H) = 154, C(2)); 25.8, 25.8, 25.7, 25.6 (4q, 1J (C,H) = 128, (CH3)3CSi); 18.1; 
18.0, 17.9; 17.8 (4s, (CH3)3CSi); -4.5; -4.7; -4.9; -5.0, -5.1; -5.1, -5.4; -5.5; (8q, 1J (C,H) = 
118 , CH3Si). 
 
HR-FAB-MS: for C37H76O8Si4+Na calcd 799.4442 found 799.4451. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 149: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.0
5.7455.7505.755.7605.765.7705.775.7805.78
4.104.204.304.404.50
3.203.303.403.503.603.703.803.90 1.801.902.002.102.202.302.402.502.60
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1,6-Anhydro-3-C-{2,6-anhydro-3,4,5,7-1-deoxy-tetrakis-O-[(tert-butyl)dimethylsilyl]-
D-glycero-L-manno-heptitol-1-C-ylidene}-2,3-dideoxy-β-D-glycero-hexopyran-4-ulose 
(150) 
 
150
O
TBSO
TBSO
OTBS
OTBS O
O
O
H
 
Methanesulfonyl chloride (98%, 0.370 mL, 4.76 mmol) was added to a stirred solution of 
148 and 149 (0.74 g, 0.959 mmol) in dry pyridine (15 mL) containing DMAP (50 mg) 
under Ar atmosphere. The mixture was stirred for 14 h and was then quenched by the 
addition of 20% aq soln of CuSO4⋅5H2O solution (30 mL). The solution was extracted 
with CH2Cl2 (3 x 50 mL), and the combined organic phases were washed with 2 M aq HCl 
(3 x 30 mL), dried (MgSO4), and then concentrated in vacuo to yield 150 as unstable 
colorless oil which was used without further purification in the next step. 
 
 144 
1,6-anhydro-3-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-erythro-hexopyran-4-ulose (151). 
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Raney Nickel (1 g) in aqueous suspension was added to a stirred solution of 150 (0.9 g, 
1.19 mmol) in THF (5 mL). The mixture was stirred at 20 °C until complete conversion of 
150 (TLC control). The mixture was diluted with Et2O (200 mL), filtrated through a pad 
of Celite. FC (9:0.5:0.5 light petroleum ether/Et2O/CH2Cl2): 390 mg (43%) of 152, and 
400 mg (44%) of 151. 
 
Data of 151: colorless oil. 
 
IR (film) 2955, 2895, 2855, 1730, 1470, 1255, 1095, 835, 775 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ 
5.69 (br s, H-C(1)); 4.53 (dd, 3J (H-(5), Hexo-C(6)) = 5.1, 3J (H-(5), Hendo-C(6)) = 0.5 , H-
C(5)); 4.22-4.19 (m, 2H, Ha-(7’), H-(3')); 4.00 (d, 2J = 8.3, 3J (Hendo-(6), H-C(5)) = 0.5, 
Hendo-C(6)); 3.90 (dd, 2J = 8.3, 3J (Hexo-(6), H-C(5)) = 5.1, Hexo-C(6)); 3.88 (t, 3J (H-(6’), 
Ha-C(7’)) = 3J (H-(6’), H-C(5’)) = 3.9, H-(6’));  3.80 (d, 3J (H-(2’), H-C(1’)) = 10.5 , 3J 
(H-(2’)); 3.74 (t, 3J (H-(4’), Ha-C(3’)) = 3J (H-(4’), H-C(5’)) = 3.2, H-(4’)); 3.70 (dd, 2J = 
11.8, 3J (Ha-C(7’), H-C(6’)) = 1.61, Ha-C(7’)); 3.40 (br s, H-(5’)); 3.00 (ddd, 3J (H-(3), 
Hendo-C(2)) = 10.5, 3J (H-(3), Hexo-C(2)) = 8.1, 3J (H-(3), H-C(1’)) = 3.8, H-(3)); 2.57 (dd, 
2J = 12.6, 3J (Hexo-(2), H-C(3)) = 8.1, Hexo-C(2)); 2.37 (ddd, 2J = 14.8, 3J (Ha-C(1’), H-
C(2’)) = 10.7, 3J (Ha-C(1’), H-C(3)) = 3.8, Ha-C(1’)); 1.79 (dd, 2J = 12.6, 3J (Hendo-(2), H-
C(3)) = 10.5, Hendo-C(2)); 1.22 (m, Hb-C(1’)); 0.97, 0.97, 0.91, 0.88 (4s, 36H, 36H-
C(SiC(CH3)3)); 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01, (8s, 24H, 24H-C(SiCH3));  
 
13C NMR (100.6 MHz, CDCl3): δ 
204.0 (s, C(4)); 100.8 (d, 1J (C,H) = 173, C(1)); 79.3 (d, 1J (C,H) = 141, C(6’)); 79.2 (d, 1J 
(C,H) = 163, C(5)); 74.5 (d, 1J(C,H) = 141, C(5’)); 73.6 (d, 1J(C,H) = 146, C(4’)); 67.3 (d, 
 145 
1J(C,H) = 147, C(3’)); 67.0 (t, 1J(C,H) = 116, C(6)); 62.2 (d, 1J(C,H) = 146, C(2’)); 58.2 
(d, 1J(C,H) = 144, C(7’)); 38.6 (d, 1J(C,H) = 128, C(2)); 38.3 (t, 1J(C,H) = 125, C(3)); 29.9 
(t, 1J(C,H) = 128, C(1’)); 25.9, 25.9, 25.7, 25.6 (4q, 1J (C,H) = 128, (CH3)3CSi); 18.4; 
18.3, 18.1; 18.0 (4s, (CH3)3CSi); -4.4; -4.6; -4.8; -4.9, -5.0; -5.1, -5.3; -5.5; (8q, 1J (C,H) = 
118 , CH3Si).; 
 
HR-FAB-MS: for C37H76O8Si4+Na calcd 783.4515; found 783.4511.. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 151: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
5.555.605.655.705.755.80 3.703.803.904.004.104.204.304.40
2.702.802.903.003.103.203.303.403.50 1.701.801.902.002.102.202.302.402.502.60
H-1
H-5
H-3'H-7' Hendo-6
Hexo-6H-6'
H-2'
H-4'Ha-7'
H-5'
H-3 Hexo-2 Hendo-2Ha-1'
Hb-1' +  impurites
 
 
 146 
1,6-Anhydro-3-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-threo-hexopyran-4-ulose 152 
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Data of 152: colorless oil.  
 
[α]25589 = -10, [α]25546 = -13, [α]25435 = -44, [α]25405 = -73 (c 0.21, CHCl3).  
 
IR (film): 2955, 2895, 2855, 1730, 1470, 1255, 1095, 835, 775 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ 
5.70 (d, 3J (H-(1), Hexo-C(2)) = 5.4 , H-C(1)); 4.53 (dd, 3J (H-(5), Hexo-C(6)) = 5.4, 3J (H-
(5), Hendo-C(6)) = 0.5 , H-C(5)); 4.19 (dd, 3J (H-(5’), H-C(4’)) = 6.5 , 3J (H-(5’), H-C(6’)) 
= 2.7, H-(5’)); 4.15 (dd, 2J = 11.8, 3J (Ha-C(7’), H-C(6’)) = 9.7, Ha-C(7’)); 4.00 (d, 3J (H-
(2’), H-C(1’)) = 10.5 , 3J (H-(2’)); 3.88 (t, 3J (H-(6’), Ha-C(7’)) = 3J (H-(6’), H-C(5’)) = 
2.7, H-(6’)); 3.77 (d, 2J = 7.3, 3J (H-(6), H-C(5)) = 0.5, Hendo-C(6)); 3.72 (t, 3J (H-(4’), Ha-
C(3’)) = 3J (H-(4’), H-C(5’)) = 3.2, H-(4’)); 3.70-3.63 (m, 2H, Hexo-(6), H-(7')); 3.49 (d, 3J 
(H-(3’), H-C(4’)) = 3.5, H-(3’)); 2.90 (m, 1H, H-(3)); 2.68 (m, 1H, Hexo-(2)); 1.67 (dd, 2J = 
12.9, 3J (Hb-C(1’), H-C(2’)) = 8.0, Hb-C(1’)); 1.46 (m, 1H, Ha-C(1')); 1.30 (m, 1H, Hendo-
C(2)); 0.97, 0.97, 0.91, 0.88 (4s, 36H, 36H-C(SiC(CH3)3)); 0.15, 0.14, 0.14, 0.12, 0.08, 
0.07, 0.01, 0.01, (8s, 24H, 24H-C(SiCH3));  
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13C NMR (100.6 MHz, CDCl3): δ 
213.0 (s, C(4)); 100.1 (d, 1J (C,H) = 173, C(1)); 79.3 (d, 1J (C,H) = 141, C(6’)); 79.0 (d, 1J 
(C,H) = 163, C(5)); 74.4 (d, 1J(C,H) = 147, C(3’)); 73.6 (d, 1J(C,H) = 146, C(4’)); 67.0 (d, 
1J(C,H) = 141, C(5’)); 67.0 (t, 1J(C,H) = 154, C(6)); 65.0 (d, 1J(C,H) = 146, C(2’)); 58.0 
(t, 1J(C,H) = 145, C(7’)); 39.0 (d, 1J(C,H) = 125, C(3)); 36.0 (t, 1J(C,H) = 128, C(2)); 30.0 
(t, 1J(C,H) = 128, C(1’)); 25.9, 25.9, 25.7, 25.6 (4q, 1J (C,H) = 128, (CH3)3CSi); 18.2; 
18.1, 18.0; 17.9 (4s, (CH3)3CSi); -4.4; -4.6; -4.8; -4.9, -5.0; -5.1, -5.3; -5.5; (8q, 1J (C,H) = 
118 , CH3Si). 
 
HR-FAB-MS: for C37H76O8Si4+Na calcd 783.4515; found 783.4542. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 152: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
5.625.645.665.685.705.725.745.76
H-1 H-5
H-5'
Ha-7'
H-2'
H-6'
Hendo-6
H-4' H-exo-6, Hb-7'
H-3' H-3
Hexo-2
4.004.104.204.304.404.50
3.503.553.603.653.703.753.803.853.90 2.652.702.752.802.852.902.95
1.101.201.301.401.501.601.701.80
Hb-1' Ha-1'
Hendo-2
+ impurities
 
 
 148 
 
1,6-Anhydro-3-C-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-
D-glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-lyxo-hexopyranose (153). 
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A THF solution of LiBH4 (0.56 mL, 1.13 mmol) was added dropwise to a solution of 152 
(0.140 mg, 0.188 mmol) in THF (5 mL) at -78 °C. The mixture was stirred for 4 h, from -
78 °C to 15 °C. Satd aq soln of NH4Cl (25 mL) was added. The reaction mixture was 
warmed to 20 °C. A satd soln of sodium potassium tartarate (25 mL) was added. The 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phases 
were dried, concentrated in vacuo. FC (light petroleum ether/Et2O 9:1) gave 110 mg of 
153 (79%), colorless oil. 
 
 [α]25589 = +4, [α]25546 = +7, [α]25435 = +9, [α]25405 = +11 (c 0.08, CHCl3). 
 
 IR (film): 3425, 2955, 2855, 1620, 1470, 1360, 1130, 865, 835, 775, 740 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ  
5.57 (br. s, H-C(1)); 4.49 (m, dd, 2J = 11.3, 3J (Ha-(7’), H-C(6’)) = 4.5, Ha-C(7’)); 4.44(d, 
3J (H-(2’), Ha-C(1’)) = 11.8, H-C(2’)); 4.36(t, 3J (H-(5), Hexo-C(6)) = 4.6, H-C(5)); 4.24-
4.17 (m, 3H, Hexo-C(6), H-C(4’), H-C(4)); 3.90 (ddt, 3J (H-(6’), Ha-C(7’)) = 3J (H-(6’), H-
C(5’)) = 4.5, 3J (H-(6’), Hb-C(7’)) = 2.5 , H-C(6’)); 3.88 (t, 3J (H-(5’), H-C(6’)) = 4.5, H-
C(5’)); 3.73 (dd, 2J = 11.3, 3J (Hb-(7’), H-C(6’)) = 2.5, Hb-C(7’)); 3.70 (dd, 2J = 7.3, 3J 
(Hexo-(6), H-C(5)) = 5.1, Hexo-C(6)); 3.46 (d, 3J (H-(3’), H-C(4’)) = 3.7, H-C(3’)); 2.56-
2.42 (m, 1H, H-C(3)); 2.05-1.90 (m, 2H, Ha-C(1’), Hendo-C(2)); 1.85-1.75 (m, 1H, Hb-
C(1’)); 1.68-1.60 (m, 1H, Hexo-C(2)); 0.97, 0.97, 0.91, 0.88 (4s, 36H, 36H-C(SiC(CH3)3)); 
0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01, (8s, 24H, 24H-C(SiCH3));  
 149 
 
13C NMR (100.6 MHz, CDCl3): δ  
100.1 (d, 1J (C,H) = 173, C(1)); 78.1 (d, 1J (C,H) = 141, C(6’)); 75.6 (d, 1J (C,H) = 163, 
C(5)); 74.4 (d, 1J(C,H) = 147, C(3’)); 63.8 (d, 1J(C,H) = 141, C(5’)); 69.2 (d, 1J(C,H) = 
146, C(4’)); 67.5 (d, 1J(C,H) = 141, C(4)); 64.8 (t, 1J(C,H) = 144, C(6)); 64.5 (d, 1J(C,H) = 
146, C(2’)); 58.6 (d, 1J(C,H) = 136, C(7’)); 36.5 (t, 1J(C,H) = 128, C(2)); 34.6 (t, 1J(C,H) 
= 128, C(1’)); 30.8 (d, 1J(C,H) = 125, C(3)); 25.9, 25.9, 25.7, 25.6 (4q, 1J (C,H) = 128, 
(CH3)3CSi); 18.4; 18.3, 18.1; 18.0 (4s, (CH3)3CSi); -4.4; -4.6; -4.8; -4.9, -5.0; -5.0, -5.3; -
5.5; (8q, 1J (C,H) = 118 , CH3Si).; 
 
HR-FAB-MS: for C37H78O8Si4+Na calcd 785.4671 found 785.4662.. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 153: 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
5.485.505.525.545.56
H-1
4.154.204.254.304.354.404.454.504.55
Ha-7' H-2'
H-5
Hexo-6, H-4', H4
3.403.503.603.703.803.904.00
H-6'
H-5' Hb-7'
Hexo-6
H-3'
H-3
Ha-1', Hendo-2 Hb-1'
Hexo-2 + impurities
1.601.802.002.202.40
 
 
 150 
4,6-Di-O-acetyl-3-C-{7-O-acetyl-2,6-anhydro-1-deoxy-3,4,5-tri-O-[(tert-
butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-α,β-D-lyxo-
hexopyranosyl acetate (154α,β). 
O
TBSO
TBSO
OTBS
OAc
O
AcO
OAc
OAc
154  
 
A catalytic amount of triethylsilyl triflate (1.3 µL) was added dropwise via a syringe to a 
solution of compound 153 (0.12 g, 0.157 mmol) in acetic anhydride (2 mL) cooled at 0 °C. 
The mixture was stirred at 0°C for 30 min, and then a satd aq soln of NaHCO3 was added. 
The mixture was extracted with CH2Cl2 (3 x 10 mL). The organic layers were dried 
(MgSO4), concentrated in vacuo, coevaporated with toluene in vacuo. The oily product so-
obtained was used directly in the next step. 
 
 [α]25589 = +50, [α]25546 = +51, [α]25435 = +99, [α]25405 = +118 (c 0.21, CHCl3). 
 
IR (film): 15735, 1435, 1370, 1220, 1030, 910, 600 cm-1.  
 
HR-FAB-MS: for C39H74O13Si3+Na calcd 857.4309; found 857.4334. 
 
 151 
4,6-Di-O-acetyl-3-C-{7-O-acetyl-2,6-anhydro-1-deoxy-3,4,5-tri-O-[(tert-
butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-3-deoxy-D-galactal (155). 
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Silica gel (870 mg) was added to a solution of 154α,β (0.286 g, 0.315 mmol) in toluene 
(10 mL) and the mixture was heated under reflux for 3 h. Filtration, washing with CH2Cl2 
(100 mL), concentration in vacuo, FC (9:0.5:0.5, light petroleum ether/Et2O/CH2Cl2): 160 
mg (60%), yellowish oil. 
 
 [α]25589 = -7, [α]25546 = -10, [α]25435 = -27, [α]25405 = -40 (c 0.09, CHCl3). 
 
IR (film): 1955, 1755, 1650, 1370, 1235, 1090, 1035, 905, 600 cm-1.  
 
1H NMR (400 MHz, CDCl3): δ 
δ 6.38 (dd, 3J (H-(1), H-C(2)) = 6.2, 4J (H-(1), H-C(3)) = 2.7, H-C(1)); 5.49 (d, 3J (H-(4), 
H-C(3)) = 3.4, H-C(4)); 5.16 (dd, 2J = 12.6, 3J (Ha-(7’), H-C(6’)) = 9.9, Ha-C(7’)); 4.72 
(dt, 3J (H-(2), H-C(1)) = 6.2, 3J (H-(2), H-C(3)) = 3.9, H-C(2)); 4.28-4.17 (m, 7H, Hexo-
C(6), Hendo-C(6), Hb-C(7’), H-C(5), H-C(6’), H-C(5’), H-C(2’)); 3.77 (t, 3J (H-(4’), H-
C(3’)) = 4.6, H-C(4’)); 3.40 (d, 3J (H-(3’), H-C(4’)) = 4.6, H-C(3’)); 2.70 (br s, H-C(3)); 
2.10-2.06 (3s, 9H, CH3COO); 1.62-1.50 (m, 1H, Ha-C(1’), 1.29-1.20 (m, 1H, Hb-C(1’), 
0.95, 0.94, 0.93 (3s, 27H, 27H-C(SiC(CH3)3)); 0.12, 0.12, 0.11, 0.10, 0.09, 0.07, (6s, 18H, 
18H-C(SiCH3)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
δ 171.0, 170.7, 170.3 (3s, -COO); 142.2 (d, 1J (C,H) = 148, C(1)); 104.0 (d, 1J (C,H) = 
146, C(2)); 75.8 (d, 1J (C,H) = 142, C(5’)); 74.4 (d, 1J (C,H) = 146, C(4’)); 74.1 (d, 1J 
(C,H) = 147, C(2’)); 73.5 (d, 1J (C,H) = 147, C(3’)); 67.1 (d, 1J (C,H) = 163, C(5)); 65.6 
(d, 1J (C,H) = 141, C(6’)); 65.0 (d, 1J(C,H) = 142, C(4)); 63.4 (t, 1J(C,H) = 145, C(7’)); 
60.2 (t, 1J(C,H) = 106, C(6)); 32.9 (d, 1J(C,H) = 125, C(3)); 32.3 (t, 1J(C,H) = 128, C(1’)); 
26.1- 25.8 (3q, 1J(C,H) = 130, CH3COO); 25.9, 25.9, 25.7 (3q, 1J (C,H) = 128, 
 152 
(CH3)3CSi); 21.1; 20.8, 20.7 (3s, (CH3)3CSi); -4.4; -4.5; -4.7; -4.7, -5.0; -5.1 (6q, 1J (C,H) 
= 118 , CH3Si). 
 
HR-FAB-MS: for C37H70O11Si3+Na calcd 797.4123; found 797.4151. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 155: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
H-1 H-4 H-7' H-2
Hex-6, Hend-6, Hb-7'
H-4'
H-3'
H-3
Ha-1' Hb-1' 
+ impurities+ impurities
, H-5, H-6', H-5', H-2'
6.3406.3506.3606.3706.3806.3906.4006.4106.420 4.704.804.905.005.105.205.305.405.50
3.803.904.004.104.20 2.702.802.903.003.103.203.303.40
 
 
 153 
(E) or (Z) 1,6-Anhydro-3-C-{2,6- anhydro-1-deoxy-3,4,5,7-tetra-O-[ (tert-butyl) 
dimethylsilyl]-D-glycero-L- manno- heptitol-1-C-ylidene} –2-[(benzyl)(methoxy) 
amino] 2,3-dideoxy-β-D-erythro-hexopyranos-4-ulose (169). 
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Trifluroacetic anhydride (TFAA) (5 mL, 35.95 mmol) was added dropwise at 0°C solution 
of alcohols 131a (11.9 g, 13.04 mmol) and pyridine (5 mL, 61.31 mmol).in CH2Cl2 (40 
ml). Stirring was continued for 1 h, then DBU (15mL, 98.70 mmol) was added, after 
stirring for 20 min. The mixture was diluted by Et2O (500 mL) and the solution was 
quenched with saturated aqueous NaHCO3 (100 mL), washed with HCl (1M) (100 mL), 
then with saturated aqueous NaHCO3 (100 mL) again, dried (MgSO4), Filtration, 
evaporation, FC ( 5% of Et2O in pentane) gave (E or Z enone 169 ) (9.00 g, 10.04 mmol, 
80 %). (Note: NMR information’s not enough to confirm Z or E enone) 
[α]25589 = +11.6, [α]25577 = -23.2, [α]25435 = -137, [α]25405 = -435 (c 0.155, CHCl3). 
 
UV (MeCN): 272 (1084), 236 (2137). 
 
IR (cm-1): 2930, 2855, 1705, 1620, 1470, 1255, 1095, 875, 835, 775, 740. 
 
1H NMR (400 MHz, CDCl3): δ 
7.34-7.17 (m, 5H, ArH); 6.88 (dd, 3J(Ha-(1’), H-(2’) = 7.1, 3J(Ha-(1’), H-(3’) = 1.9, H-
C(1’)); 6.04 (s, H-C(1)); 5.33 (d, 3J (H-(2’), H-(1’)) = 7.1, H-C(2’)); 4.61 (t, 3J (H-C(5), 
Hexo-C(6)) = 3.4, H-C(5)); 4.31 (dd, 3J(H-C(5’), H-C(6’)) = 6.5, 3J (H-C(5’), HC-(4’)) = 
2.5, H-C(5’)); 4.21 (dd, 2J = 12.3, 3J (Ha-C(7’), H-C(6’)) = 8.9, Ha-C(7’)); 4.03 (dd, 3J (H-
(3’), H-(4’)) = 4.0, 4J(H-C(3’), H-(1’)) = 1.9, H-C(3’)); 3.94 (dd, 3J (H-(6’), Ha-(7’)) = 8.9, 
3J(H-C(6’), H-(5’)) = 6.5, H-C(6’)); 3.90 (d, 2J = 13.9, Hendo-C(6)); 3.85 (d, 2H, 2J = 13.9, 
H-C(NCH2Ph)); 3.80 (bs, H-C(2)); 3.76-3.68 (m, 3H, Hexo-C(6), Hb-C(7’), H-C(4’)); 3.14 
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(s, 3H, H-(OCH3)); 0.97, 0.90, 0.86, 0.75 (4s, 36H, 36H-C(SiC(CH3)3)); 0.16, 0.09, 0.07, 
0.05, 0.02, -0.09, -0.13, -0.13 (8s, 24H, 24H-C(SiCH3)).  
 
13C NMR (100.6 MHz, CDCl3): δ 
195.5 (s, C(4)); 155.3 (d, 1J(C,H) = 179, C(1’)); 138.9 (s, C(3));138.8 (s, C(arom)); 129.8 
(d, 1J(C,H) = 159, C(arom)); 128.0 (d, 1J(C,H) = 156, C(arom)); 127.3 (d, 1J(C,H) = 156, 
C(arom)); 99.9 (d, 1J (C,H) = 179, C(1)); 79.7 (d, 1J(C,H) = 147, C(6’)); 78.8(d, 1J (C,H) 
= 159, C(5)); 73.9 (d, 1J(C,H) = 154, C(4’));73.6 (d, 1J (C,H) = 141, C3’); 67.6 (t, 1J (C,H) 
= 146, C(NCH2Ph); 67.0 (d, 1J (C,H) = 146, C(2’)); 67.0 (d, 1J(C,H) = 146, C(5’)); 64.8 
(d, 1J(C,H) = 143 , C(2)); 60.8 (q, 1J(C,H) = 140, H(OCH3)); 59.7 (t, 1J(C,H) = 143, 
C(7’)); 56.4 (t, 1J(C,H) = 154, C(6)); 26.0, 25.9, 25.7, 25.6 (4q, 1J (C,H) = 125, 
(CH3)3CSi); 18.2; 18.1, 18.0, 17.9(4s, (CH3)3CSi); -4.4; -4.6; -4.7; -4.8, -5.1; -5.3, -5.4; -
5.5 (8q, 1J (C,H) = 118 , CH3Si). 
 
MALDI-HRMS Calcd for (M + Na) C45H83NO9Si4Na 916.5043; found 916.5034. 
 
Anal. calcd for C45H83NO9Si4 (894.48): C 60.42, H9.35, N 1.57; found: C 60.45, H 9.36, 
N 1.56. 
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1H-NMR (400 MHz, CDCl3) spectrum of 169: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
H-1' H-1
H-2'
6.806.826.846.866.886.906.926.946.966.98
5.805.906.006.106.206.30 5.265.285.305.325.345.365.385.40
3.703.803.904.004.104.204.304.404.504.60
H-5
H-5'
Ha-7'
H-3'
H-6'
Hendo-6
CH2Ph
H-2
Hexo-6
Hb-7'
H-4'
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1,6-Anhydro-3-{2,6-anhydro-1-deoxy-3,4,5,7-tetra-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}–2-[(N-benzyl-N-methoxy)amino]-2,3-dideoxy-β-D-
xylo-hexopyran-4-ulose (170). 
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Raney Nickel (1g) in aqueous suspension was added to a stirred solution of 169 (2.2 g, 
2.46 mmol) in ethanol (5mL). The mixture was stirred at 70 oC and under 50 atm of H2 
until complete conversion of 169 (TLC control). The mixture was diluted with CH2Cl2 
(200mL) and filered through a pad of Celite. Evaporation, the residue was disolvend in 20 
mL solution of 5:1 THF: MeOH containing 1 % aq.KOH, then the mixture was stirred for 
3 h. The mixture was diluted with CH2Cl2 (200mL), washed with water (50mL), dried 
(MgSO4). Filtration, evaporation, FC (9:1 , light petroleum ether/Et2O) gave 1.9g (87 %) 
of 170a, colorless oil. 
[α]25589 = +9.1, [α]25577 = +25.1, [α]25435 = +33.7, [α]25405 = +16.6 (c 0.175, CHCl3). 
 
IR (cm-1): 2895, 2855, 1725, 1255, 875, 835, 775, 740. 
 
1H NMR (400 MHz, CDCl3): δ 
 7.50-7.24 (m, 5H, ArH); 6.04 (s, H-C(1)); 4.56 (d, 3J (H-C(5), Hexo-C(6)) = 5.3, H-C(5)); 
4.31 (d, 3J = 13.0, Ha-C(NCH2Ph)); 4.24 (dd, 3J(H-C(5’), H-C(6’)) = 6.5, 3J (H-C(5’), HC-
(4’)) = 2.5, H-C(5’)); 4.14 (dd, 2J = 11.7, 3J (Ha-C(7’), H-C(6’)) = 9.6, Ha-C(7’)); 4.01 (d, 
3J (H-(2’), H-(1’)) = 10.8, H-C(2’)); 3.88-3.78 (m, 3H, Hb-C(NCH2Ph), Hendo-C(6), H-
C(6’)); 3.75 (t, 3J(H-C(4’), H-C(5’)) = 2.5, H-C(4’)); 3.70 (dd, 2J = 7.1, 3J (Hexo-C(6), HC-
(5)) = 5.3, Hexo-C(6)); 3.65 (d, 2J = 11.7, Hb-C(7’)); 3.60 (br d, 3J (H-(3’), H-(4’)) = 3.5, 
H-C(3’)); 3.33 (s, 3H, H-(OCH3)); 3.22 (m, 1H, , H-C(3)); 2.62 (br s, 1H, H-C(2)); 2.01 (t, 
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2J = 12.7, 3J (Ha-C(1’), H-C(2’)) = 10.8, Ha-C(1’)); 1.47 (m, 1H, Hb-C(1’)); 0.97, 0.96, 
0.92, 0.87 (4s, 36H, 36H-C(SiC(CH3)3)); 0.13, 0.11, 0.11, 0.11, 0.10, 0.07, 0.00, -0.01 (8s, 
24H, 24H-C(SiCH3)).  
 
13C NMR (100.6 MHz, CDCl3): δ 
213.3 (s, C(4)); 138.8 (s, C(arom)); 129.8 (d, 1J(C,H) = 159, C(arom)); 128.0 (d, 1J(C,H) = 
156, C(arom)); 127.0 (d, 1J(C,H) = 156, C(arom)); 99.8 (d, 1J (C,H) = 179, C(1)); 78.8 (d, 
1J(C,H) = 147, C(6’)); 78.6(d, 1J (C,H) = 159, C(5)); 74.3 (d, 1J (C,H) = 141, C3’); 73.8 
(d, 1J(C,H) = 154, C(4’)); 67.5 (d, 1J(C,H) = 146, C(5’)); 67.4 (d, 1J(C,H) = 143 , C(2)); 
67.0 (t, 1J(C,H) = 154, C(6)); 64.4 (d, 1J (C,H) = 146, C(2’)); 61.3 (q, 1J(C,H) = 140, 
H(OCH3)); 58.5 (t, 1J(C,H) = 143, C(7’)); 57.2 (t, 1J (C,H) = 146, C(NCH2Ph); 42.4 (d, 
1J(C,H) = 126, C(3)); 27.8 (d, 1J(C,H) = 126, C(1’)); 26.0, 25.9, 25.8, 25.7 (4q, 1J (C,H) = 
125, (CH3)3CSi); 18.2; 18.1, 18.0, 17.9 (4s, (CH3)3CSi); -4.2,-4.4; -4.6; -4.9; -5.0; -5.4, -
5.5; -5.8 (8q, 1J (C,H) = 118 , CH3Si). 
 
MALDI-HRMS Calcd for (M + Na) C45H85NO9Si4Na 918.5199; found 918.5178. 
 
Anal. calcd for C45H85NO9Si4 (896.49): C 60.29, H9.56, N 1.56; found: C 60.24, H 9.50, 
N 1.57. 
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1H-NMR (400 MHz, CDCl3) spectrum of 170a: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
H-arom
H-1 H-5
Ha-NCH2Ph H-5'
Ha-7' H-2'
5.805.906.006.106.206.30
4.004.104.204.304.404.504.60 3.103.203.303.403.503.603.703.803.90
Hb-NCH2Ph
Hendo-6
H-4'Hexo-6
Hb-7'H-3'
OCH3
H-3
H-2
Ha-1'
Hb-1'
1.401.601.802.002.202.402.602.80
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1,6-Anhydro-3-{(2,6-anhydro-1-deoxy-3,4,5,7-tetra-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}–2-[(N-benzyl-N-methoxy)amino]-2,3-dideoxy-β-D-
erythro-hexopyran-4-ulose (170b). 
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Copper cyanide (153 mg, 1.71 mmol) was suspended in THF (7 mL) and chilled to -20 
C. A 1.64 M solution of n-BuLi in hexanes (0.96 mL, 1.53 mmol) was added dropwise. 
The brown solution was stirred at -20 C for 30 min, and then the temperature was 
lowered to -50 C. A 1 M solution of DIBAL in hexanes (3.4 mL, 3.4 mmol) was added 
slowly dropwise. The dark brown solution was allowed to stir at -50 C for 1 h before the 
enone 169 (150 mg, 1.68 mmol) was added as a solution in 3:1 THF/HMPA (4 mL). The 
temperature was raised to -20 C over the next 10 min and then the mixture was allowed 
to stir at -20 C for 1 h. The reaction was quenched with a saturated aqueous solution of  
NH4Cl  at -20 C and allowed to warm to ambient temperature over 30 min. The mixture 
was filtered and extracted with ether. The organic layer was evaporated and then 
partitioned between ether and, sequentially, saturated aqueous solution of  NH4Cl, water, 
and brine. The organic layer was dried (Na2SO4), filtered through silica gel, and 
evaporated to yield the crude reduction product (120 mg) as a pale-yellow oil. (This 
procedure is problematic because the reproducibility and the difficultly to avoid 1,2 
reduction ). 
A 0.1 M solution of the Dess-Martin periodinane in CH2Cl2 (1 mL, 0.1 mmol) was added 
to a solution of the crude oil from reduction in CH2Cl2. After 30 min, and again after 1 h, 
additional portions (1 mL each) of periodinane were added. After 2 h, the reaction was 
complete (TLC). A solution of 1:1 10% aqueous Na2S2O4/1 M aqueous NaOH (20 mL) 
was added and the mixture was allowed to stir for 30 min. The mixture was then 
partitioned between ether and, sequentially, water and brine. The organic layer was dried 
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(MgSO4), and evaporated, FC (9:1 , light petroleum ether/Et2O) gave 170b ( 100 mg, 1.12 
mmol, 65 %), clear oil Rf (20% ether/petroleum ether) = 0.48.  
 
IR (cm-1): 2900, 2865, 1730, 1250, 870, 835, 770, 735. 
 
 1H NMR (400 MHz, CDCl3): δ 
 7.33-7.22 (m, 5H, ArH); 6.05 (s, H-C(1)); 4.50 (d, 3J (H-C(5), Hexo-C(6)) = 5.2, H-C(5)); 
4.44 (dd, 2J = 12.0, 3J (Ha-C(7’), H-C(6’)) = 8.9, Ha-C(7’)); 4.29 (d, 3J (H-C(2), H-C(3)) = 
7.7, H-C(2)); 4.34 (dd, 3J(H-C(5’), H-C(6’)) = 6.5, 3J(H-C(5’), H-C(4’)) = 2.7, 3J (H-
C(5’)); 4.10 (d, 3J = 14.5, Ha-C(NCH2Ph)); 4.05 (dd, 2J = 8.3, Hendo-C(6)); 3.95 (ddd, 
3J(H-C(6’), Ha-C(7’)) = 8.9, 3J(H-C(6’), H-C(5’)) = 6.5, 3J(H-C(6’), Hb-C(7’)) = 2.2, 3J 
(H-C(6’); 3.88 (dd, 2J = 8.3, 3J (Hexo-C(6), HC-(5)) = 5.2, Hexo-C(6)); 3.83 (dd, 3J (H-
C(4’), HC-(3’)) = 4.1, 3J (H-C(4’), HC-(5’)) = 3.1, H-C(4’)); 3.74 (dd, 2J = 12.0, 3J (Hb-
C(7’), H-C(6’)) = 2.2, Hb-C(7’)); 3.59 (d, 3J (H-C(3’), HC-(4’)) = 4.1, H-C(3’)); 3.54 (d, 3J 
= 14.5, Hb-C(NCH2Ph); 3.35 (ddd, 3J(H-C(3), Ha-C(1’)) = 11.4, 3J(H-C(3), H-C(2)) = 7.7, 
3J(H-C(3), Hb-C(1’)) = 3.7, 3J (H-C(3)); 3.23 (s, 3H, H-(OCH3)); 2.45 (ddd, 2J = 14.8, 
3J(Ha-C(1’), H-C(3)) = 11.4, 3J(Ha-C(1’), H-C(2’)) = 3.5, Ha-C(1’)); 1.43 (dd, 2J = 14.8, 
3J(Hb-C(1’), H-C(3)) = 3.7, Hb-C(1’)); 0.97, 0.92, 0.92, 0.84 (4s, 36H, 36H-
C(SiC(CH3)3)); 0.16, 0.13, 0.11, 0.10, 0.09, 0.08, 0.07, 0.06 (8s, 24H, 24H, C(SiCH3)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
 204.3 (s, C(4)); 139.1 (s, C(arom)); 129.5 (d, 1J(C,H) = 159, C(arom)); 128.1 (d, 1J(C,H) 
= 156, C(arom)); 127.0 (d, 1J(C,H) = 159, C(arom)); 100.6 (d, 1J (C,H) = 179, C(1)); 
79.4(d, 1J (C,H) = 159, C(5)); 79.1 (d, 1J(C,H) = 147, C(6’)); 74.5 (d, 1J (C,H) = 141, 
C(3’); 74.0 (d, 1J(C,H) = 154, C(4’)); 67.7 (d, 1J(C,H) = 146, C(5’)); 66.4 (t, 1J(C,H) = 
154, C(6)); 65.5 (d, 1J(C,H) = 143 , C(2)); 61.8 (d, 1J (C,H) = 146, C(2’)); 61.2 (q, 1J(C,H) 
= 140, H(OCH3)); 58.3 (t, 1J(C,H) = 143, C(7’)); 57.7 (t, 1J (C,H) = 146, C(NCH2Ph); 
40.2 (d, 1J(C,H) = 125, C(3)); 24.4 (d, 1J(C,H) = 128, C(1’)); 25.9, 25.8, 25.7, 25.6 (4q, 1J 
(C,H) = 125, (CH3)3CSi); 18.1; 17.9, 17.4, 17.2(4s, (CH3)3CSi); -4.4,-4.5; -4.6; -4.8; -4.9; -
5.2, -5.3; -5.4 (8q, 1J (C,H) = 118 , CH3Si). 
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MALDI-HRMS Calcd for (M + Na) C45H85NO9Si4Na 918.5199; found 918.5178. 
 
Anal. calcd for C45H85NO9Si4 (896.49): C 60.29, H9.56, N 1.56; found: C 60.24, H 9.50, 
N 1.57. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 170b: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
Harom
H-1
H-5
Ha-7'
H-5'
Hendo-6
H-6'
Hexo-6
H-4'
Hb-7' H-3'
H-2 
Ha-NCH2Ph
Hb-NCH2Ph
impurities
H-3
OCH3
Ha-1' Hb-1'
5.986.006.026.046.066.086.10 3.603.804.004.204.40
3.263.283.303.323.343.363.383.403.423.44 2.402.452.502.55 1.381.401.421.441.461.48
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1,6-Anhydro-3-C-{2,6-anhydro-1-deoxy-3,4,5,7-tetra-O-[(tert-butyl)dimethylsilyl]-D-
glycero-L-manno-heptitol-1-C-yl}–2-[(N-benzyl-N-methoxy)amino]-2,3-dideoxy-β-D-
galacto-hexopyranose (171). 
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171  
A THF solution of LiBH4  (7.0 mL, 14.0 mmol) was added dropwise to a solution of 170a 
(3.50 mg, 3.84 mmol) in 50 ml of THF at –78 oC. The mixture was warmed to - 40 oC 
within 5min and stirred for 3h. An aq. NH4Cl solution (25 ml) was added. The reaction 
mixture was warmed to 20 oC. An aq. solution of sodium potassium tartarate (25ml) was 
added. The aq. phase was extracted with CH2Cl2 (100 mL/3 times). The combined org. 
phases were dried, concentrated in vacuo. FC(4:1 , light petroleum ether/Et2O) gave 3.22 g 
(92 %) of 171, colorless oil. (If the procedure applied correct, and the reagent was pure 
(LiBH4), no glucose analogue will obtain).  
 
[α]25589 = +33, [α]25577 = +35, [α]25435 = +60, [α]25405 = +66 (c 0.37, CHCl3). 
 
IR (film): 3475, 2950, 2855, 1715, 1630, 1475, 1255, 1095, 835, 780, 740 cm-1 
 
1H NMR (400 MHz, CDCl3): δ 7.45-7.39 (m, 2H,.ArH); 7.38-7.23 (m, 3H, ArH); 5.69 (s, 
H-C(1)); 4.50 (t, 3J (H-C(5), Hexo-C(6)) = 5.1, H-C(5)); 4.47-4.38 (m, 3H, H-C(2’), H-
C(4), Ha-C(7’)); 4.24 (dd, 3J(H-C(5’), H-C(6’)) = 6.7, 3J (H-C(5’), HC-(4’)) = 2.8, H-
C(5’)); 4.22 (d, 2J = 7.4, Hendo-C(6)); 4.05 (d, 2J = 13.4, Ha-C(NCH2Ph)); 3.92 (ddd, 3J(H-
(6’), Ha-(7’) = 9.6, 3J(H-(6’), H-(5’) = 6.7, 3J (H-C(6’), Hb-C(7’)) = 2.2, H-C(6’)); 3.83-
3.76 (m, 2H, Hb-C(NCH2Ph), H-C(4’)); 3.73 (dd, 2J = 12.5, 3J (Hb-C(7’), H-C(6’)) = 2.2, 
Hb-C(7’)); 3.56 (dd, 2J = 7.4, 3J(Hexo-C(6), H-(5)) = 5.4, Hexo-C(6)); 3.44 (d, 3J(H-C(3’), 
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H-(4’)) = 3.5, H-C(3’)); 3.25 (s, 3H, H-(OCH3)); 2.75 (d, 3J(H-C(2), H-C(3)) = 3.2, H-
C(2)); 2.63 (m, 1H, H-C(3)); 1.96 (ddd, 2J = 14.4, 3J(Ha-(1’), H-(3) = 10.9, 3J(Ha-(1’), H-
(2’) = 3.8, Ha-C(1’)); 1.78 (ddd, 2J = 14.4, 3J(Hb-(1’), H-(3) = 11.5, 3J(Hb-(1’), H-(2’) = 
2.9, Hb-C(1’)); 1.00, 0.95, 0.94, 0.90 (4s, 36H, 36H-C(SiC(CH3)3)); 0.13, 0.12, 0.11, 0.10, 
0.08, 0.06, 0.03, 0.01 (8s, 24H, 24H-C(SiCH3)).  
 
13C NMR (100.6 MHz, CDCl3): δC 138.8 (s, C(arom)); 130.4 (d, 1J(C,H) = 159, C(arom)); 
128.3 (d, 1J(C,H) = 156, C(arom)); 127.4 (d, 1J(C,H) = 156, C(arom)); 101.8 (d, 1J (C,H) 
= 179, C(1)); 78.7 (d, 1J(C,H) = 147, C(6’)); 75.6(d, 1J (C,H) = 159, C(5)); 74.8 (d, 
1J(C,H) = 141, C(3’)); 74.2 (d, 1J (C,H) = 154, C4’); 69.8 (d, 1J(C,H) = 143 , C(2)); 67.8 
(d, 1J(C,H) = 146, C(5’)); 67.3 (d, 1J (C,H) = 146, C(2’)); 64.2 (t, 1J(C,H) = 144, C(4)); 
63.3 (t, 1J(C,H) = 154, C(6)); 61.8 (q, 1J(C,H) = 122, C(OCH3)); 60.2 (t, 1J (C,H) = 145, 
C(NCH2Ph); 59.1 (t, 1J(C,H) = 143, C(7’)); 33.6 (t, 1J(C,H) = 130, C(1’)); 32.7 (d, 1J(C,H) 
= 126, C(3)); 26.4, 26.4, 26.3, 26.2(4q, 1J (C,H) = 125, (CH3)3CSi); 18.7; 18.5, 18.4; 
18.4(4s, (CH3)3CSi); -3.9; -4.0; -4.2; -4.4, -4.5; -4.5, -4.8; -4.9; (8q, 1J (C,H) = 118 , 
CH3Si).  
 
MALDI-HRMS Calcd for (M + Na) C45H87NO9Si4Na 920.5356; found 920.5350. 
 
Anal. calcd for C45H85NO9Si4 (898.52): C 60.15, H9.76, N 1.56; found: C 60.03, H 9.76, 
N 1.58. 
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1H-NMR (400 MHz, CDCl3) spectrum of 171: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
H-1
H-arom
H-5
H2'
H-4
Ha-7'
5.605.625.645.665.685.705.725.745.76 3.403.603.804.004.204.40
1.802.002.202.402.602.80
Hendo-6
H-5'
Ha-NCH2Ph
H-6'
Hb-NCH2Ph
H-4'
Hb-7' Hexo-6
H-3'
H-2
H-3
Ha-1' Hb-1'OCH3
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1,6-Anhydro-3-C-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-[(tert-butyl)dimethylsilyl]-
D-glycero-L-manno-heptitol-1-C-yl}-2-azido-2,3-dideoxy-β-D-galacto-hexopyranose 
(173) 
1
23
4
5
6
1'
2'
3'
4'
5' 6'
7'
O
TBSO
TBSO
OTBS
OTBS O
OHO
173
N3
 
To a stirred mixture of metallic sodium (184 mg, 8.0 mmol, 24 equiv) in liquid NH3 (10 
mL) at -78 oC was added a solution of 171 (300 mg, 0.329 mmol) in dry THF (5 mL). 
After 30 min at -78 oC, NH4Cl (540 mg, 10 mmol, 30 equiv) was added and ammonia was 
allowed to evaporate at 20 oC. After the addition of H2O (20 ml), the aqueous phase was 
extracted with CH2Cl2 (20 ml, 3 times). The combined org. phases were dried, 
concentrated in vacuo. The residue was dissolved in MeOH (10 ml), then 10% Pd on 
charcoal (35 mg) was added. The degassed mixture was stirred under H2  atmosphere (1 
atm.) at 20°C for 12 h. The catalyst was filtered off, the solvent evapored and the residue 
was dissolved in 1 ml of CH2Cl2, 1 mg of CuSO4 in 2 ml of H2O was added, then 
triethylamine (131 µl, 0.987 mmol) was added, followed by MeOH (7 ml). The 
dichloromethane solution of trifluoromethanosulfonyl azide freshly prepared (1 ml, 0.6 M, 
0.6 mmol) was added at once. The reaction was stirred until TLC showed reaction to be 
complete. Then the mixture was extracted by CH2Cl2 (15 ml, 3 times). These combined 
org. phases were dried, concentrated in vacuo. FC (7:3, light petroleum ether/ether): 220 
mg (81 %, 3 steps) of 173, colorless oil. 
 
 
[α]25589 = +34, [α]25577 = +22, [α]25435 = +38, [α]25405 = +50 (c 0.15, CHCl3). 
 
IR (film): 3470, 2950, 2860, 2120, 1645, 1470, 1250, 1090, 835, 775, 735 cm-1. 
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1H NMR (400 MHz, CDCl3): δ  
5.38 (s, H-C(1)); 4.46-4.34 (m, 3H, H-C(2’), H-C(5), Ha-C(7’)); 4.32 (dd, 3J(H-C(4), H-
C(3)) = 7.4, 3J(H-C(4), H-C(5)) = 4.9, H-C(4)); 4.20 (dd, 3J(H-C(5’), H-C(6’)) = 6.5, 3J 
(H-C(5’), HC-(4’)) = 2.8, H-C(5’)); 4.15 (d, 2J = 7.4, Hendo-C(6)); 4.13 (m, 1H, H-C(6’));  
3.76 (t, 3J(H-C(4’), H-C(3’)) = 3.4, H-C(4’)); 3.69 (dd, 2J = 12.6, 3J (Hb-C(7’), H-C(6’)) = 
2.5, Hb-C(7’)); 3.63 (dd, 2J = 7.4, 3J(Hexo-C(6), H-(5)) = 4.9, Hexo-C(6)); 3.41 (d, 3J(H-
C(3’), H-C(4’)) = 3.4, H-C(3’)); 3.25 (br s, H-C(2)); 2.60 (m, 1H, H-C(3)); 1.87 (m, 2H, 
3J(Ha-(1’), Hb-C(1’)); 0.93, 0.91, 0.90, 0.88 (4s, 36H, 36H-C(SiC(CH3)3)); 0.11, 0.10, 
0.09, 0.08, 0.08, 0.07, 0.07, 0.06 (8s, 24H, 24H-C(SiCH3)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
101.5 (d, 1J(C,H) = 179, C(1)); 78.3 (d, 1J(C,H) = 147, C(6’)); 75.6 (d, 1J(C,H) = 159, 
C(5)); 74.3 (d, 1J(C,H) = 141, C(3’)); 73.8 (d, 1J(C,H) = 154, C4’); 67.3 (d, 1J(C,H) = 146, 
C(5’)); 66.0 (t, 1J(C,H) = 144, C(4)); 64.8 (d, 1J(C,H) = 143 , C(2)); 64.4 (d, 1J(C,H) = 
146, C(2’)); 63.7 (t, 1J(C,H) = 154, C(6)); 58.6 (t, 1J(C,H) = 143, C(7’)); 37.5 (d, 1J(C,H) 
= 126, C(3)); 32.7 (t, 1J(C,H) = 130, C(1’)); 25.9, 25.8, 25.8, 25.6 (4q, 1J(C,H) = 125, 
(CH3)3CSi); 18.2; 18.1, 18.0; 17.9 (4s, (CH3)3CSi); -4.4; -4.6; -4.7; -4.8, -4.9, -5.2, -5.3; -
5.4 (8q, 1J (C,H) = 118 , CH3Si). 
 
MALDI-HRMS Calcd for (M + Na) C37H77N3O8Si4Na 826.4685; found 826.4650. 
 
Anal. calcd for C37H77N3O8Si4 (804.36): C 55.25, H9.65, N 5.22; found: C 55.15, H 9.57, 
N 5.19. 
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1H-NMR (400 MHz, CDCl3) spectrum of 173: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
5.305.325.345.365.385.405.425.445.46
H-1 H-2
'
H-5
Ha-7'
H-4 H-5'
Hendo-6
H-6'
H-4'
Hb-7' Hexo-6
H-3'
H-2
H-3 Ha-1'
Hb-1'
CDCl3
3.904.004.104.204.304.40
3.203.303.403.503.603.703.80 1.802.002.202.402.60
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4-O-Acetyl-1,6-anhydro-3-C-[2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-acetyl-D-
glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-β-D-galacto-hexopyranose 
(174). 
1
23
4
5
6
1'
2'
3'
4'
5' 6'
7'
O
AcO
AcO
OAc
OAc O
OAcO
174
N3
 
The tert-butyldimethylsilyl-protected 173 (600 mg, 0.733 mmol) was dissolved in THF (4 
mL), a solution of TBAF in THF  (4 mL, 4.0 mmol) was added, and the solution was 
stirred for 3 h at room temperature. The mixture was evaporated to dryness, then dissolved 
in pyridine (5 mL). A catalytic amount of DMAP (10 mg, 0.08 mmol) was added, then 
acetic anhydride (3 mL, 31.80 mmol) was added, and the solution was stirred for 2 days at 
20 oC. Then MeOH (5 mL) was added, the mixture was evaporated to dryness, then 
dissolved in ethyl acetate (25 mL). The solution was quenched with 5 % aqueous HCl (10 
ml), washed successively with saturated aqueous solution of NaHCO3 (5 mL), water and 
brine and dried (MgSO4). Evaporation of the filtrate, FC (1:1, light petroleum 
ether/EtOAc) gave 355 mg (89 %) of 174, white solid.  
 
m.p. 46-47°C. 
 
[α]25589 = +95, [α]25577 = +102, [α]25435 = +192, [α]25405 = +277 (c 0.38, CHCl3). 
 
IR (film): 3455, 2965, 2135, 1750, 1735, 1435, 1375, 1235, 1135, 1060, 1025, 910 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
5.37 (s , H-C(1)); 5.32 (s , H-C(5’)); 5.15 ((t, 3J(H-C(4), H-C(3)) = 6.5, H-C(4)); 5.11-5.08 
(m, 2H, H-C(6’), H-C(3’)); 4.58 (t, 2H, 3J (H-C(5), Hexo-C(6))= 4.6, H-C(5)); 4.22-4.12 
(m, 2H, Ha-C(7’), H-C(2’)); 4.10-3.95 (m, 2H, Hb-C(7’), H-C(4’)); 3.84 (d, 2J=8.0, Hendo-
C(6)); 3.52 (dd, 2J=8.0, 3J(Hexo-C(6),H-C(5))= 4.6, Hexo-C(6)); 3.45 (d, 3J(H-C(2), H-C(3)) 
= 4.6, H-C(2)); 2.17 (m, 1H, H-C(3)); 2.04, 2.01, 2.00, 1.99, 1.95 (5s, 15H, 
CH3COO);1.90 (m, 1H, Ha-C(1’)); 1.64 (m, 1H, Hb-C(1’)). 
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13C NMR (100.6 MHz, CDCl3): δ 
δ 170.3, 169.7, 169.6, 169.4, 169.4 (5s, -COO); 101.4 (d, 1J(C,H) = 176, C(1)); 72.3 (d, 
1J(C,H) = 159, C(5)); 71.3 (d, 1J(C,H) = 147, C(2’)); 68.4 (d, 1J(C,H) = 145, C(4’)); 68.3 
(d, 1J(C,H) = 155, C(6’)); 67.4 (d, 1J(C,H) = 150, C(3’)); 67.2 (d, 1J(C,H) = 153, C(5’)); 
66.5 (d, 1J(C,H) = 153, C(4)); 63.4 (t, 1J(C,H) = 153, C(6)); 63.1 (d, 1J(C,H) = 149, C(2)); 
61.4 (t, 1J(C,H) = 146, C(7’)); 35.3 (d, 1J(C,H) = 132, C(3)); 23.0 (t, 1J(C,H) = 127, 
C(1’)); 20.5- 20.2 (5q, 1J(C,H) = 130, 5 CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C23H31N3O13Na 580.1755; found 580.1704. 
 
Anal. calcd for C23H31N3O13•Ac2O (659.59): C 49.16, H 5.65, N 6.37; found: C 48.99, H 
5.45, N 6.28. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 174: 
1.52.02.53.03.54.04.55.05.56.06.57.07.5
H-1
H-5'
H-4
Ha-7'
H-2'H-5
H-6'
H-3'
Hb-7'
H-4'
Hendo-6
Hexo-6
H-3
H-2
Ha-1' Hb-1'
CDCl3
5.055.105.155.205.255.305.355.40
3.803.853.903.954.004.054.104.154.20
3.423.443.463.483.503.523.543.56
1.601.701.801.902.002.102.20
4.544.564.584.604.62
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15:1 Mixture of 1,4,6-O-acetyl-3-C-[2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-acetyl-D-
glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-and-β-D-galacto-
hexopyranose (178α,β). 
2'
3'
4'
5' 6'
7'
O
AcO
AcO
OAc
OAc
178α
1
23
4
5
6
1'
O
AcO
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OAc
 
174 (320 mg, 0.575 mmol) was dissolved in Ac2O (5 mL ). After cooling to -40 oC, 
TMSOTf (0.123 mL, 0.683 mmol) was added (syringe) and the mixture stirred for 1 h. 
CH2Cl2 (30 ml ) was added and the reaction quenched with a saturated aqueous solution of 
NaHCO3 (10 mL), the organic phase was collected and extracted with H2O, and then with 
brine and dried (MgSO4). Solvent evaporation and FC (hexanes:EtOAc, 2:1 1:3) gave 
400 mg (98 %) of a 15/1 mixture of 178α and 178β (360 mg, 95 %), white foam; Rf= 0.53 
(PE/EtOAc 1:1);  
 
[α]25589 = +131, [α]25577 = +141, [α]25435 = +276, [α]25405 = +320 (c 0.075, CHCl3). 
 
IR (film): 2135, 1750, 1445, 1370, 1240, 1030, 910, 600 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
Data for the α anomer: 6.32 (d , 3J(H-C(1), H-C(2)) = 3.4, H-C(1)); 5.42 (t, 3J(H-C(5’),H-
C(6’))= 2.9, H-C(5’)); 5.35 ((br s, H-C(4)); 5.20-5.15 (m, 2H, H-C(3’), H-C(4’)); 4.53 (dd, 
2J=11.5, 3J(Ha-C(7’),H-C(6’))= 7.7, Ha-C(7’)); 4.38 (dt, 3J(H-C(2’),Ha-C(1’))= 8.3, 3J(H-
C(2’),Ha-C(1’))= 2.5, H-C(2’)); 4.23 (t, 3J (H-C(5), Hexo-C(6))= 6.2, H-C(5)); 4.15 (m, 1H, 
H-C(6’)); 4.11-3.95 (m, 3H, Hb-C(7’), Ha-C(6), Hb-C(6)); 3.45 (dd, 3J(H-C(2), H-C(3)) = 
12.0, 3J(H-C(2), H-C(1)) = 3.4, H-C(2)); 2.36 (m, 1H, H-C(3)); 2.17, 2.11, 2.10, 2.07, 
2.05, 2.04, 2.02 (7s, 21H, CH3COO); 1.95 (m, 1H, Ha-C(1’)); 1.17 (m, 1H, Hb-C(1’)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
Data for the α anomer: 170.4, 170.3, 169.9, 169.8, 169.7, 169.5, 168.8 (7s, -COO); 90.3 
(d, 1J(C,H) = 175, C(1)); 69.7 (d, 1J(C,H) = 170, C(6’)); 69.4 (d, 1J(C,H) = 162, C(5)); 
68.3 (d, 1J(C,H) = 165, C(4’)); 67.7 (d, 1J(C,H) = 162, C(3’)); 66.9 (d, 1J(C,H) = 151, 
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C(5’)); 66.7 (d, 1J(C,H) = 164, C(2’)); 66.0 (d, 1J(C,H) = 150, C(4)); 61.8 (t, 1J(C,H) = 
158, C(6)); 60.5 (t, 1J(C,H) = 153, C(7’)); 57.5 (d, 1J(C,H) = 166, C(2));33.3 (d, 1J(C,H) = 
135, C(3)); 23.0 (t, 1J(C,H) = 126, C(1’)); 21.4- 19.9 (7q, 1J(C,H) = 120, 7 CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C27H37N3O16Na 682.2072; found 682.2067 
 
Anal. calcd for C27H37N3O16 (659.5932): C 49.16, H5.65, N 6.37; found: C 50.26, H 5.79, 
N 6.22. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 178α: 
 
1.01.5 2.0 2.53.03.54.04.55.05.5 6.0 6.5 7.0 7.5 
6.24 6.26 6.28 6.306.32 6.34 6.36 6.38 6.40 5.105.205.305.405.50 5.60
4.00
4.104.20 4.30 4.40 4.50 
H-5' H-4
3.34 3.363.383.403.423.443.463.483.50
H-1(α) 
H-1(β) 
H-4'
H-3'
Ha-7' H-2' H-5 
H-6' 
Hb-7'
Ha-6
Hb-6 H-2(α)
H-2(β)
H-3 Ha-1'
Hb-1' 
impurities
0.801.001.20 1.40 1.60 1.80 2.002.202.40
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4,6-O-Acetyl-3-C-[2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-O-acetyl-D-glycero-L-manno-
heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-galacto-hexopyranosyl bromide (179α). 
2'
3'
4'
5' 6'
7'
O
AcO
AcO
OAc
OAc
179α
1
23
4
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A solution of 178α,β (500 g, 0.759 mmol) and anhydrous TiBr4 (0.99 mg, 1.35 mmol) in 
anhydrous CH2Cl2 (10 mL) was stirred at 20 oC for 12 h. After the addition of CH2Cl2 
(150 mL), the solution was washed with ice-cold H2O (50 mL, twice) and dried (MgSO4). 
Solvent evaporation in vacuo and quick FC (hexane: EtOAc, 1:1) gave 470 mg (91 %) of 
179α, yellow foam, that was dried and stored at -20 oC until its use; Rf= 0.55 (PE/EtOAc 
1:1); 
 
[α]25589 = +199, [α]25577 = +160, [α]25435 = +306, [α]25405 = +364 (c 0.16, CHCl3). 
 
IR (film): 3440, 2970, 2110, 1755, 1375, 1235, 1055 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
6.64 (d , 3J(H-C(1), H-C(2)) = 3.1, H-C(1)); 5.41 (t, 3J(H-C(5’),H-C(6’))= 3.4, H-C(5’)); 
5.39 ((bs, H-C(4)); 5.20-5.11 (m, 2H, H-C(3’), H-C(4’)); 4.53 (dd, 2J=10.0, 3J(Ha-
C(7’),H-C(6’))= 9.2, Ha-C(7’)); 4.45-4.33 (m, 2H, H-C(2’), H-C(5)); 4.20-3.90 (m, 4H, 
Hexo-C(6), H-C(6’), Hendo-C(6), Hb-C(7’)); 3.52 (dd, 3J(H-C(2), H-C(3)) = 11.7, 3J(H-C(2), 
H-C(1)) = 3.1, H-C(2)); 2.40 (m, 1H, H-C(3)); 2.12-2.04 (6s, 18H, CH3COO); 1.90 (m, 
1H, Ha-C(1’)); 1.15 (m, 1H, Hb-C(1’));  
 
13C NMR (100.6 MHz, CDCl3): δ 
δ 170.8, 170.4, 169.8, 169.8, 169.7, 169.5 (7s, -COO); 92.0 (d, 1J(C,H) = 184, C(1)); 72.1 
(d, 1J(C,H) = 147, C(5)); 70.0 (d, 1J(C,H) = 142, C(6’)); 68.5 (d, 1J(C,H) = 163, C(4’)); 
67.7 (d, 1J(C,H) = 152, C(3’)); 67.0 (d, 1J(C,H) = 146, C(5’)); 66.0 (d, 1J(C,H) = 146, 
C(2’)); 65.8 (d, 1J(C,H) = 150, C(4)); 61.4 (t, 1J(C,H) = 152, C(6)); 60.8 (t, 1J(C,H) = 149, 
C(7’)); 60.1 (d, 1J(C,H) = 147, C(2));34.4 (d, 1J(C,H) = 140, C(3)); 23.3 (t, 1J(C,H) = 130, 
C(1’)); 21.2- 20.0 (6q, 1J(C,H) = 123, 6 CH3COO). 
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MALDI-HRMS Calcd for (M + K) C27H38N3O16K 719.0861; found 719.4910. 
 
1H-NMR (400 MHz, CDCl3) spectrum of 179α: 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.0
6.556.606.656.70 5.105.155.205.255.305.355.405.45
4.304.354.404.454.504.554.604.65
3.954.004.054.104.154.20 3.443.463.483.503.523.543.563.58 2.252.302.352.402.452.50
1.821.841.861.881.901.921.941.96 1.081.101.121.141.161.181.20
H-1
Ha-7'
H-3'H-5' H-4 H-4' H-2' H-5
Hexo-6
H-6'
Hendo-6
Hb-7'
H-2
H-3
Ha-1' Hb-1'
solvent 
impurities
 
 174 
3:1 mixturer of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-{4,6-O-Acetyl-3-C-[2,6-
anhydro-1-deoxy-3,4,5,7-tetrakis-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-
azido-2,3-dideoxy-α-D-galacto-pyranosyl}-L-serine tert-butyl ester (180α). 
2'
3'
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A mixture of N-Fmoc-Serine-OtBu (240 mg, 0.606 mmol), anhydrous CH2Cl2 (10 mL), 
AgClO4 (260 mg, 1.21 mmol), 2,4,6-collidine (168 µL, 1.21 mmol), and molecular sieves 
(4Å, 1 g) was stirred at 25 oC for 10 min. A solution of bromide 179 (400 mg, 0.590 
mmol) in anhydrous CH2Cl2 (10 mL) was added slowly (syringe) to the stirred mixture 
over 30 min. After the system had been stirred at 25 oC for 5 h, CH2Cl2 (100 mL) was 
added and the mixture was filtered through a pad of Celite (washing with CH2Cl2). 
Solvent evaporation and FC (hexanes/EtOAc 1:1) gave a 3:1 mixture of 180α and 180β 
(420 mg, 73%) as a white foam; Rf=0.52 (PE/EtOAc 1:1). (Note gradiant and slow 
chromatography give pure α).  
 
[α]25589 = +81, [α]25577 = +91, [α]25435 = +197, [α]25405 = +236 (c 0.12, CHCl3). 
 
IR (film): 3330, 2920, 2850, 2105, 1735, 1515, 1370, 1215, 1040, 730 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ  
Data for the α anomer: 7.82-7.29 (4 m, 8H, ArH); 6.23 (d, 3J(H-N, H-C*Ser) = 8.3, H-N); 
5.46 (br s, 1H, H-C(5’)); 5.34 (br s, 1H, H-C(4)); 5.26-5.15 (m, 2H, H-C(3’), H-C(4’)); 
4.97 (d , 3J(H-C(1), H-C(2)) = 3.4, H-C(1)); 4.59 (dd, 2J=11.7, 3J(Ha-C(7’),H-C(6’))= 7.1, 
Ha-C(7’)); 4.51 (dt, 3J(H-C*(Ser), H-(Nfmoc)) = 8.3, 3J(H-C*(Ser), Ha-C(Ser)) = 3J(H-
C*(Ser), Hb-C(Ser)) = 3.1, H-C*(Ser)); 4.48-4.34 (m, 3H, H-C(2’), Ha-C(Fmoc), Hb-
C(Fmoc)); 4.28-3.90 (m, 8H, Hb(C7’), H(C6’), Ha(C6), Hb(C6), H(C5), H-C*(Fmoc), Ha-
C(Ser), Hb-C(Ser); 3.33 (dd, 3J(H-C(2), H-C(3)) = 12.2, 3J(H-C(2), H-C(1)) = 3.2, H-
C(2)); 2.50 (m, 1H, H-C(3)); 2.12-2.04 (6s, 18H, CH3COO); 1.93 (m, 1H, Ha-C(1’)); 1.52 
(s, 9H, (CH3)3C);1.48 (m, 1H, Hb-C(1’)). 
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13C NMR (100.6 MHz, CDCl3): δ 
 Data for the α anomer: 170.9, 170.4, 170.0, 169.9, 169.8, 169.6, (6s, -COO); 156.0 (s, 
C(Carbamate); 143.6 (s, C(Fmoc)); 141.0 (s, C(Fmoc)); 127.7 (d, 1J(C,H) = 159, 
C(Fmoc)); 127.6 (d, 1J(C,H) = 159, C(Fmoc)); 125.1 (d, 1J(C,H) = 158, C(Fmoc)); 119.9 
(d, 1J(C,H) = 158, C(Fmoc)); 98.5 (d, 1J(C,H) = 184, C(1)); 82.7 (s, C(CH3)3); 70.3 (d, 
1J(C,H) = 153, C(6’)); 69.5 (t, 1J(C,H) = 153, CH2(Ser)); 68.3 (d, 1J(C,H) = 148, C(4’)); 
68.2 (d, 1J(C,H) = 146, C(5)); 67.2 (t, 1J(C,H) = 150, CH2(Fmoc)); 65.4 (d, 1J(C,H) = 149, 
C(5’)); 66.9 (d, 1J(C,H) = 148, C(4)); 66.9 (d, 1J(C,H) = 149, C(3’)); 66.9 (d, 1J(C,H) = 
143, C(2’)); 62.4 (t, 1J(C,H) = 155, C(6)); 60.4 (t, 1J(C,H) = 151, C(7’); 58.1 (d, 1J(C,H) = 
142, C(2)); 54.7 (d, 1J(C,H) = 138, C∗(Ser)); 47.1 (d, 1J(C,H) = 130, C*(Fmoc)); 32.9 (d, 
1J(C,H) = 129, C(3)); 27.9 (q, 3C, 1J(C,H) = 128, (CH3)CO); 24.1 (d, 1J(C,H) = 139, 
C(1’)); 20.6-20.2 (6q, 1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C47H58N4O19Na 1005.3593; found 1005.3590. 
 
Anal. calcd for C47H58N2O19·DCCl3 (1103.3626): C 52.25, H5.48, N 5.08; found: C 52.36, 
H 5.52, N 5.56. 
 
MALDI-HRMS spectrum of 180α: 
C47H58N4O19Na 
Calcd: 1005.3593.
 found 1005.3590.
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1H-NMR (400 MHz, CDCl3) spectrum of 180α: 
H-1
Ha-7'
H-3'
H-5' H-4
H-4'
H-2'
H-5
Ha-6H-6' Hb-6
Hb-7'
H-2 H-3
Ha-1'
Hb-1'
solvent 
impurities
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
6.056.106.156.206.256.306.35 4.905.005.105.205.305.40
3.904.004.104.204.304.404.504.60 3.063.083.103.123.143.163.183.20 1.1201.1301.1401.1501.160 1.901.921.941.961.98
H-NHSer
H*-Ser
CH2Fmoc H*-Fmoc
Ha-Ser
Hb-Ser
OC(CH3)3
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2-D-COSY 1H-NMR (400 MHz, CDCl3) spectrum of 180α: 
ppm (f2)
1.02.03.04.05.06.07.0
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N-[(9H-fluoren-9-ylmethoxy)carbonyl]-{4,6-O-Acetyl-3-C-[2,6-anhydro-1-deoxy-
3,4,5,7-tetra-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-Acetamido-2,3-dideoxy-
α-D-galacto-pyranosyl}-L-serine tert-butyl ester (181). 
2'
3'
4'
5' 6'
7'
O
AcO
AcO
OAc
OAc
181
1
23
4
5
6
1'
O
AcO
AcHN
OAc
O
COOt-Bu
NHFmoc
 
A solution of 350 mg (0.356 mmol) of 180α in 15 mL of a 3:2:1 THF/AcOH/Ac2O was 
treated with 3.5 g of Zn powder. In 1 h the reaction was filtered through a sintered glass 
funnel, concentrated, and purified by FC with 95:5 CH2Cl2/MeOH to give 320 mg (90%) 
of 181 (only α) as white foam; Rf=0.52 (CH2Cl2/MeOH, 9:1); 
 
[α]25589 = -5.5, [α]25577 = +29, [α]25435 = +91, [α]25405 = +127 (c 0.055, CHCl3). 
 
IR (film): 3665, 3330, 2970, 2900, 1740, 1730, 1680, 1525, 1450, 1370, 1220, 1045 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
 7.85-7.13 (4 m, 8H, ArH); 6.32 (d, 3J(H-N, H-C*Ser) = 8.6, H-N); 6.02 (d, 3J(H-N, H-
C(2)) = 9.9, NHAc); 5.41 (t, 3J(H-C(5’), H-C(6’)) = 2.9, H-C(5’)); 5.24 (br s, H-C(4)); 
5.26-5.15 (m, 1H, H-C(4’)); 5.07 (dd, 3J(H-C(3’),H-C(4’))= 8.8,  3J(H-C(3’),H-C(2’))= 
3.2, H-C(3’)); 4.75 (d , 3J(H-C(1), H-C(2)) = 3.1, H-C(1)); 4.57-4.35(m, 5H, Ha-C(7’), H-
C*(Ser), Ha-C(Ser), Hb-C(Ser), H-C(2’)); 4.30-3.80(m, 9H, H-C(2), Ha-(C6), Hb(C6), H-
C(5), H-C(6’), H-C*(Fmoc), Ha-C(Fmoc), Hb-C(Fmoc), Hb(C7’)); 2.22 (m, 1H, H-C(3)); 
2.15-1.96 (7s, 21H, CH3COO); 1.67 (m, 1H, Ha-C(1’)); 1.49 (s, 9H, (CH3)3C);1.14 (m, 
1H, Hb-C(1’)). 
 
13C NMR (100.6 MHz, CDCl3): δ 
172.4 (s, NHOCCH3); 170.5, 170.4, 170.1, 169.9, 169.5, 169.3, (6s, -COO); 156.1 (s, 
C(Carbamat); 143.7 (s, C(Fmoc)); 141.3 (s, C(Fmoc)); 127.8 (d, 1J(C,H) = 159, C(Fmoc));  
127.0 (d, 1J(C,H) = 159, C(Fmoc)); 124.8 (d, 1J(C,H) = 158, C(Fmoc)); 120.1 (d, 1J(C,H) 
= 158, C(Fmoc)); 98.01 (d, 1J(C,H) = 184, C(1)); 82.7 (s, C(CH3)3); 70.3 (d, 1J(C,H) = 
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153, C(6’)); 68.6 (t, 1J(C,H) = 153, CH2(Ser)); 68.4 (d, 1J(C,H) = 148, C(4’)); 68.2 (d, 
1J(C,H) = 146, C(5)); 68.1 (d, 1J(C,H) = 149, C(5’)); 68.0 (d, 1J(C,H) = 148, C(4’)); 67.1 
(d, 1J(C,H) = 149, C(3’)); 66.9 (t, 1J(C,H) = 150, CH2(Fmoc));  66.4 (d, 1J(C,H) = 143, 
C(2’)); 62.7 (t, 1J(C,H) = 155, C(6)); 61.4 (t, 1J(C,H) = 151, C(7’); 54.9 (d, 1J(C,H) = 122, 
C(2)); 47.2 (d, 1J(C,H) = 138, C∗(Ser)); 47.1 (d, 1J(C,H) = 130, C*(Fmoc)); 34.3 (d, 
1J(C,H) = 129, C(3)); 28.1 (q, 3C, 1J(C,H) = 128, (CH3)CO); 22.2 (d, 1J(C,H) = 139, 
C(1’)); 20.8-20.5 (6q, 1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS Calcd for (M + K) C49H62N2O20K 1037.3533; found 1037.3589. 
 
Anal. calcd for C49H62N2O20 (999.02): C 58.91, H6.26, N 2.80; found: C 58.97, H 6.34, N 
2.74. 
MALDI-HRMS spectrum of 181: 
Calcd for: C49H62N2O20K 
Calcd:1037.3533.
found 1037.3589.
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1H-NMR (400 MHz, CDCl3) spectrum of 181: 
H-1 Ha-7'
H-3'
H-5'
H-4 H-4'
H-2'
H-5Ha-6
H-6'
Hb-6
Hb-7'
H-2
H-3
Ha-1' Hb-1'
H-NHSer H*-Ser
CH2Fmoc
H*-Fmoc
Ha-Ser
Hb-Ser
OC(CH3)3
6.006.106.206.306.40 5.055.105.155.205.255.305.355.40 4.304.404.504.604.704.80
3.803.904.004.104.204.30 2.162.182.202.222.242.26 1.601.621.641.661.681.701.721.74 1.051.101.151.20
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
+ impurities
 
 181 
3-C-[2,6-anhydro-1-deoxy-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-
2,3-dideoxy-α-D-galacto-pyranosyl-L-serine182: 
2'
3'
4'
5' 6'
7'
O
HO
HO
OH
OH
182
1
23
4
5
6
1'
O
HO
AcHN
OH
O
COOH
NH2
 
Product 2 (40 mg, 0.060 mmol) was dissolved in 1:1 mixture of DMF/morpholine (5 mL), 
after stirring at 20 oC for 2 h, the mixture was co-evaporated with toluene under vacuum, 
FC (CH2Cl2, MeOH 9:1), then the residue was disolved in 90 % TFA in water and allowed 
to stir for 1h, then the mixture was co-evaporated with toluene under vacuum, the residue 
was dissolved in MeOH, 2 drops of NaOMe solution (1M) were added. After 1h the 
mixture was neutralized by adding Dowex 50WX8-100, the mixture was stirred for 5 min, 
filtrated,and  evaporated HPLC gave 17 ( 15 mg, 80 %) as a white solid. 
 
m.p. (137°C, discompose). 
 
IR (film): 3285, 2927, 1668, 16645, 1539, 1430, 1186, 1129, 1035, 963, 837 cm-1. 
 
 1H NMR (400 MHz, CD3OD): δ 
4.75 (d , 3J(H-C(1), H-C(2)) = 3.1, H-C(1)); 4.23 (dd, 3J(H-C(2), H-C(3)) = 12.9, 3J(H-
C(2), H-C(1)) = 3.4, H-C(2)); 4.22-4.10(m, 5H, H-C*(Ser), Ha-C(Ser), Hb-C(Ser), H-
C(5’), H-C(4)); 4.23 (dd, 2J = 11.5, 3J(Ha-C(7’), H-C(6’)) = 4.1, Ha-C(7’)); 4.06-3.65(m, 
11H, H-C(2’), H-C(3’), H-C(4’), H-C(5’), H-C(6’), Hb-C(7’), H-C(5), H-C(4), NHAc, 
NH2(Ser)); 3.33(m, 2H, Ha-C(6), Hb-C(6)); 2.12 (m, 1H, H-C(3)); 2.02(s, 3H, 
CH3CON);1.70 (m, 1H, Ha-C(1’), Hb-C(1’)). 
 
13C NMR (100.6 MHz, CDCl3): δ  
177.0 (s, COOH); 172.4 (s, NHOCCH3); 98.7 (d, 1J(C,H) = 184, C(1)); 73.7 (d, 1J(C,H) = 
153, C(6’)); 73.0 (d, 1J(C,H) = 148, C(4’)); 71.1 (d, 1J(C,H) = 146, C(5)); 69.9 (t, 1J(C,H) 
= 153, CH2(Ser)); 69.7 (d, 1J(C,H) = 143, C(2’)); 69.2 (d, 1J(C,H) = 149, C(3’)); 66.0 (d, 
1J(C,H) = 149, C(5’)); 65.2 (d, 1J(C,H) = 148, C(4)); 62.5 (t, 1J(C,H) = 155, C(6)); 61.7 (t, 
1J(C,H) = 151, C(7’); 48.2 (d, 1J(C,H) = 122, C(2)); 47.2 (d, 1J(C,H) = 138, C∗(Ser)); 35.5 
(d, 1J(C,H) = 129, C(3)); 22.4 (d, 1J(C,H) = 139, C(1’)); 21.9 (q, 1J(C,H) = 130, 
CH3CON). 
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MALDI-HRMS Calcd for (M + Na) C18H32N2O12Na 491.1853; found 491.1855. 
MALDI-HRMS spectrum of 182: 
Calcd for: C18H32N2O12Na 
Calcd491.1853
found 491.1855.
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1H-NMR (400 MHz, CDCl3) spectrum of 182: 
1.41.61.82.02.22.42.62.83.03.23.43.63.84.04.24.44.64.85.05.25.4
4.704.724.744.764.784.804.82 4.104.154.204.25
3.653.703.753.803.853.903.954.004.05
3.203.253.303.353.403.45 1.401.501.601.701.801.902.002.102.202.30
H-1
Ha-7'
H-2 H-4
H*-Ser H-5'
Ha-Ser
Hb-Ser
H-2'
H-3'
H-4'
H-5'
Hb-7'
H-6'
H-5
H-4
H-NHAc
Hb-1'
H-NHSer
Ha-1'
H-3
H-1
CD3OD
Ha-6
Hb-6
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General Peptide Coupling Reactions.  
To a solution of Fmoc-protected glycosylamino acid (1.05 eq) dissolved in 
dimethylformamide, at –0°C  a mixture of 1-hydroxy-7-aza-1,2,3-benzotriazole (1.5 eq) 
and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (1.5 eq), 
sym-collidine (3 eq) was added,  and stirred for 15 min followed by addition of the amine 
(1.0 eq). The reaction mixture was stirred at 0 °C for 1 h and allowed to slowly warm up 
to room temperature and stirred for 3 h, during which time the reaction mixture was 
concentrated in vacuo and the residue was purified by flash column chromatography on 
silica gel using a gradient of methanol in dichloromethane.  
 
General Fmoc Deprotection: 
 The Fmoc-protected compound was dissolved in 5:1 dimethylformamide: piperidine and 
stirred at room temperature for 2 h, time during which the reaction mixture was 
concentrated in vacuo and the residue was purified by flash column chromatography on 
silica gel using a gradient of methanol in dichloromethane. 
 
General t-Butyl Ester Deprotection: 
A solution of t-butyl protected acid was dissolved in 95% aq TFA (10mL) and stirred at 
room temperature for 1 h. The solution was then co-evaporated with toluene several times 
to give the corresponding acid which was used without further purification. 
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N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-
galactopyranosyl}-N-[3-((tert-butoxycarbonyl)amino)propyl]-L-serinamide (184). 
OAc
O
OAc
AcO
AcO
OAc
O
N3
AcO
O
AcO
NHFmoc
O
H
N NHBoc
184
 
To a solution of acid 183 (90 mg, 0.092 mmol) dissolved in DMF (5ml), at 0°C a mixture 
of HOAt (18 mg, 0.138 mmol) and HATU (53 mg, 0138 mmol), sym-collidine (40 µl, 
0.276 mmol) in 1ml DMFwas added,  and stirred for 15 min followed by addition of the 
amine 197a (17 mg, 0.092). The reaction mixture was stirred at 0 °C for 1 h and allowed 
to slowly warm up to room temperature and stirred for 1 h, during which time the reaction 
mixture was concentrated in vacuo and FC (light petroleum ether/EtOAc 1:2) gave 92 mg 
(88 %) of 184, white foam.  
 
IR (film): 3335,2970, 2110, 1740, 1510, 1450, 1370, 1220, 1025, 935, 880 cm-1. 
 
1H NMR (400 MHz, CDCl3):  δ  
7.80-7.26 (4 m, 8H, ArH); 6.91 (s, H-N Propyl); 6.04 (d, 3J(H-N, H-C*) = 8.0, H-N); 5.56 
(s, H-C(4)); 5.38 (dd, 3J(H-C(1’), H-C(3)) = 9.60, 3J(H-C(1’), H-C(2’)) = 2.56, H-C(1’)); 
5.32 (dd, 3J(H-C-(5’), H-C(6’)) = 6.72, 3J(H-C(5’), H-C(4’)) = 3.20, H-C(5’)); 5.216 (t, 
3J(H-C(4’), H-C(3’)) = 3.52,H-C(4’)); 4.96 (d, 3J(H-C(1), H-C(2)) = 2.88, H-C(1)); 4.83 
(d, 3J(H-C(4’), H-C(3’)) = 3.52, H-C(3’)); 4.75 (dd, 2J = 12.8, 3J(H-C(6exo), H-C(5)) = 
9.92, H-C(6exo)); 4.54-4.44 (m, 2H, H-C(2’), H-C*(Ser)); 4.43-4.31(m, 3H, Hendo-C(6), H2-
C(fmoc)); 4.30-4.11 (m, 5H, Ha-C(7’) , H-C(6’), H-C(5), H-C(fmoc), H2-C(Ser)); 4.30-
4.11 (m, 2H, Hb-C(7’) , H2-C(Ser)); 3.43 (dd, 3J(H-C(2), H-C(3)) = 12.16, 3J(H-C(2), H-
C(1))= 2.88, H-C(2)); 3.30 (bs, 2H, 2H-C(CONHCH2)); 3.15 (br s, 2H, 2H-
C(BocNHCH2)); 2.59 (d, 3J(H-C(3), H-C(2)) = 12.16, H-C(3)); 2.25-1.94 (7s, 21H, 
CH3COO);1.55 (br s, 2H, 2H -C(NHCH2CH2CH2NH);1.42 (s, 9H, (CH3)3C).  
 
13C NMR (100.6 MHz, CDCl3): δ 
 170.7, 170.4, 170.3, 169.9, 169.8, 168.9, 168.7, 168.4 (8s, -CO); 155.8 (s, C(carbamate); 
155.0 (s, C(carbamate); 143.6 (s, C(Fmoc)); 141.2 (s, C(Fmoc)); 127.6 (d, 1J(C,H) = 159, 
 186 
C(Fmoc)); 126.9 (d, 1J(C,H) = 159, C(Fmoc)); 125.1 (d, 1J(C,H) = 158, C(Fmoc)); 119.8 
(d, 1J(C,H) = 158, C(Fmoc)); 99.3 (d, 1J(C,H) = 184, C(1)); 79.0 (s, C(CH3)3); 72.9 (d, 
1J(C,H) = 153, C(6’)); 70.7 (t, 1J(C,H) = 153, CH2(Ser)); 68.8 (d, 1J(C,H) = 146, C(5)); 
66.8 (t, 1J(C,H) = 150, CH2(Fmoc)); 66.6 (d, 1J(C,H) = 148, C(4’)); 66.6 (d, 1J(C,H) = 
139, C(1’)); 66.4 (d, 1J(C,H) = 149, C(3’)); 65.8 (d, 1J(C,H) = 151, C(4)); 65.4 (d, 1J(C,H) 
= 149, C(5’)); 64.6 (d, 1J(C,H) = 143, C(2’)); 62.1 (t, 1J(C,H) = 151, C(7’)); 59.4 (t, 
1J(C,H) = 155, C(6)); 55.0 (d, 1J(C,H) = 138, C∗(Ser)); 54.9 (d, 1J(C,H) = 142, C(2)); 47.0 
(d, 1J(C,H) = 130, C(Fmoc)); 37.0 (d, 1J(C,H) = 129, C(3)); 36.9 (t, 1J(C,H) = 151, 
C(BocNHCH2));36.1 (t, 1J(C,H) = 151, C(CONHCH2)); 29.9 (t, 1J(C,H) = 151, 
C(NHCH2CH2CH2NH)); 28.0 (q, 3C, 1J(C,H) = 128, (CH3)CO); 20.8-20.4 (7q, 1J(C,H) = 
130, CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C49H60N4O21Na 1163.4284, Found 1163.4208;  
 
Anal. calcd for C53H68N6O22 (1141.13): C 55.78, H6.01, N 7.36; found: C 55.74, H 5.96, 
N 7.35. 
 
MALDI-HRMS spectrum of 184: 
 
Calcd for C49H60N4O21Na 
Calcd:  1163.4284.
Found: 1163.4208
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1H-NMR (400 MHz, CDCl3) spectrum of 184: 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
6.656.706.756.806.856.906.957.007.057.10 4.805.005.205.405.605.80
3.803.904.004.104.204.304.404.504.60
2.602.803.003.203.403.60
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N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-
galactopyranosyl}-D-seryl-rac-N-[3-({[(1,1-dimethylethyl)oxy]carbonyl} 
amino)propyl]-O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-O-acetyl-D-
glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-galactopyranosyl}-D-
serinamide (185). 
 
FmocHN
N
H
H
N
O
O
NHBoc
O
RO
185
OAc
O
OAc
AcO
AcO
OAc
O
N3
AcOAcO
OAc
O
OAc
AcO
AcO
OAc
O
N3
AcOAcO
 
The Fmoc-protected compound 184 (70 mg, 0.061 mmol) was dissolved in 5:1 DMF: 
piperidine (5ml) and stirred at room temperature for 1 h, time during which the reaction 
mixture was concentrated in vacuo and the residue was dissolved in 1 ml DMF. In a 
separated flask a solution of acid 183 (70 mg, 0.071 mmol) dissolved in DMF (3 ml), at 
0°C a mixture of HOAt (14 mg, 0.107 mmol) and HATU (41 mg, 0107 mmol), sym-
collidine (31 µl, 0.215 mmol) in 1ml DMFwas added, and stirred for 15 min followed by 
addition of the solution of amine from the first flask via syringe. The reaction mixture was 
stirred at 0 °C for 1 h and allowed to slowly warm up to room temperature and stirred for 
1 h, during which time the reaction mixture was concentrated in vacuo and FC (light 
petroleum ether/EtOAc 1:2) gave 92 mg (80 % for two steps) of 185, white foam.  
IR (film): 3360,2940, 2110, 1735, 1510, 1450, 1370, 1215, 1040, 940 cm-1. 
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1H NMR (400 MHz, CDCl3):  δ 7.80-7.26 (4 m, 8H, ArH); 6.10-5.80 (m, 2H); 5.60-5.25 
(m, 6H); 5.25-4.70 (m, 8H); 4.70-3.80(m, 21H); 3.50-3.00 (m, 6H), 2.70-2.55(m, 2H); 
2.30-1.85 (m, 42H); 1.70-1.20 (m, 13H); 
 
MALDI-HRMS Calcd for (M + Na) C83H108N10O40Na 1907.6622, Found 1907.6612;  
 
Anal. calcd for C83H108N10O40 (1884.66): C 52.86, H 5.77, N 7.43; found: C 52.77, H 
5.72, N 7.40. 
 
MALDI-HRMS spectrum of 185: 
 
Calcd for C83H108N10O40Na 
Calcd:  1907.6622. 
Found: 1907.6612.
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1H-NMR (400 MHz, CDCl3) spectrum of 185: 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.0
4.805.005.205.405.605.806.00 3.804.004.204.404.60
2.602.803.003.203.40
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N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-
galactopyranosyl}-D-seryl-O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-
O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-
galactopyranosyl}-D-seryl-rac-N-[3-({[(1,1-dimethylethyl)oxy]carbonyl} 
amino)propyl]-O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-O-acetyl-D-
glycero-L-manno-heptitol-1-C-yl]-2-azido-2,3-dideoxy-α-D-galactopyranosyl}-D-
serinamide (186a). 
 
H
N
N
H
H
N
O
O
NHBoc
O
O 186a
OAc
O
OAc
AcO
AcO
OAc
O
N3
AcOAcO
OAc
O
OAc
AcO
AcO
OAc
O
N3
AcOAcO
FmocHN
O
O
OAc
O
OAc
AcO
AcO
OAc
O
N3
AcOAcO
 
The Fmoc-protected compound 185 (40 mg, 0.021 mmol) was dissolved in 5:1 DMF: 
piperidine (3ml) and stirred at room temperature for 1 h, time during which the reaction 
mixture was concentrated in vacuo and the residue was dissolved in 1 ml DMF. In a 
separated flask a solution of acid 183 (23 mg, 0.024 mmol) dissolved in DMF (1 ml), at 
0°C a mixture of HOAt (4.7 mg, 0.036 mmol) and HATU (14 mg, 0.036 mmol), sym-
collidine (11 µl, 0.073 mmol) in 1ml DMFwas added, and stirred for 15 min followed by 
addition of the solution of amine from the first flask via syringe. The reaction mixture was 
stirred at 0 °C for 1 h and allowed to slowly warm up to room temperature and stirred for 
3 h, during which time the reaction mixture was concentrated in vacuo and FC (light 
petroleum ether/EtOAc 1:2) gave 44 mg (72 %, for two steps) of 186a, white foam.  
IR (film): 3355,2935, 2110, 1740, 1510, 1455, 1365, 1215, 1040, 940 cm-1. 
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1H NMR (400 MHz, CDCl3): δ 
7.80-7.26 (4 m, 8H, ArH); 6.10-5.80 (m, 3H); 5.60-5.25 (m, 9H); 5.25-4.70 (m, 12H); 
4.70-3.80(m, 30H); 3.50-3.00 (m, 7H), 2.70-2.55(m, 3H); 2.30-1.85 (m, 63H); 1.70-1.20 
(m, 13H); 
 
MALDI-HRMS Calcd for (M + Na) C113H148N14O58Na 2651.8959, Found 2651.8909; 
 
 Anal. calcd for C113H148N14O58 (2628.89): C 51.60, H 5.67, N 7.45; found: C 51.63, H 
5.78, N 7.41. 
 
MALDI-HRMS spectrum of 186a: 
 
Calcd for  C113H148N14O58Na
Calcd:  2651.8959
Found: 2651.8909;
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1H-NMR (400 MHz, CDCl3) spectrum of 186a: 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.0
5.705.805.906.006.106.206.306.406.506.60 4.805.005.205.405.60
3.803.904.004.104.204.304.404.504.60 2.402.602.803.003.203.403.60
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N-acetyl-O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-O-acetyl-D-
glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-
galactopyranosyl}-D-seryl-O-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-
O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-
galactopyranosyl}-D-seryl-rac-N-(3-{[(acetylthio)acetyl]amino}propyl)-O-{4,6-di-O-
acetyl-3-C-[(1R)-2,6-anhydro–1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-
C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galactopyranosyl}-D-serinamide (187a). 
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The Fmoc-protected compound 186a (40 mg, 0.015 mmol) was dissolved in 5:1 DMF: 
piperidine (3ml) and stirred at room temperature for 1 h, time during which the reaction 
mixture was concentrated in vacuo and the residue was dissolved in 4:4:1 mixture of 2,6-
lutidine/CH3COSH/Ac2O (2 mL). After stirring at 20 oC for 18 h the mixture was co-
evaporated with toluene under vacuum (10-3Torr). FC (hexanes:EtOAc, 4:1 0:1 then 5 % 
MeOH in CH2Cl2), evaporation, the residue dissolved in 95% aq TFA (4 mL) and stirred 
at room temperature for 1 h. The solution was then co-evaporated with toluene several 
times to give the corresponding acid which was used without further purification. The 
formed amine was dissolved in CH2Cl2 (2ml), at 0 oC DIEA ( 4 µl, 0.03 mmol) was added 
then followed by the addition SAMA-OPfp ( 5mg, 0.017 mmol) then the reaction mixture 
was stirred at 0 oC for 1 h. After the addition of CH2Cl2 (10 mL), the solution was washed 
with ice-cold H2O (50 mL, twice) and dried (MgSO4). Solvent evaporation in vacuo and 
quick FC (CH2Cl2: MeOH, 95:5) gave 30 mg (75 %) of 187a, yellow foam, that was dried 
and stored at -20 oC until its use. 
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IR (film): 3315, 2960, 2920, 2850, 1735, 1655, 1380, 1245, 1035, 800 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
6.02-5.10(m, 14 H); 5.01-2.90(m, 52H); 2.85-1.70(m, 32H).  
 
MALDI-HRMS Calcd for (M + Li-Ac) C103H146N8O59SLi 2477.8551, Found 2477.8540; 
 
MALDI-HRMS spectrum of 187a: 
 
Calcd for C103H146N8O59SLi 
Calcd:  2477.8551.
Found: 2477.8540.
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1H-NMR (400 MHz, CDCl3) spectrum of 187a: 
2.02.53.03.54.04.55.05.56.06.57.07.5
5.205.405.605.806.00
3.804.004.204.404.604.805.00
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N-acetyl-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-
acetyl)amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-D-seryl-O-{3-C-[(1R)2,6-anhydro-
D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galacto-
pyranosyl}-D-seryl-rac-N-{3-[(mercaptoacetyl)amino]propyl}-O-{3-C-[(1R)2,6-
anhydro-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-
galacto-pyranosyl}-D-serinamide (187b). 
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The peracetylated compound 187a (20 mg, 0.0079 mmol) was dissolved in MeOH, 2 µl of 
NaOMe solution (1M) were added. After 1h the mixture was neutralized by adding Dowex 
50WX8-100, the mixture was stirred for 5 min, filtrated,and  evaporated HPLC gave 187b 
6.9 mg (55 %) as a white foam. 
 
MALDI-HRMS Calcd for (M – H2O) C61H101N8O37S- 1569.5994, Found 1569.6000; 
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MALDI-HRMS spectrum of 186b: 
Calcd for C61H101N8O37S-
 
Calcd:  1569.5994.
Found: 1569.6000;
 
 
 
HPLC chromatogram of 186b: 
 
 
AU
0.000
0.010
0.020
0.030
0.040
0.050
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00
CH3CN:  ( 0 to 100 %)
H2O:       ( 100 to 0 %)
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N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-{4,6-di-O-acetyl-3-C-[(1R)-2,6-anhydro–
1,3,4,5,7-penta-O-acetyl-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-
dideoxy-α-D-galactopyranosyl}-N-[2-(tritylthio)ethyl]-D-serinamide (189). 
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To a solution of acid 188 (70 mg, 0.07 mmol) dissolved in DMF (3.5ml), at 0°C a mixture 
of HOAt (13.7 mg, 0.105 mmol) and HATU (40.3 mg, 0.105 mmol), sym-collidine (30.4 
µl, 0.210 mmol) in 1ml DMFwas added,  and stirred for 15 min followed by addition of 
the amine 197b (22 mg, 0.07 mmol). The reaction mixture was stirred at 0 °C for 1 h and 
allowed to slowly warm up to room temperature and stirred for 1 h, during which time the 
reaction mixture was concentrated in vacuo and FC (5 % MeOH in CH2Cl2) gave 80 mg 
(87 %) of 189, white foam. 
 
[α]25589 = +44, [α]25577 = +55, [α]25435 = +109, [α]25405 = +130 (c 0.19, CH2Cl2). 
 
IR (film): 3315, 3055, 2960, 1735, 1655, 1505, 1370, 1220, 1030, 845 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ  
8.00-7.00 (4 m, 23H, ArH); 6.17 ( m, 1H, H-N); 5.72 (d, 3J(H-N, H-C*) = 10.4, H-N); 
5.50 (s, H-C(4)); 5.40-5.30 (m, 3H, H-C(1’), H-C(5’), H-N); 5.26 (t, 3J(H-C(4’), H-C(5’)) 
= 3.4,H-C(4’)); 4.75-4.65 (m, 2H, H-C(1), Hexo-C(6)); 4.60 (td, 3J(H-C(2), H-C(3)) = 12.9, 
3J(H-C(2), H-(NAc)) = 10.0, 3J(H-C(2), H-C(1)) = 3.4, H-C(2)); 4.52-4.35 (m, 5H, H2-
C(Fmoc), H-C(Ser), H-C(2’), H-C(3’), Hendo-C(6), ); 4.26-4.17 (m, 3H, H-C(Fmoc), H-
C(6’), Ha-C(7’)); 4.14-4.06 (m, 1H, H-C(5)); 3.97-3.87 (m, 3H, H2-C(Ser), Hb-C(7’)); 
3.13-2.97 (m, 2H, NCH2); 2.57-2.36 (m, 3H, H-C(3), SCH2); 2.22-1.87 (8s, 24H, 
CH3COO);  
13C NMR (100.6 MHz, CDCl3): δ  
170.7, 170.4, 170.3, 170.2, 169.9, 169.5, 169.1, 169.0, 168.9 (9s, -COO); 162.6 (s, 
C(carbamate); 144.4 (s, C(Tr)); 143.6 (s, C(Fmoc)); 141.3 (s, C(Fmoc)); 129.4 (d, 1J(C,H) 
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= 155, C(Tr)); 128.1 (d, 1J(C,H) = 153, C(Tr)); 127.7 (d, 1J(C,H) = 159, C(Fmoc)); 127.0 
(d, 1J(C,H) = 159, C(Fmoc)); 126.9 (d, 1J(C,H) = 150, C(Tr)); 124.9 (d, 1J(C,H) = 158, 
C(Fmoc)); 120.0 (d, 1J(C,H) = 158, C(Fmoc)); 98.3 (d, 1J(C,H) = 169, C(1)); 72.9 (d, 
1J(C,H) = 149, C(6’)); 68.8 (d, 1J(C,H) = 140, C(5)); 68.4 (t, 1J(C,H) = 153, CH2(Ser)); 
67.1 (t, 1J(C,H) = 150, CH2(Fmoc)); 67.0 (d, 1J(C,H) = 149, C(3’)); 66.6 (d, 1J(C,H) = 
149, C(4’)); 66.4 (d, 1J(C,H) = 160, C(4)); 65.6 (d, 1J(C,H) = 159, C(5’)); 65.5 (d, 1J(C,H) 
= 148, C(1’)); 65.2 (d, 1J(C,H) = 139, C(2’)); 64.9(s, C(C(Ph)3); 62.24 (t, 1J(C,H) = 163, 
C(7’)); 59.7 (t, 1J(C,H) = 151, C(6)); 55.0 (d, 1J(C,H) = 138, C∗(Ser)); 47.1 (d, 1J(C,H) = 
130, C(Fmoc)); 43.5 (d, 1J(C,H) = 130, C(Ser)); 41.3 (t, 1J(C,H) = 153, CH2NH); 38.0 (d, 
1J(C,H) = 128, C(3)); 36.1 (t, 1J(C,H) = 153, CH2STr); 23.4 (q, 1J(C,H) = 129, CH3CON); 
21.1-20.6 (7q, 1J(C,H) = 130, CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C68H75N3O21SNa 1324.4511, Found 1324.4510; 
 
MALDI-HRMS spectrum of 189: 
 
Calcd for:  C68H75N3O21SNa 
Calcd:  1324.4511.
Found: 1324.4510.
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1H-NMR (400 MHz, CDCl3) spectrum of 189: 
2.02.53.03.54.04.55.05.56.06.57.07.58.0
0.70 0.75 0.80 0.85 0.90 0.95 1.00 0.88 0.90 0.92 0.94 0.96 0.98 1.00 1.02
1.06 1.08 1.10 1.12 1.14 1.16
impurities
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N-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-
manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-D-
seryl-rac-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl) 
amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-N-{2-[(triphenylmethyl)thio]ethyl} -D-
serinamide (190). 
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The Fmoc-protected compound 189 (79 mg, 0.061 mmol) was dissolved in 5:1 DMF: 
piperidine (5ml) and stirred at room temperature for 1 h, time during which the reaction 
mixture was concentrated in vacuo and the residue was dissolved in 1 ml DMF. In a 
separated flask a solution of acid 188 (70 mg, 0.07 mmol) dissolved in DMF (3 ml), at 0°C 
a mixture of HOAt (14 mg, 0.107 mmol) and HATU (41 mg, 0107 mmol), sym-collidine 
(31 µl, 0.215 mmol) in 1ml DMFwas added, and stirred for 15 min followed by addition 
of the solution of amine from the first flask via syringe. The reaction mixture was stirred 
at 0 °C for 1 h and allowed to slowly warm up to room temperature and stirred for 1 h, 
during which time the reaction mixture was concentrated in vacuo and FC (5 % MeOH in 
CH2Cl2) gave 105 mg (83 % for two steps) of 190, white foam.  
[α]25589 = +87, [α]25577 = +110, [α]25435 = +186, [α]25405 = +214 (c 0.07, CHCl3). 
 
IR (film): 3335, 3060, 2965, 1735, 1655, 1510, 1370, 1215, 1025, 940 cm-1. 
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1H NMR (400 MHz, CDCl3):  δ 
 7.90-7.00 (4 m, 23H, ArH); 6.75(m, NH); 6.36(m, NH); 5.97(m, NH); 5.80(m, NH); 5.65-
5.10 (m, 4H); 4.89-3.40(m, 27H); 3.31-2.8 (m, 4H), 2.70-2.3(m, 2H); 2.30-1.85 (m, 42H); 
1.70-1.20 (m, 48H). 
 
MALDI-HRMS Calcd for (M + Na) C100H119N5O40SNa 2084.7049, Found 2084.7023; 
MALDI-HRMS spectrum of 190: 
Calcd for: C100H119N5O40SNa 
Calcd:  2084.7049, 
Found: 2084.7023;
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1H-NMR (400 MHz, CDCl3) spectrum of 190: 
2.02.53.03.54.04.55.05.56.06.57.07.58.0
5.806.006.206.406.606.807.00 5.105.205.305.405.505.60
3.403.603.804.004.204.404.604.805.00 2.402.602.803.003.20
NH
NH NH
NH
NH
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N-acetyl-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl) 
amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-D-seryl-O-{3-C-[(1R)2,6-anhydro-D-
glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galacto-
pyranosyl}-D-seryl-rac-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-manno-heptitol-1-C-yl]-
2-[(N-acetyl) amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-N-[2-(acetylthio)ethyl]-D-
serinamide (191). 
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The Fmoc-protected compound 190 (43 mg, 0.021 mmol) was dissolved in 5:1 DMF: 
piperidine (3ml) and stirred at room temperature for 1 h, time during which the reaction 
mixture was concentrated in vacuo and the residue was dissolved in 1 ml DMF. In a 
separated flask a solution of acid 183 (23 mg, 0.023 mmol) dissolved in DMF (1 ml), at 
0°C a mixture of HOAt (4.7 mg, 0.036 mmol) and HATU (14 mg, 0.036 mmol), sym-
collidine (11 µl, 0.073 mmol) in 1ml DMFwas added, and stirred for 15 min followed by 
addition of the solution of amine from the first flask via syringe. The reaction mixture was 
stirred at 0 °C for 1 h and allowed to slowly warm up to room temperature and stirred for 
3 h, during which time the reaction mixture was concentrated in vacuo and the residue was 
dissolved in5:1 DMF: piperidine (3ml) and stirred at room temperature for 1 h, time 
during which the reaction mixture was concentrated in vacuo and the residue dissolved in 
95% aq TFA (3 mL) and stirred at room temperature for 1 h. The solution was then co-
evaporated with toluene several times to give the corresponding acid which was used 
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without further purification. The residue was dissolved in pyridine (1 ml) and Ac2O (1m  
ml)  and stirred at room temperature for 2 h. The solution was then co-evaporated with 
toluene several times then FC (5 % MeOH in CH2Cl2) gave 35 mg (68 %) of 186a, white 
foam. 
 
[α]25589 = +33.3, [α]25577 = +66.7, [α]25435 = +193.3, [α]25405 = +253.3 (c 0.015, CHCl3). 
 
IR (film): 3320, 2960, 2925, 2845, 1740, 1655, 1370, 1220, 1025, 795 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 
6.02-5.10(m, 14 H); 5.01-2.90(m, 52H); 2.85-1.70(m, 30H).  
 
MALDI-HRMS Calcd for (M + Na) C102H143N7O59SNa 2464.8023, Found 2464.8069; 
 
MALDI-HRMS spectrum of 191: 
 
Calcd for:  C102H143N7O59SNa
 
Calcd:  2464.8023.
Found: 2464.8069;
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1H-NMR (400 MHz, CDCl3) spectrum of 191: 
2.02.53.03.54.04.55.05.56.06.57.07.5
5.86.06.26.46.66.87.07.27.47.67.8 5.105.205.305.405.505.60
3.804.004.204.404.604.80
2.402.602.803.003.203.403.60
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N-acetyl-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl) 
amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-D-seryl-O-{3-C-[(1R)2,6-anhydro-D-
glycero-L-manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galacto-
pyranosyl}-D-seryl-rac-N-(2-mercaptoethyl)-O-{3-C-[(1R)2,6-anhydro-D-glycero-L-
manno-heptitol-1-C-yl]-2-[(N-acetyl)amino]-2,3-dideoxy-α-D-galacto-pyranosyl}-D-
serinamide (192). 
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The peracetylated compound 191 (20 mg, 0.0082 mmol) was dissolved in MeOH, 2 µl of 
NaOMe solution (1M) were added. After 1h the mixture was neutralized by adding Dowex 
50WX8-100, the mixture was stirred for 5 min, filtrated, and evaporated. HPLC gave 
187b 10.2 mg (82 %) as a white foam. 
 
MALDI-HRMS Calcd for (M + Na) C58H99N7O37SNa 1540.5698, Found 1540.5609; 
 
Anal. calcd for C58H99N7O37S (1518.50): C 45.88, H6.57, N 6.46; found: C 45.72, H 6.52, 
N 6.50. 
 209 
 
 
MALDI-HRMS spectrum of 192: 
 
Calcd for: C58H99N7O37SNa
 
Calcd:  1540.5698.
Found: 1540.5609.
 
 
 
HPLC chromatogram of 192: 
CH3CN (0 to 100%)
H2O :   (100 to 0%)
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N-acetyl-{3-C-[(1R)-2,6-anhydro-D-glycero-L-manno-heptitol-1-C-yl]}-2-[(N-benzyl-
N-methoxy)amino]-2,3-dideoxy-β-D-galactopyranosyl}-N-[2-(thio)ethyl]-D-
serinamide (195). 
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To a solution of acid 193 (75.5 mg, 0.07 mmol) dissolved in DMF (3.5ml), at 0°C a 
mixture of HOAt (13.7 mg, 0.105 mmol) and HATU (40.3 mg, 0.105 mmol), sym-
collidine (30.4 µl, 0.210 mmol) in 1ml DMFwas added,  and stirred for 15 min followed 
by addition of the amine 197b (22 mg, 0.07 mmol). The reaction mixture was stirred at 0 
°C for 1 h and allowed to slowly warm up to room temperature and stirred for 1 h, during 
which time the reaction mixture was concentrated in vacuo. and the residue was dissolved 
in5:1 DMF: piperidine (3ml) and stirred at room temperature for 1 h, time during which 
the reaction mixture was concentrated in vacuo and the residue dissolved in 95% aq TFA 
(3 mL) and stirred at room temperature for 1 h. The solution was then co-evaporated with 
toluene several times to give the corresponding acid which was used without further 
purification. The residue was dissolved in Ac2O (1m  ml)  and stirred at room temperature 
for 30 min. The solution was then co-evaporated with toluene several times FC (5 % 
MeOH in CH2Cl2) gave peracetylated sugar. The latter was dissolved in MeOH, 2 µl of 
NaOMe solution (1M) was added. After 1h the mixture was neutralized by adding Dowex 
50WX8-100, the mixture was stirred for 5 min, filtrated, and evaporated gave 195 37 mg 
(80 %) as a brown foam. 
 
 FC (5 % MeOH in CH2Cl2) gave 35 mg (68 %) of 186a, white foam. 
 
 
[α]25589 = -346.7, [α]25577 = -560.0, [α]25435 = -426.7, [α]25405 = -413.3 (c 0.0075, MeOH). 
 211 
 
 
1H NMR (400 MHz, CD3OD): δ  
 7.44-7.04 (m, 5H, H-C(arom)); 4.88 (d, 3J(H-C(1), H-C(2)) = 8.0, H-C(1)); 4.80 (m, H-
C(4)); 4.54 (t, 3J(H-C*(Ser),H2-C(Ser) = 5.0, H-C*(Ser) );4.31-4.22 (m, H-C(1’), Ha-
C(CH2Ph); 4.10 (dd, 2J = 10.6, 3J(H2-C(Ser), H-C*(Ser)= 5.8, H2-C(Ser)); 4.06-3.95 (m, 
3H, H-C(5), Ha-C(C6), H-C(C3’), H-C(C3’)); 3.91-3.72 (m, 3H, H-C(2’), Hb-(CH2Ph), H-
C(C4’)); 3.70-3.57 (m,3H, Hb-C(6), Ha-C(7’), Hb-C(7’)); 3.50-3.31 (m,3H, Ha-C(NCH2), 
Hb-C(NCH2), H-C(C6’)); 3.25.3.11 (m, 4H, H-C(OCH3), H-C(2)); 2.74-2.63 (m,2H, Ha-
C(HSCH2), Hb-C(HSCH2)); 2.84 (dt, 3J(H-C(2), H-C(3)) = 12.3, 3J(H-C(2), H-C(1)) = 8.0, 
H-C(2)); 2.20 (br d, 3J(H-C(3), H-C(2)) = 12.3, 3J(H-C(3)); 1.99 (s, 3H, CH3COO). 
 
13C NMR (100.6 MHz, CDCl3): δ  
173.4(s, -COO); 172.3(s, -COO); 140.5 (s, C(arom)); 130.9 (d, 1J(C,H) = 162, C(arom)); 
129.1 (d, 1J(C,H) = 158, C(arom)); 128.1 (d, 1J(C,H) = 158, C(arom)); 104.0(d, 1J(C,H) = 
159, C(1)); 79.6 (d, 1J(C,H) = 150, C(6’)); 78.3 (d, 1J(C,H) = 157, C(4’)); 72.5 (d, 1J(C,H) 
= 144, C(2’)); 70.5 (d, 1J(C,H) = 139, C(5)); 69.8 (d, 1J(C,H) = 149, C(5’)); 69.7 (t, 
1J(C,H) = 153, CH2(Ser)); 68.9 (d, 1J(C,H) = 150, C(4)); 68.6 (d, 1J(C,H) = 139, C(1’)); 
67.6 (d, 1J(C,H) = 155, C(3’)); 63.4 (q, 1J(C,H) = 130, OCH3); 63.0 (t, 1J(C,H) = 149, 
C(NCH2Ph)); 63.0 (t, 1J(C,H) = 148, C(7’)); 61.5 (d, 1J(C,H) = 139, C(2)); 60.0 (t, 1J(C,H) 
= 149, C(6)); 55.1 (d, 1J(C,H) = 138, C∗(Ser)); 42.0 (d, 1J(C,H) = 127, C(3)); 39.9 (t, 
1J(C,H) = 148, C(NCH2-)); 39.9 (t, 1J(C,H) = 133, C(HSCH2-)); 21.1 (q, 1J(C,H) = 130, 
CH3COO). 
 
MALDI-HRMS Calcd for (M + Na) C28H45N3O13SNa 686.2571; found 686.6705. 
 
Anal. calcd for C28H45N3O13S (663.73): C 50.67, H6.83, N 6.33; found: C 50.69, H 6.82, 
N 6.22. 
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1H-NMR (400 MHz, CDCl3) spectrum of 195: 
2.02.53.03.54.04.55.05.56.06.57.07.5
3.603.804.004.204.404.604.80 3.103.153.203.253.303.353.403.45
2.202.302.402.502.602.70
+ impurities
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Protocol: Coupling of Synthetic Peptide to Carrier Protein Using MBS 
Coupling of Synthetic Peptide to Carrier Protein Using MBS  
1. Dissolve 5mg keyhole limpet hemocyanin (KLH) in 0.5ml 0.01M Phosphate 
Buffer (pH 7.0)  
2. Dissolve 3mg m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) in 200µl 
Dimethyl Formamide (DMF), prepared fresh  
3. Add 70µl MBS/DMF to KLH solution; gently stir at RT for 30min  
4. Pre-equilibrate Sephadex G-25column with 0.05M Phosphate Buffer (pH 6.0); 
load KLH reaction mixture. Elute the column with 0.05M Phosphate Buffer (pH 
6.0)  
5. Collect 3.5ml (in 7 fractions) MBS/KLH conjugate solution  
6. Dissolve 5mg synthetic peptide in 1ml PBS  
7. Add peptide solution to MB/KLH conjugate  
8. Adjust pH to 7.3 with 0.1M HCl or 0.1M NaOH  
9. Stir 3 hrs at RT  
10. Pass through another Sephadex G-25 column to remove the unbound peptide, 
using water as buffer  
11. Collect 3.5ml (in 7 fractions) of cluster-MBS-KLH conjugate solution  
12. Lyophilize the conjugate  
The collection fraction procedure in point 5 and 11: 
1. Mix 100µl of water with 100µl bradford reagent in microwell plate. 
2. You will observe a brown color in this mixture.  
3. After 1 min add 10 µl from the collected fractions solution to the wells. 
4. Collect the fractions that transform the color into dark blue with each other in a 
small flask, then put this fractions in dialysis tube cutoff 30,000 ( look to the 
following Fiqure). 
5. After the dialysis lyophilize the conjugate  
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Analysis of the collected fraction microwell plate  
1. add 100µl Bradford solution, and100µl of double distilled water
2. add 10µl of the collected fractions.
3. the blue color is indicatating the presence of protein exist in 
corresponding fractions.
H
G
F
A
B
C
D
E
1 2 3 4 5 6 7 8 9 10 11 12  
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